date,adjusted_abs,adj_direction,cleaned,headline_word,dict_score,target_var
2012-01-13,0.1647936711853703,negative,nestle decline comment unit bid report,6,-1,0
2012-01-27,0.6479853713683092,negative,fda approves inlyta kidney cancer,5,2,0
2012-01-31,0.7960452134236351,negative,generic take toll profit trim view citing stronger dollar,9,-1,0
2012-02-07,0.2244448563941903,positive,india spin off animal dealtalk nestle lead scoop up baby formula unit dealtalk nestle lead scoop up baby formula unit,20,0,0
2012-02-14,0.2664360865804682,positive,best hope alzheimer best hope alzheimer,6,0,0
2012-02-21,0.0975911703156473,positive,eye tie ups chinese drugmakers,5,0,0
2012-02-23,1.9860229940340648,negative,mead danone vie nestle unit source mead danone vie nestle unit source,12,0,1
2012-02-24,0.4936956571211626,positive,mead danone fight nestle unit source,6,0,0
2012-02-27,0.2097457897520138,positive,buy vitamin maker emergen brand,5,1,0
2012-02-28,0.4797769672291618,negative,recall expired lot prevnar vaccine,5,-1,0
2012-03-01,1.209638121278589,positive,durect partner end pain deal,5,0,0
2012-03-02,0.0673217142457938,negative,nestle danone mead battle unit,5,0,0
2012-03-07,0.2038190226627545,negative,bayer novartis mull animal unit report,6,-1,0
2012-03-12,0.2720605824375166,positive,ceo spin off likely animal,5,0,0
2012-03-13,0.3793994158301617,positive,india biocon retain milestone payment deal india biocon fall cancel sale deal update scrap insulin deal india biocon scrap insulin deal india biocon corrected india biocon retain milestone payment deal deutsche cut biocon target exit,35,-1,0
2012-03-15,0.6701428772687756,negative,bayer make non binding offer unit paper ceo pay jump turnaround effort,12,-1,0
2012-03-28,0.0958560604666258,positive,astellas extends deal sell lipitor japan,6,0,0
2012-04-10,1.383698995812832,positive,court rule face asbestos suit court rule face asbestos suit,10,0,1
2012-04-17,0.0201536404616398,positive,nestle near deal baby formula unit wsj nestle near deal baby formula unit wsj close selling nutrition unit nestle wsj,20,0,0
2012-04-18,0.9654562926925347,positive,nestle near buying baby formula source nestle near buying baby formula source pulse stock watch halliburton berkshire,17,0,0
2012-04-19,0.1298398719754789,positive,text fitch credit negative potential nestle buy unit,8,1,0
2012-04-20,0.8403819894938103,positive,danone raise bid baby food unit report danone raise bid baby food unit report,14,1,0
2012-04-23,0.0430120376816445,positive,brief moody nutrition sale credit negative update nestle win pricey battle baby food unit nestle sell part asset report nestle win pricey battle baby food unit nestle buy nutrition bln nestle sell part asset report rpt nestle buy baby food unit bln,42,2,0
2012-04-25,0.2644364277680111,negative,text nestle aaa rtgs afrmd baby unit bid,8,0,0
2012-04-26,0.0898241421316559,positive,danone discipline prevented win,4,1,0
2012-04-27,0.0773679044449249,negative,text summary,2,0,0
2012-05-01,1.1460236157710413,negative,fda approves pfizerprotalix gaucher lookout mid size deal profit solid despite lipitor loss beat profit forecast helped cost cut,19,2,0
2012-05-04,0.642347595486481,positive,lyrica fall short pain study preview panel seen backing arthritis hope,11,-1,0
2012-05-07,0.2397865670238141,positive,fda staff question arthritis benefit,5,1,0
2012-05-09,1.7082651337785193,positive,fda adviser back arthritis,4,0,1
2012-05-16,1.9071445532203413,positive,effective rare child cancer,4,1,1
2012-05-17,1.1297418067901632,positive,rpt effective rare child cancer,5,1,0
2012-05-22,0.928496763285136,negative,fda staff shoot down rare disease fda staff shoot down rare disease,12,0,0
2012-05-24,0.0297791365727384,positive,fda panel vote rare disease,5,0,0
2012-05-25,0.2792877217937861,positive,corrected panel split rare disease panel split rare disease,9,0,0
2012-05-31,0.5512277174488212,negative,dealtalk danone eyeing latam asset post nestle deal,8,0,0
2012-06-01,1.4660156893724907,positive,webmd name executive ceo,4,0,1
2012-06-06,0.8116576127025654,negative,job cut highlight irish exposure patent expiry,7,0,0
2012-06-07,0.0763039407579047,positive,plan animal ipo aim potential animal ipo,7,0,0
2012-06-12,0.7418355949388777,negative,cv rite aid sue over depression,6,0,0
2012-06-18,0.1495991271024621,negative,fda seek rare disease,4,0,0
2012-06-19,0.569383920632438,negative,survey show dim faith alzheimer,5,0,0
2012-06-20,0.0140115329727019,negative,cdc recommends expanded use vaccine cdc recommends expanded use vaccine cdc recommends expanded use vaccine,15,0,0
2012-06-21,1.935095513925722,positive,pain lyrica get added approval,5,1,1
2012-06-22,0.2170627278256232,negative,novartis astra win eu okay loses eu agency back astra antibiotic not gaucher,13,2,0
2012-06-25,0.4813644860322097,positive,fda rebuff bristolpfizer clot preventer fda rebuff bristolpfizer clot preventer bristolpfizer clot preventer delayed,14,0,0
2012-07-05,0.4233036638395138,negative,ok lupin generic nerve pain ok lupin generic nerve pain sued retailer generic lipitor delay yank breast colon claim centrum vitamin,21,-1,0
2012-07-19,0.2660286815646673,positive,court upholds lyrica patent protection court upholds lyrica patent protection,10,0,0
2012-07-20,0.5155898305899465,positive,win eu backing lung cancer,5,1,0
2012-07-23,0.5892703266100807,positive,jj alzheimer fails big trial jj alzheimer fails big trial lyrica doe not hurt sperm study,16,-1,0
2012-07-24,0.0947030292911432,negative,hope dim alzheimer trial failure pulse apple western union pulse apple western union devry ryder system,16,0,0
2012-07-27,0.3955515345984484,negative,return right acura product,4,0,0
2012-07-31,2.091269774415294,positive,beat forecast helped cost cut name bank animal ipo beat street look past animal ipo beat street flirt high,19,2,1
2012-08-06,0.2761290505214897,negative,jj scrap alzheimer study fails jj scrap alzheimer study fails alzheimer fails key study,14,-1,0
2012-08-07,2.6448068383572387,negative,settle foreign bribery case settle foreign bribery case,8,0,1
2012-08-08,0.2579553385306132,positive,former ceo kindler join lux capital,6,0,0
2012-08-10,0.1296821282982474,positive,torisel fails combination study,4,-1,0
2012-08-13,0.8692622871683597,negative,animal unit zoetis file ipo animal unit file go public pay million astrazeneca otc nexium marketing right,17,-1,0
2012-08-21,0.617704840490918,negative,fda extends review arthritis month,5,0,0
2012-08-23,0.9867146024847062,positive,settle impax patent suit over generic detrol la,8,0,0
2012-08-30,0.2199623916239068,positive,fda warns use revatio child,5,0,0
2012-09-04,0.2641506826750017,negative,fda approves leukemia fda approves leukemia,6,2,0
2012-09-07,0.8003573680631315,negative,mylan settle patent suit generic detrol la,7,0,0
2012-09-26,0.5218519974432345,positive,fda decide pfizerbristol blood thinner fda decide pfizerbristol blood thinner,10,0,0
2012-10-04,0.598313058564437,negative,prevenar vaccine meet trial goal,5,0,0
2012-10-05,0.6637682182053073,positive,appeal india decision revoke cancer patent,6,0,0
2012-10-09,0.6344086486747003,positive,pay million lawsuit over celebrex agrees mln settlement celebrex security class action suit pay mln lawsuit over celebrex,18,-1,0
2012-10-11,0.2148172415952332,negative,pain safe rival pill trial,5,1,0
2012-10-17,0.2984448191767574,negative,kidney cancer fails initial treatment,5,-1,0
2012-10-22,0.6350659867331521,negative,buy maker attention deficit million buy maker attention deficit mln,10,1,0
2012-10-24,0.7592249411367935,positive,lung cancer get conditional eu approval,6,1,0
2012-11-01,2.3337371305146903,negative,sale weak vaccine emerging slump make go no go decision remoxy see emerging sale rising high single digit percentage range down pct premarket result quarterly revenue fall far short forecast,30,-2,1
2012-11-02,0.8891689419184057,positive,nestle baby food deal cleared chinese authority nestle baby food deal cleared chinese authority,14,0,0
2012-11-05,0.0826605371005984,negative,experimental cholesterol promising study,4,1,0
2012-11-06,0.2536314708983411,negative,fda approves treat rheumatoid arthritis arthritis win approval ready challenge humira arthritis win approval challenge humira,16,3,0
2012-11-07,0.9713459567809112,positive,return eu selling right auxilium hand disorder,7,0,0
2012-11-08,1.1610312057416472,positive,expects generic competition canada viagra ruling canada supreme court strip viagra patent canada top court rule viagra patent case,19,0,0
2012-11-12,0.3278594569515403,negative,pay million lawsuit over pristiq,5,-1,0
2012-11-16,0.350719907287611,positive,daily lyrica trial fails meet goal calpers others sue opt class action calpers others sue opt class action,18,0,0
2012-11-19,0.8503933963478039,negative,daily lyrica met goal trial fibromyalgia,6,0,0
2012-11-20,0.5368251550261549,positive,get eu nod blood clot preventer,6,1,0
2012-12-05,1.7105510706220572,positive,breast cancer delay progression month,5,-1,1
2012-12-07,0.4980957932867569,negative,billion revolving credit back spinoff rlpc 1b rc back spinoff gold dust vanishes missouri,14,0,0
2012-12-12,0.5558211735345653,negative,pay million settle protonix case,5,-1,0
2012-12-13,0.0924079580462589,negative,launch animal unit ipo early raise bln wsj launch animal unit ipo early raise billion wsj,16,2,0
2012-12-18,0.0111500091425575,positive,cut job lipitor sale decline report cut job lipitor sale decline report,12,-2,0
2012-12-28,0.0863826034270931,positive,fda approves anti clotting eliquis,5,2,0
2013-01-03,0.0056362748600879,negative,italy philogen sign licence deal,5,1,0
2013-01-08,0.4416949443192042,positive,win eu approval expand use prevenar child,7,3,0
2013-01-14,0.8975574259457941,positive,considers purchase india agila specialty report,6,0,0
2013-01-16,0.0239667744808103,negative,zoetis win strong response 65bn debut bond sale,8,1,0
2013-01-17,0.1807180965990307,positive,ipo could value zoetis up billion ipo could value zoetis up bln unit zoetis expects raise up bln ipo,19,1,0
2013-01-18,1.3038525852458571,negative,eu agency back leukaemia,4,0,0
2013-01-22,0.011832311126847,negative,uk nice back wider use bm anti clot,8,0,0
2013-01-25,0.0035521463321863,negative,prevnar vaccine win expanded approval age prevnar vaccine win approval age,11,2,0
2013-01-29,2.811023012320324,positive,wrapup profit beat street generic take toll stock future tick lower ford rise early wrapup beat street generic take toll q4 result top forecast give cautious view q4 result top estimate profit beat street generic take toll fourth result top forecast give cautious view,44,2,1
2013-02-14,0.130207763121648,positive,drugmakers weigh carve abbott set pace dealtalk drugmakers weigh carve abbott set pace nestle working divestments buy cfo,18,1,0
2013-03-05,0.476443306139851,positive,get celebrex patent extension sue generic,6,0,0
2013-03-25,0.3574560093871026,negative,treat tuberculosis short supply,4,0,0
2013-03-26,0.7622418526625818,positive,lung cancer pill rejected uk cost agency,7,0,0
2013-03-27,0.1398601399634325,positive,get rebuff uk cost body cancer,6,0,0
2013-03-28,0.4608384139483501,positive,fails win dismissal shareholder class action lawsuit over celebrex bextra fails end lawsuit over bextra celebrex safety,17,0,0
2013-04-02,0.8588568952651698,positive,novartis abbott weigh bid brazil ache source exclusive novartis abbott weigh bid brazil ache source,15,0,0
2013-04-03,0.3296727560335943,positive,court upholds mln verdict over neurontin court upholds million verdict over neurontin,12,0,0
2013-04-10,1.5576685692336725,positive,cancer win special status jump,5,1,1
2013-04-15,1.6000670167839235,positive,nestle make deal mexico competition body mexico nestle sell baby food,11,0,1
2013-04-25,1.5164822784939913,negative,arthritis rejected european regulator arthritis rejected european regulator,8,0,1
2013-04-29,0.460074948668665,positive,jointly develop diabetes,3,0,0
2013-04-30,4.707817371686374,negative,expects prevnar sale stengthen later result fall short trim profit forecast down pct premarket result fall short trim profit view ha understanding fda needed step remoxy pain pain therapeutic durect soar remoxy comment,33,0,1
2013-05-10,0.0941874920949548,positive,yet decide pain therapeutic painkiller,5,0,0
2013-05-20,0.8917998792169923,negative,halt study lymphoma unlikely help survival,6,0,0
2013-05-22,2.548570170474318,positive,plan unwind remaining majority stake zoetis spin off zoetis stake shareholder up premarket plan unwind remaining majority stake zoetis,19,0,1
2013-05-23,0.3591855524723963,negative,feature take shot vaccine evasive superbug rpt feature take shot vaccine evasive superbug,13,0,0
2013-06-12,0.8628995474664447,positive,teva sun pharma pay bln settle patent suit settle patent lawsuit teva sun pharma bln,15,-1,0
2013-06-24,1.3716829384921692,negative,shareholder snap up remaining zoetis,5,0,1
2013-07-01,1.4070971592184067,negative,novartis join bidding onyx source,5,0,1
2013-07-10,0.2811253079418874,positive,get eu approval wider use prevenar vaccine refile get eu approval wider use prevenar vaccine,15,1,0
2013-07-15,0.4514870827483364,negative,get fresh cancer rejection uk cost body,7,0,0
2013-07-18,1.2102646441967346,negative,not move forward takeover bid onyx source,7,0,0
2013-07-29,0.8863140921282042,positive,split generic branded unit internally split generic branded operation,9,0,0
2013-07-30,0.4400812458899228,positive,settle marketing case related rapamune earnings top estimate reiterates forecast settle marketing case dating wyeth conduct income beat estimate stand full outlook cost control help weather weak wrapup cost control help weather weak,33,1,0
2013-08-02,0.7232353480959519,positive,analysis small cap fund try boeing,6,0,0
2013-09-27,1.7219338255402006,positive,corrected fda warns tygacil raise risk death fda warns tygacil raise risk death,13,1,1
2013-09-30,0.0038754672786245,negative,bayer name brandicourt head bayer appoints brandicourt head,8,0,0
2013-10-03,0.0947938799596981,positive,fda approves menopause symptom,4,2,0
2013-10-08,0.1630770062217457,negative,reshaped plan fine tune research spending,6,0,0
2013-10-09,0.1045375082971533,positive,show mixed result psoriasis trial show mixed result psoriasis trial,10,0,0
2013-10-22,0.3419241908203974,positive,commits developing pain therapeutic painkiller continue developing pain therapeutic painkiller,10,0,0
2013-10-29,1.1256822615913764,positive,3rd qtr profit beat estimate oncology shine q3 profit beat estimate oncology shine corrected 3rd qtr profit beat estimate oncology shine third profit beat estimate oncology shine,27,1,0
2013-11-18,0.2401593071055363,negative,get fda approval additional use xeljanz rheumatoid arthritis,8,2,0
2013-11-21,0.6502166912423668,negative,gsk initiate novel combination therapy study patient melanoma,8,0,0
2013-11-22,0.031060259605331,negative,novartis chase hot breast cancer area,6,0,0
2013-11-25,0.1618185164601437,positive,india press set change india management structure line global model mint,11,0,0
2013-12-04,0.1712803125315742,positive,expand clinical access researcher patient,5,1,0
2013-12-09,0.1274048388207216,negative,high court leaf intact mln verdict justice leave intact neurontin verdict high court leaf intact million verdict,17,0,0
2013-12-16,0.6232103757273677,negative,iemens cooperate diagnostic test,4,0,0
2013-12-17,0.0455915025195152,negative,allow teva sell generic viagra,5,0,0
2013-12-31,0.6687925082016655,negative,china halt import paperwork glitch,5,0,0
2014-01-14,0.4164530622963402,positive,exclusive valeant actavis mylan eye generic unit,7,0,0
2014-01-27,0.937123784321503,negative,lung cancer fails late stage study lung cancer fails large study,11,-1,0
2014-01-28,1.9669014021872933,positive,stock wall st recovers future up turkey rate hike stock wall st rebound fed apple sink,16,1,1
2014-02-03,2.908427905716393,positive,breast cancer succeeds mid stage trial,6,0,1
2014-02-04,2.044632976177363,positive,pulse microsoft aol zynga furiex enzo biochem,7,0,1
2014-02-06,0.6988168385394955,negative,beat back generic competition lyrica,5,1,0
2014-02-13,0.231564920049454,negative,face legal action australian competition regulator,6,-1,0
2014-02-24,1.12999952970243,positive,prevnar prevents pneumonia elderly study study show prevenar prevents pneumonia people older,12,0,0
2014-03-06,1.1145241465211453,negative,recall antidepressant report wrong bottle,5,-1,0
2014-03-12,1.3838920436602289,negative,court invalidates celebrex patent reissue prevnar almost half elderly pneumonia study court invalidates celebrex patent generic loom,17,0,1
2014-03-25,0.5733791158111012,positive,lung cancer beat chemo previously untreated patient,7,1,0
2014-04-03,0.4730219139206348,positive,integragen jump pct collaboration deal apple others form go slow patent lobby group apple others form go slow patent lobby group,21,-1,0
2014-04-07,1.8799244125177528,negative,stock wall st flat momentum stock stabilize drag stock wall street fall broad weakness drag,15,-3,1
2014-04-17,0.3920508039153558,positive,teva settle patent lawsuit over blockbuster painkiller teva settle patent lawsuit over painkiller celebrex teva settle patent suit over celebrex,20,1,0
2014-04-21,1.667797770057078,positive,agrees million settlement over generic neurontin agrees mln settlement over generic neurontin astrazeneca cancer pipeline seen draw,17,0,1
2014-04-22,0.0007865486748803,negative,astrazeneca up pct higher takeover approach novartis shake up astrazeneca report lift pharma stock,14,1,0
2014-04-24,0.8818927822035638,negative,astrazeneca flag cancer advance silent bid talk,7,0,0
2014-04-29,1.3394469995466671,negative,pay cash top billion win astrazeneca ceo fly pitch astra deal uk pay cash top bln win astrazeneca rpt fitch astrazeneca combo would achieve strategic aim weak pipeline fuel hunger astrazeneca tax arbitrage hasten deal,35,1,1
2014-04-30,1.8096039867375069,negative,gsk staying sideline astra fight uk lawmaker plan probe pursuit astrazeneca,11,-1,1
2014-05-05,2.7605339590549227,negative,sale way off mark pursues astrazeneca day researcher would massive presence astra merger signal open hostile option astrazeneca 1st sale disappoint generic drag result rpt expected patient face astrazeneca rejection,30,-2,1
2014-05-07,1.0986121467215335,negative,british pm tell want commitment astrazeneca deal astrazeneca takeover would benefit science british pm want assessment takeover bid astrazeneca uk consider takeover test astrazeneca cameron spokesman astrazeneca takeover would benefit science british pm want commitment potential astrazeneca takeover,38,1,0
2014-05-09,0.6291352595329758,negative,sign rare disease deal uk university britain want binding pledge astrazeneca bid under fire europe weighs next astra move,19,1,0
2014-05-12,0.6291401703229393,negative,commitment uk legally binding rd head press case astrazeneca deal considers raising bid astrazeneca bloomberg defends powerhouse astra deal ceo brace grilling rpt commitment uk legally binding defends powerhouse astra deal ceo brace grilling,34,0,0
2014-05-15,0.7405710948003241,positive,eu almunia ha not discussed astrazeneca bid regulator promising cancer help astrazeneca fight sweden finance minister ready hear astra bid,20,1,0
2014-05-16,0.1403822806501864,negative,wedish minister urge astra owner consider rebuff weden fight back move astra threatens job apply early approval breast cancer,19,0,0
2014-05-21,0.2515750785545334,positive,ee later slim deal hope prop up astrazeneca astra need fresh start later,13,1,0
2014-05-22,0.0611435794065196,positive,blackrock want astra talk later date source blackrock want astra talk later date source,14,0,0
2014-05-23,0.9740275327528748,negative,psoriasis succeeds late stage trial,5,0,0
2014-05-27,0.2077396112274421,negative,astrazeneca fall walk away,4,-1,0
2014-05-28,0.0730994154481301,positive,italy seek anti trust compensation roche novartis,7,0,0
2014-05-29,0.5510678079259423,negative,hisun pharma unit jv luxembourg ha started production cancer meeting showcase astrazeneca prized,13,0,0
2014-06-02,0.1558176751443207,positive,pay million neurontin settlement pay mln neurontin settlement,8,-1,0
2014-06-11,0.1103601261500886,positive,astra quest failed due,4,0,0
2014-06-12,0.7759406279352454,positive,hsbc could big winner shareholder case,6,0,0
2014-06-13,0.0331996842733106,negative,linked payouts complex fix next astra bid dealtalk linked payouts complex fix next astra bid,15,0,0
2014-06-18,0.0462167518632261,positive,french cellectis surge sign cancer deal cellectis rise pct deal sign cancer immunotherapy deal france cellectis,16,3,0
2014-06-27,0.0759285351755068,positive,clot win eu green light wider use,7,1,0
2014-07-08,0.4721142938687195,negative,win dismissal class action ahead trial,6,1,0
2014-07-16,1.438489337944393,positive,clotting dose reduces bleeding rate,5,0,1
2014-07-25,0.0262367553978348,negative,astrazeneca result get lift bid foe,6,1,0
2014-07-28,0.3385732158445842,negative,need deal loom larger earnings report,6,0,0
2014-07-29,0.79950888349547,negative,beat forecast oncology grow leaf guessing intention astra looking deal decline comment interest astrazeneca,14,1,0
2014-07-30,0.7215895072948508,negative,buy baxter vaccine unit mln buy baxter vaccine unit million corrected buy baxter vaccine mln,15,1,0
2014-07-31,0.0609441802946086,positive,astrazeneca raise forecast seeing off astra ceo nov day focus progress no comment astrazeneca smash forecast q2 seeing off,19,1,0
2014-08-01,0.8630482839275588,positive,bid gsk ha merit corrected threat manager force staff lockout mumbai factory threat manager force staff lockout mumbai factory,19,0,0
2014-08-06,0.4888337299746137,negative,reach mln settlement over marketing rapamune pay mln state settle rapamune claim pay million state settle rapamune claim,18,-1,0
2014-08-08,0.0869862108433983,negative,insight confronts surge lawsuit over lipitor confronts surge lawsuit over lipitor,11,1,0
2014-08-12,0.4624510264366166,negative,help 23andme unravel genetic tie bowel disease,7,0,0
2014-08-21,0.5338728756203115,negative,back astrazeneca end move seen likely,6,0,0
2014-08-26,1.6299801889020804,positive,test xalkori lung cancer immunotherapy rpt test xalkori lung cancer immunotherapy,11,0,1
2014-09-02,0.3925041943012686,negative,exclusive back normal astrazeneca ceo despite rumor,7,0,0
2014-09-04,0.0425975877013096,positive,vectura partner novartis sign marketing deal uk,7,1,0
2014-09-12,0.0908677484021014,negative,ranbaxy win dismissal lawsuit over generic lipitor ranbaxy win dismissal lawsuit direct purchaser plaintiff over generic lipitor,17,1,0
2014-09-23,0.1416839991804419,positive,approach actavis gauge interest deal bloomberg approach actavis gauge interest deal bloomberg,12,0,0
2014-10-14,0.1898656343372495,negative,fda staff recommend keep black box warning anti smoking,9,0,0
2014-10-16,1.6523819401157658,negative,fda vote keep black box warning anti smoking fda panel vote keep severe warning anti smoking,16,0,1
2014-10-23,0.1024183009363799,negative,court upholds patent cancer board authorizes billion repurchase,8,1,0
2014-10-24,1.0137097811989015,positive,billion buyback plan deflates astrazeneca bid hope,7,0,0
2014-10-27,0.1373661039375528,negative,end deal pain therapeutic develop durect pain,7,0,0
2014-10-28,0.9403400969079768,negative,beat q3 forecast mum likely future deal executive treasury rule hamstring inversion deal beat sale profit forecast mum future deal ceo inversion deal still potential option,26,1,0
2014-10-29,1.5262450264342475,positive,meningitis vaccine win approval fda meningitis vaccine win approval,9,2,1
2014-11-06,0.400316299782788,negative,india unit report q2 loss plant lockout cost tax change weaken case bid astrazeneca ceo,15,-1,0
2014-11-13,0.1127672090482034,negative,gate foundation expand contraceptive access poor nation,7,0,0
2014-11-14,0.2874718758536398,negative,astrazeneca not game town deal hungry dealtalk astrazeneca not game town deal hungry,13,0,0
2014-11-17,0.1295701850385633,negative,deal make competitive immuno oncology dampens astra bid hope german cancer deal kgaa deal exclusive german cancer immunotherapy deal,19,0,0
2014-11-18,0.3131171630233798,positive,astrazeneca ceo hard comment whether return astrazeneca trumpet solo strength cancer snubbing,12,0,0
2014-12-03,0.1838560751378004,positive,wada sign deal ped information,5,1,0
2014-12-08,0.605749693399027,positive,bet gene therapy technology come age,6,0,0
2014-12-11,1.16612327477138,negative,fda warns antipsychotic could cause fatal skin reaction,8,0,0
2014-12-22,0.0096266833306435,positive,thailand press expects pharma recovery bangkok post,7,0,0
2015-01-08,0.2663118535170428,positive,fda talk prescription detail key breast cancer,7,0,0
2015-01-12,1.150888189513799,positive,partner dna research firm study lupus disease,7,0,0
2015-01-13,0.7257454835169597,negative,developing pcsk9 pill vaccine lower cholesterol,6,0,0
2015-01-20,0.7013722309719972,positive,msf slam expensive vaccine urge gsk cut,7,0,0
2015-01-26,0.8444018227109495,positive,cut vaccine poor gavi group seek billion cut vaccine poor gavi group seek bln,14,-1,0
2015-01-27,0.7092996336039437,positive,forecast disappoints crimped generic dollar pay million avert class action trial ceo doesnt need big deal,16,-1,0
2015-02-03,0.2770809393165985,negative,fda approves high profile breast cancer fda approves ibrance breast cancer,11,2,0
2015-02-06,0.8221578236102589,positive,rpt hospira deal bet spike specialty generic,7,0,0
2015-02-09,0.1461024257725984,positive,billion accelerated buyback deal goldman sachs bln accelerated buyback deal goldman sachs,12,0,0
2015-02-20,0.1641373573671556,negative,sanofi bos could earn total le,6,0,0
2015-02-26,0.0838312156641318,negative,lament narrow recommendation meningitis vaccine novartis meningitis vaccine scope narrow,10,0,0
2015-03-09,0.2378313963284695,negative,fda warns seizure alcohol risk chantix fda warns seizure alcohol risk chantix fda decline remove serious warning chantix fda decline remove serious warning chantix,24,-1,0
2015-03-12,0.1711854953417413,negative,pain lyrica fails study adolescent fibromyalgia hunt vaccine protect young old,11,-1,0
2015-03-23,2.53062408193675,positive,resume late stage study testing pain resume study testing pain,10,0,1
2015-04-02,0.2141019963971979,negative,shutter vaccine sale china,4,0,0
2015-04-13,0.5352898493201419,negative,mylan settle viagra patent litigation,5,0,0
2015-04-14,0.3622940651902717,negative,spar zoloft plaintiff over deadline expert,6,0,0
2015-04-15,0.0651365065537312,positive,astrazeneca science move bid approved breast cancer impress latest study,10,0,0
2015-04-17,0.7240966786462577,positive,win first trial over zoloft birth defect risk,8,1,0
2015-04-28,0.6358930374389948,negative,quarterly revenue fall stronger dollar cut full forecast stronger dollar,10,-1,0
2015-04-30,0.0478266905494795,negative,exclusive mystery bidder rare disease drugmaker sobi source,8,0,0
2015-05-11,0.3009037360299671,positive,dksh support expansion lao,4,0,0
2015-05-13,0.7591323227282509,negative,group ada doesnt entitle blind worker driver show early promise xalkori resistant lung cancer study,15,1,0
2015-05-18,0.3400963728522499,negative,geratherm medical apoplex medical technology cooperate field stroke,8,0,0
2015-05-28,0.5209982440284477,positive,fda app prof treat rare lung disease fda approves treat rare lung disease,13,2,0
2015-06-11,0.110114100755343,positive,jury clear second trial alleging zoloft birth defect jury clear second trial over zoloft,14,1,0
2015-07-07,0.7952323837365327,positive,zoloft plaintiff set spar second hearing expert witness,8,0,0
2015-07-14,0.2890313961986468,positive,offer concession bid win eu okay hospira deal,8,2,0
2015-07-15,0.2423520076395124,negative,refile indian unit intends close navi mumbai plant,8,0,0
2015-07-28,1.698069186220308,positive,revenue profit beat vaccine sale rise revenue fall,8,2,1
2015-08-04,0.0848393694583338,positive,win eu approval billion hospira buy corrected win eu approval bln hospira buy,13,3,0
2015-08-06,0.9816920021433416,negative,britain rap over huge jump epilepsy britain rap over inflated epilepsy cma issue statement objection flynn pharma anti epilepsy probe,20,-1,0
2015-08-07,0.2632501374439377,positive,revive cancer rev up immune system insight revive cancer rev up immune system rpt insight revive cancer rev up immune system,21,0,0
2015-09-09,0.3848631696744209,negative,evotec enters licence collaboration agreement,5,0,0
2015-09-10,1.5054181766689825,positive,loses uk patent case over use lyrica pain,8,0,1
2015-09-18,0.2259517768880115,negative,judge trim poultry vaccine suit zoetis,6,0,0
2015-09-30,0.6089737526458361,negative,lift fy adjusted profit forecast hospira buy,7,2,0
2015-10-01,1.0871388959021289,positive,kgaa avelumab alliance track corrected kgaa avelumab alliance track,9,0,0
2015-10-14,0.6613291908148411,positive,fda decline expand approval arthritis,5,1,0
2015-10-27,2.632650741818787,positive,profit beat vaccine sale rise begin human trial oral form pcsk9 inhibitor treat cholesterol revenue fall pct strong dollar,19,2,1
2015-10-28,0.1673504934580183,positive,allergan considering combination cnbc citing,5,0,0
2015-10-30,2.272668413370904,negative,rpt allergan spark fresh tax inversion angst capitol hill,9,0,1
2015-11-02,2.4833790812913925,positive,factbox allergan put focus tax inversion rule,7,0,1
2015-11-03,0.5466405297479993,negative,partner south africa produce pneumococcal vaccine gsk bos silent report drugmaker rebuffed,12,0,0
2015-11-04,1.278937803562319,negative,kgaa widen development cancer immunology,5,0,0
2015-11-06,0.5918731269812016,negative,big spending hard lobbying eye tax home rpt big spending hard lobbying eye tax home allergan deal would set up split rpt allergan deal would set up split,28,0,0
2015-11-13,0.7634385339640781,positive,allergan deal refocuses tax inversion rule allergan deal refocuses tax inversion rule,12,0,0
2015-11-16,1.8513154656321529,negative,insight ha shifted profit overseas exclusive moelis clinch advisory role help eric cantor source ha shifted profit overseas,18,0,1
2015-11-17,0.8015975455720858,negative,rpt insight ha shifted profit overseas,6,0,0
2015-11-18,0.2479996851078247,negative,discussing allergan offer source discussing allergan offer source kgaa receive fda breakthrough status avelumab allergan talk accelerate amid inversion clamp down,21,1,0
2015-11-19,2.975907693294888,negative,unveils inversion rule unlikely thwart ervier get right cellectis cancer cell therapy bln plan high risk low benefit allergan final stage merger talk cnbc exclusive negotiating allergan break up fee source fund optimistic allergan piled bid allergan final stage merger talk cnbc,42,1,1
2015-11-20,0.7050837461269777,negative,exclusive allergan ceo agree combined role source,7,0,0
2015-11-24,1.9088440711617196,positive,aunders get key job allergan combine delay split material adverse event allergan get no support scaredy arb politician slam tax avoiding allergan deal,23,-1,1
2015-11-25,2.829469262250228,positive,war chest stealthily rebuilt allergan lyrica show no relief post traumatic nerve pain,13,0,1
2015-11-27,0.3580400085943402,negative,rpt decade mission pay off guggenheim deal king,8,-1,0
2015-12-03,0.1498738386308096,negative,block key plaintiff expert zoloft mdl,6,0,0
2015-12-14,0.1309524534828465,negative,suit over advil marketing get green light,7,0,0
2015-12-22,0.7225801339698856,negative,defeat nyu claim cancer royalty,5,0,0
2016-01-08,0.1762275470110097,negative,hike over,2,0,0
2016-01-12,1.0321286929692142,negative,allergan combined pipeline underappreciated allergan research chief immuno oncology pipeline underappreciated,11,0,0
2016-01-13,0.4618046738807613,positive,car cancer therapy could outshine rival weighing sale hospira pump bloomberg weighing sale hospira pump bloomberg court upholds patent cancer sutent,21,1,0
2016-01-22,1.6264158685345365,negative,loses cancer patent term fight federal circuit,7,0,1
2016-01-28,1.5694070390487205,negative,biosimilar win norwegian infliximab biosimilar tender,6,1,1
2016-02-02,1.7027788666416188,positive,revenue rise pneumonia vaccine sale jump forecast disappoints see no legal roadblock allergan merger,14,1,1
2016-02-03,1.1635291292705574,negative,jj evaluating technology zika vaccine,5,0,0
2016-02-08,0.2729126360758616,negative,unveils management line up combined create operating unit allergan deal close,11,0,0
2016-02-12,1.272124689189913,negative,novartis sandoz buy biosimilar infliximab eea,6,1,0
2016-02-16,0.1551307304720417,negative,unit pay mln medicaid rebate settlement corrected unit pay mln medicaid rebate settlement,13,-1,0
2016-03-11,1.4616507028230918,positive,medecins sans frontieres file block patent pneumonia vaccine india fda approves lung cancer expanded use,15,2,1
2016-03-14,1.1832474528363337,negative,indian court stay ban corex cough syrup tv corrected indian court grant stay ban popular cough syrup indian court grant temporary relief cough syrup ban,25,-1,0
2016-03-18,0.0158411970974103,negative,xeljanz meet goal ulcerative colitis trial,6,1,0
2016-03-28,1.0564237272184474,negative,appeal court upholds verdict diet case,6,0,0
2016-03-30,0.3722162087573144,negative,allergan get request additional information ftc,6,0,0
2016-03-31,1.1873017952663043,negative,press release pricing fake,4,0,0
2016-04-04,2.587444141830808,positive,allergan conducting review department treasury action refile inversion rule threaten allergan deal conducting review treasury action wont speculate potential impact statement wont speculate impact treasury inversion move,27,0,1
2016-04-07,0.6803433903487033,positive,stick ceo allergan deal scrapped,5,0,0
2016-04-08,1.0633262082267891,negative,rating affirmed off watch terminated acquisition plan outlook stable,9,1,0
2016-04-12,0.7117737412592806,negative,lawsuit over celebrex bextra safety revived must face revived celebrex bextra safety lawsuit,13,0,0
2016-04-19,0.543210325871657,positive,report confimatory approved cancer ibrance,5,0,0
2016-04-20,0.9384596714211436,positive,canada partnered rexall service called onestopmeds,6,0,0
2016-04-27,0.3571101711215996,negative,pay million resolve wyeth false claim lawsuit,7,-1,0
2016-04-28,0.6348480531297551,positive,declares second dividend,3,0,0
2016-04-29,0.0678312911885359,negative,obi extends manufacturing agreement,4,0,0
2016-05-03,3.614218826835758,positive,doe not expect seek tax inversion deal near term ceo still interested deal losing allergan approach medivation potential takeover source report q1 adjusted earnings,24,0,1
2016-05-04,0.3323841908652647,negative,exclusive approach medivation potential takeover source,6,0,0
2016-05-05,0.5284903527176033,positive,mull actually strategy,3,-1,0
2016-05-10,1.3025180285797466,negative,canada canada ha given conditional approval ibrance tm first dosing dart candidate phase study trigger milestone payment macrogenics,18,1,0
2016-05-12,0.0614157249290592,positive,report pct passive stake wave life science,7,0,0
2016-05-13,0.8714189664513095,positive,present result phase trumenba study block use lethal injection block use lethal injection ny time baupost took mln allergan stake deal collapsed,22,0,0
2016-05-17,0.1151763102449354,negative,anacor deal showcase wave eczema therapy ban lethal sale complicates execution state buy anacor billion deal access eczema gel,19,0,0
2016-05-18,0.3945683527834642,positive,cancer show promise combo keytruda novartis breast cancer set take ibrance german immunotherapy show promise rare skin cancer ibrance delay breast cancer progression study ibrance delay breast cancer progression study,30,0,0
2016-05-19,0.979599192449343,positive,park therapeutic announce initial subject hemophilia trial right chief urge firm follow lead death penalty,15,0,0
2016-05-20,0.4467525927128513,positive,ema acceptance trumenba marketing authorization application review,7,0,0
2016-05-23,0.0712101847553325,negative,europe lift warning smoking cessation,5,1,0
2016-05-26,0.2042283606798811,positive,anacor received rival bid deal filing anacor reveals receiving rival bid deal filing,13,0,0
2016-05-31,0.4503034786950688,positive,biorap technology enters agreement billion debt offering,7,0,0
2016-06-03,0.2174950657202856,negative,ex oppenheimer adviser arrested trading employee tip,7,0,0
2016-06-07,0.413791123841345,negative,announces positive top line result second phase oral xeljanz trial,10,1,0
2016-06-08,0.8508435915063339,positive,fda advisory committee recommend alo extended release capsule approval fda panel back approval opioid painkiller present rheumatoid arthritis xeljanz fda panel back approval opioid painkiller,25,1,0
2016-06-09,0.3067636008205698,positive,dksh expand collaboration thailand,4,1,0
2016-06-10,0.891112019175877,positive,icon announces service agreement icon signed agreement,7,0,0
2016-06-14,0.9163233238702496,positive,hire buy bowel right drugmaker shire buy bowel right hire license investigational gastric,13,1,0
2016-06-20,0.1742285713852265,positive,oracle announces selection oracle cloud clinical management,7,0,0
2016-06-23,0.954125840481712,negative,declares q3 dividend,3,0,0
2016-06-24,1.7984824044180892,positive,completes acquisition anacor,3,0,1
2016-06-28,0.0898884725193172,positive,invest mln china hub first asia invest million china hub first asia additional late stage study cholesterol met goal,19,0,0
2016-07-01,0.812391930721823,positive,bind therapeutic file motion sale asset accepting stalking horse bid,10,0,0
2016-07-06,0.460153466560298,negative,leukemia bosulif ha backing uk national institute care excellence bloomberg germany begin large ovarian cancer trial,16,0,0
2016-07-07,0.1889684833552785,negative,refile germany kgaa initiate phase iii trial court approves bankrupt bind sale plan following offer,15,1,0
2016-07-08,0.5105709540519587,negative,announces positive top line result phase trac trial,8,1,0
2016-07-12,0.4773742907895117,negative,fda expands use best selling pneumonia vaccine receives fda approval prevnar,11,3,0
2016-07-13,0.207113002230741,positive,publishes result pivotal phase study crisaborole topical ointment,8,0,0
2016-07-19,0.1016598104090604,positive,get prequalification multi dose vial presentation prevenar,7,0,0
2016-07-25,0.380467246530658,positive,park therapeutic announce first cohort hemophilia phase trial bind therapeutic bidder join stalking horse bid,15,1,0
2016-07-26,0.0897832797693398,positive,exclusive teva mylan eye brazil venture source bind therapeutic determines mln bid highest,13,0,0
2016-07-28,0.6039295295673486,negative,western oncolytics announce immuno oncology research collaboration bind therapeutic entered asset purchase agreement announces positive top line result phase maintenance trial oral xeljanz,23,2,0
2016-07-29,0.4384881570275611,positive,anofi celgene interested medivation cnbc citing source,7,0,0
2016-08-01,1.2214201658702573,positive,acquires bamboo therapeutic beef up gene therapy arsenal,8,0,0
2016-08-05,0.007148695665804,positive,astrazeneca hit bid helped woe,5,1,0
2016-08-11,0.4071354115113168,negative,offsetting foreign currency exposure wa bln,6,0,0
2016-08-12,0.3967506124574971,negative,appaloosa lp dissolve stake rental sec filing,7,0,0
2016-08-15,0.0832636697478239,positive,paulson cut stake jana partner dissolve sole stake nxp semiconductor,10,0,0
2016-08-16,0.3956564840072563,negative,circuit reject apotex challenge antibiotic patent,6,-2,0
2016-08-19,0.4505445979632871,negative,fda approves troxyca er extended release capsule cii pain management,10,2,0
2016-08-22,0.3956556259830379,negative,medivation buy seen prescribing boost cancer roster billion medivation deal medivation deal not affect split up decision acquire medivation bln buy medivation bln deal medivation pay fee mln upon deal termination update boost cancer roster bln medivation deal,38,1,0
2016-08-24,0.2579666794105928,negative,astrazeneca sell antibiotic buy antibiotic astrazeneca,6,1,0
2016-08-30,0.4902182044783987,negative,clovis enters first amendment license agreement clovis,7,0,0
2016-08-31,0.0550435777083246,positive,european commission ha approved xalkori treatment adult lung cancer,9,0,0
2016-09-07,0.2104559756499147,positive,appoints chief scientific officer neuroscience research,6,0,0
2016-09-08,0.1161316051717542,negative,ceo clinton plan curb would hurt consumer antolrx announces series equity funding jdrf orion equity partner,16,0,0
2016-09-09,0.6077670742696828,positive,medivation file premerger notification clinton spokeswoman defends plan comment,9,0,0
2016-09-12,0.1781709422608246,positive,fda staff neuropsychiatric risk quit smoking varies study trial design ha limitation fda staff flag concern quit smoking study rpt fda staff flag concern quit smoking study,27,-1,0
2016-09-14,0.2562529216083575,negative,fda panel recommends dropping serious warning chantix fda panel vote favor removing boxed warning quit smoking chantix,17,0,0
2016-09-15,0.4100234526940083,negative,investigational ertugliflozin met primary endpoint oncoimmune announces option license agreement,10,0,0
2016-09-16,0.2012374234517722,negative,ema advisory panel recommends nod breast cancer report positive top line result reflection b537 study pf ema panel recommends nod breast cancer,22,2,0
2016-09-20,0.4707999080888481,positive,teva take aim lillypfizer pain,5,0,0
2016-09-22,1.0093781229470131,negative,declares fourth dividend,3,0,0
2016-09-23,0.870035428191196,positive,announces expiration hart scott rodino waiting period acquisition medivation,9,0,0
2016-09-27,0.0559962175715522,negative,fitch scrapped split decision not affect rating,7,0,0
2016-09-28,0.0234017640977413,negative,completes acquisition medivation showcase progress broad based oncology portfolio esmo congress,11,0,0
2016-10-04,0.628546107092065,positive,theravance biopharma unit enters fourth amendment,6,0,0
2016-10-06,0.8070239472191099,negative,sell nyc hq end cnbc citing dj icu medical buy infusion therapy bln sell infusion icu medical take stake seek modern headquarters manhattan icu medical buy hospira infusion system bln cash stock seek modern manhattan headquarters,36,1,0
2016-10-10,0.3718515765945618,negative,exelixis face off kidney cancer announces result phase trac clinical trial exelixis compete kidney cancer trial,16,0,0
2016-10-11,0.1651879514365406,negative,transgene announces collaboration kgaa darmstadt germany evaluate combination tg4001 avelumab,10,0,0
2016-10-13,0.6098532237775123,negative,loses appeal uk patent case over use lyrica pain icu medical termination right connection hospira deal include payment mln,19,0,0
2016-10-17,0.1426783588742264,negative,start shipping biosimilar version jj remicade set start shipping remicade biosimilar next month begin shipping inflectra wholesaler late,18,1,0
2016-10-18,0.0416215346683124,negative,jj lose ground fear answer remicade,6,0,0
2016-10-19,0.5420263776143686,negative,awarded grant evaluate vaccine newborn cdc acip vote recommend dosing schedule vaccination trumenba,13,0,0
2016-10-20,0.0026197650578763,positive,debiopharm report clinical collaboration kgaa,5,0,0
2016-10-21,1.1530816503575458,negative,advent bain gain edge bid brazil venture source,8,1,0
2016-11-01,1.2937516028535434,negative,novartis breast cancer get fda fast track take discontinues global development bococizumab investigational pcsk9 inhibitor q3 adjusted eps cholesterol fizzle hitting q3 worldwide ibrance revenue mln mln last cholesterol lost potency wks,32,0,0
2016-11-02,0.8142945798412349,negative,china approves vaccine prevenar prevenar receives approval use china vaccine prevenar gain approval china,14,3,0
2016-11-03,1.9582196971222543,negative,park therapeutic report updated hemophilia phase trial,7,0,1
2016-11-04,0.4781779520151685,positive,ltd sept qtr profit up pct fuelcell energy announces completion megawatt power plant installation,14,0,0
2016-11-07,0.9390350518057478,negative,present additional research xeljanz rheumatologic disease,6,0,0
2016-11-08,0.7137214873552788,negative,closing british site not brexit related,6,0,0
2016-11-09,6.006462103865951,positive,novartis cut win uk approval cancer exclusive weighs sale spin off consumer unit source,14,2,1
2016-11-10,4.015697576170973,positive,deliver eliquis scientific session win eu approval ibrance novartis ready rival,11,3,1
2016-11-11,2.456869638499859,negative,offer cut pneumonia shot humanitarian crisis announces major expansion humanitarian assistance program,12,0,1
2016-11-14,0.7229194811551154,negative,paulson cut stake raise stake facebook billion debt offering announces tender offer collaborate national cancer institute,16,1,0
2016-11-15,1.2435264160900683,negative,announces result phase opal clinical development program investigating xeljanz,9,0,0
2016-11-18,0.5641411011936603,negative,announces pricing tender offer pct senior note due sue texas agency releasing confidential information,14,0,0
2016-11-21,0.4692501884280498,negative,global supply president retire,4,0,0
2016-11-22,0.9555404054615968,negative,quintilesims form collaboration kgaa darmstadt germany generate real world insight usage anti cancer therapy across europe,16,0,0
2016-11-29,1.0097866175414971,positive,german get fda priority review cancer,6,1,0
2016-11-30,0.9291393090443356,positive,herceptin biosimilar succeeds key breast cancer study announces positive top line result pivotal comparative reflection b3271002 study pf,18,1,0
2016-12-01,1.7481975734267683,negative,pain lyrica meet goal late stage pediatric epilepsy study ibm announced collaboration utilize ibm watson discovery,16,1,1
2016-12-05,0.7273394234777686,negative,blood cancer top standard therapy untreated patient blood cancer bosulif effective untreated patient avillion announce positive top line result phase bfore study bosulif,23,3,0
2016-12-07,2.4804481398478795,negative,medadvisor sign patient engagement program appeal aspect decision uk cma britain fine record million huge hike uk cma fine flynn pharma epilepsy hike britain fine record mln huge hike,29,1,1
2016-12-09,1.8523249521987808,positive,akili present positive digital biomarker study,6,1,1
2016-12-12,2.3229849072805453,positive,declares first dividend,3,0,1
2016-12-13,0.6597593885219633,positive,ab initio biotherapeutics announces strategic collaboration discover gpcr activating antibody,10,0,0
2016-12-14,0.794965960169014,positive,xtandi fails progression trial jj zytiga phase plato study not meet primary endpoint inteliwise sign deal fda approves eczema ointment fda approves ointment chronic itchy skin condition xtandi fails progression trial jj zytiga,33,2,0
2016-12-16,0.4692781005873336,positive,fda drop black box warning anti smoking chantix fda drop black box warning anti smoking ema recommends approval lifmior,19,0,0
2016-12-19,0.248192411558501,negative,catalyst bioscience secures right manufacturing process marzeptacog alfa wyeth llc wholly owned subsidiary portola pharmaceutical enters loan agreement receives approval european union nimenrix infant six week age older,28,1,0
2016-12-20,0.3248358861552392,negative,draper build preclinical microphysiological system help predict clinical outcome,9,1,0
2016-12-21,1.0915988723709913,negative,bioinvent enters research collaboration issue,5,0,0
2016-12-23,0.2864801680448003,positive,astrazeneca completes sale antibiotic completes acquisition small molecule anti infective astrazeneca,11,0,0
2016-12-30,0.3347247434372979,positive,growth hormone deficiency opko fails study,6,0,0
2017-01-04,0.2838682507798173,positive,absorption system announces technology licensing agreement park therapeutic announces mln milestone payment escape lipitor mdl diabetes link fails,18,-1,0
2017-01-05,1.040695294178262,positive,announces positive top line result study potential humira biosimilar,9,1,0
2017-01-18,0.3145690224869657,negative,enters delegation authority astrazeneca pharma india,6,0,0
2017-01-26,0.0725863592484388,positive,report positive top line result phase study investigational clostridium difficile vaccine,11,1,0
2017-01-27,0.6045497931366772,positive,receives positive chmp opinion europe xeljanz,6,1,0
2017-01-30,0.2700722240109421,positive,ltd dec qtr profit up pct,6,0,0
2017-01-31,1.3502154998182525,positive,q4 lyrica ih revenue wa bln mln yr ago see prevnar sale flat slightly down ceo no need alter pricing practice report q4 reported diluted eps profit miss vaccine sale lag cost rise quarterly revenue slip,36,-2,1
2017-02-02,0.1235504803164921,positive,hire jpmorgan weigh bln portfolio sale bloomberg citing source hire jpmorgan weigh sale bloomberg uk agency breast cancer expensive hire jpmorgan weigh sale bloomberg,24,0,0
2017-02-03,0.445284654429301,positive,commences billion accelerated repurchase,4,0,0
2017-02-06,0.6150481659055074,positive,icu medical completes acquisition hospira infusion system,7,0,0
2017-02-13,0.2594525811635995,positive,report pct stake icu medical,5,0,0
2017-02-14,0.0297831520468472,positive,paulson ups stake,3,0,0
2017-02-16,0.4133943100493753,positive,announces top line result oral strategy trial xeljanz compared humira,10,0,0
2017-02-17,0.1576324978116883,negative,crohn disease patient show similar efficacy safety profile inflectra remicade,10,0,0
2017-02-21,0.5955204492306798,negative,fda accepts regulatory submission inotuzumab ozogamicin,6,0,0
2017-02-22,0.0004313831496682,negative,six swiss approved delisting cancel listing kingdom,7,0,0
2017-02-23,1.3315084212029094,positive,ronald blaylock elected board director monitoring potential impact related change aca,11,0,1
2017-02-24,0.4603157083163056,positive,subpoenaed over patient assistance plan announces pricing bln debt offering,10,0,0
2017-02-28,0.1968275424209298,negative,fda warns over contaminated kansa plant fda accepts biologics license application avelumab priority review kgaa get priority review bladder cancer,20,1,0
2017-03-01,0.5205041670198751,negative,park therapeutic spk granted access priority program,7,1,0
2017-03-06,0.1946780975711215,negative,announce fda ema filing acceptance,5,1,0
2017-03-09,0.2860385740132809,positive,ervier announce fda clearance ind application ucart19,7,2,0
2017-03-13,0.050484243789417,negative,novartis win fda approval breast cancer aiming ibrance,8,3,0
2017-03-14,0.70514618417028,positive,launch zavicefta uk germany novartis win approval breast cancer compete ibrance,11,3,0
2017-03-15,0.3327844333747887,positive,announces approval china fda xeljanz ny jury convict ex law firm partner insider trading king deal,16,1,0
2017-03-16,0.3808396400586278,negative,ceo ian read total compensation wa mln,7,0,0
2017-03-23,0.4154832912389494,negative,fda approves german immunotherapy skin cancer,6,2,0
2017-03-24,0.7730882120271065,negative,ltd news usfda observation hospira vizag unit doe not relate india,11,0,0
2017-03-28,0.7861963277531858,negative,uda enters feasibility agreement,4,0,0
2017-03-30,0.2601591798911284,negative,take fight over missouri court reach 8th circuit,8,0,0
2017-04-07,0.0726220059695359,positive,sue block generic eliquis,4,0,0
2017-04-10,0.2354764640589368,negative,roche alecensa notch trial win xalkori,6,1,0
2017-04-18,0.1721647457161745,negative,hitgen enter research collaboration license agreement build screen novel dna encoded library,12,1,0
2017-04-19,0.495809190157459,negative,receives subpoena intravenous saline solution probe,6,-1,0
2017-04-25,0.5225864021965565,negative,aquinnah receives mln investment,4,0,0
2017-04-27,0.0543555556372865,negative,declared q2 dividend common stock insphero announces agreement develop novel assay predicting induced liver injury alkros1 inhibitor granted breakthrough therapy designation fda,22,2,0
2017-05-02,0.5409683651949715,negative,prescription growth analyst deal prescription growth analyst deal quarterly profit rise pct q1 adjusted earnings,15,3,0
2017-05-03,0.2950835528524598,negative,appeal court revives nyu royalty case announces fda filing acceptance supplemental application xeljanz,13,0,0
2017-05-08,0.0729211288160502,negative,multi extension collaboration bill melinda gate foundation child investment fund foundation,11,0,0
2017-05-09,0.1174700182849042,negative,immuno oncology win approval bladder cancer beat amended eliquis case over bleeding risk,13,3,0
2017-05-10,0.2694569515308553,negative,strike deal sangamo broadening hemophilia pipeline angamo therapeutic announce collaboration hemophilia gene therapy,13,1,0
2017-05-17,0.6394371079254113,positive,medivation deal show promise breast cancer study medivation deal show promise breast cancer study,14,1,0
2017-05-24,0.5133087874075626,negative,recommends shareholder reject below mini tender offer trc capital must face lipitor injury lawsuit california state court judge,18,-1,0
2017-05-25,0.1347356484171502,negative,fda committee recommends approval epoetin alfa biosimilar,7,1,0
2017-05-26,0.0415123497087943,negative,report pct stake psivida corp sec filing,7,0,0
2017-05-30,0.0557699899057739,positive,eu approves trumenba help prevent meningococcal group disease adolescent adult,10,1,0
2017-05-31,1.6432690397971128,positive,announces acceptance regulatory submission fda european agency sutent,8,0,1
2017-06-02,0.8525577431644171,negative,defeat appeal linking zoloft birth defect refile hike average pct ft defeat appeal over zoloft birth defect hike average financial time defeat appeal over zoloft biopharma first weighted average net selling increase ytd pct,34,0,0
2017-06-05,0.5101804788112174,negative,roche alecensa best xalkori lung cancer trial delay lung cancer growth longer astra iressa study delay lung cancer growth longer astra iressa study,23,0,0
2017-06-06,0.5458488231566139,negative,receives fda fast track designation tafamidis transthyretin cardiomyopathy,8,0,0
2017-06-09,3.364372566562368,positive,astellas announce amendment clinical research protocol phase prosper trial enzalutamide,10,1,1
2017-06-13,0.8559608054240164,negative,roche aspen face south african probe cancer,7,-1,0
2017-06-14,0.4643930717880162,positive,basilea announces license agreement antifungal cresemba denies over charging cancer south africa exclusive right distribute commercialize cresemba europe,18,0,0
2017-06-15,0.5595188125722017,positive,fda update shortage,3,0,0
2017-06-19,0.0742460418191592,negative,begin phase clinical trial evaluate investigational group streptococcus vaccine,9,0,0
2017-06-20,1.6978887959720357,positive,effector therapeutic collaborate evaluate immuno oncology combination microsatellite stable colorectal cancer,11,1,1
2017-06-21,0.9782056101317992,positive,receives canada approval ibrance hr her2 metastatic breast cancer,9,1,0
2017-06-22,0.5765641128459342,positive,set quarterly dividend,3,0,0
2017-06-27,0.012434754292212,positive,expects hire additional employee over coming support research research development facility chesterfield missouri,13,0,0
2017-06-30,0.3053913853048318,negative,besponsa approved eu adult patient relapsed refractory cell precursor acute lymphoblastic leukemia,12,0,0
2017-07-11,0.644081183027545,negative,fda advisory committee vote favor mylotarg acute myeloid leukemia,9,0,0
2017-07-13,0.0125881875252309,positive,fda accepted supplemental nda ulcerative colitis treatment mersana therapeutic report passive stake mersana sec filing,15,0,0
2017-07-20,0.2824898146893795,negative,basilea completes license agreement cresemba,5,0,0
2017-07-21,0.0898580964685868,negative,kgaa skin cancer get ema nod approval kgaa chmp recommends approval avelumab,12,2,0
2017-07-24,0.4535939469838213,negative,announces positive top line result,5,1,0
2017-07-25,0.9033562371760008,negative,adviser charged insider trading king deal pleads guilty,8,0,0
2017-07-28,0.5718593702189412,positive,federal judge toss eliquis case,5,0,0
2017-08-01,0.46413412789027,negative,delay major awaits tax reform clarity quarterly revenue slip report q2 worldwide ibrance revenue mln mln q2 earnings,18,-2,0
2017-08-02,0.4351558014701107,positive,corrected report second result,4,0,0
2017-08-08,0.1560337004430034,positive,avara pharmaceutical buy italy sterile facility,6,1,0
2017-08-10,1.3218406964610852,positive,doj antitrust division investigating greenstone generic sec,7,0,1
2017-08-14,0.8108646183819346,negative,oros fund management dissolve stake tesla conocophillips paulson dissolve stake ups appaloosa dissolve stake snap,15,0,0
2017-08-17,0.3300663914678758,positive,receives fda approval besponsa based typical duration treatment total cost besponsa fda approves rare blood cancer fda approves leukemia besponsa,20,4,0
2017-08-22,0.1447783725318618,positive,india grant patent pneumonia vaccine blow aid group,8,0,0
2017-08-23,0.6300329779952096,positive,refile india grant patent pneumonia vaccine blow aid group,9,0,0
2017-08-25,0.2478764954330081,positive,sangamo update early stage trial blood disorder therapy,8,0,0
2017-08-29,0.0248541430933668,negative,fda ema accept regulatory submission bosuliffor,6,0,0
2017-09-01,0.0234953269932169,negative,fda approves leukemia corrected fda approves leukemia fda approves mylotarg treatment acute myeloid leukemia,14,2,0
2017-09-11,0.4214296737517387,negative,indicated improvement patient,3,0,0
2017-09-14,1.9429879521281943,positive,corrected astellas prostate cancer clear late stage trial astellas prostate cancer promising late stage trial astellas pharma positive top line result phase prosper trial xtandi corrected astellas prostate cancer succeeds key trial astellas report positive top line result phase prosper trial xtandi,42,3,1
2017-09-19,0.3814060777945549,negative,announces outcome fda advisory committee meeting sutent,7,0,0
2017-09-20,1.487267893831845,positive,sue johnson johnson over remicade biosimilar file suit jj over remicade contract file lawsuit johnson,15,0,1
2017-09-21,0.2123647035081832,positive,kgaa cancer bavencio get eu nod,6,1,0
2017-09-27,0.0354960646937074,positive,declares fourth dividend,3,0,0
2017-09-28,0.3031551657001419,positive,sue sun pharmaceutical block generic bosulif,6,0,0
2017-10-10,0.4555929971267414,positive,weighs billion sale consumer weighs bln sale consumer mulling sale consumer reviewing strategic alternative consumer,15,0,0
2017-10-11,0.0197342125995314,negative,nestle ha no comment consumer,5,0,0
2017-10-12,0.1253405015709252,negative,fda approves lyricaxc2xae cr extended release tablet cv,8,2,0
2017-10-16,1.1240034006560928,negative,present result phase study investigational alk inhibitor lorlatinib,8,0,0
2017-10-18,1.1199582956207157,negative,report pct passive stake rhythm pharmaceutical filing,7,0,0
2017-10-25,0.1917299652966053,positive,gsk look consumer asset offered sale gsk bid consumer unit stoking dividend fear,13,0,0
2017-10-26,1.2907691827901857,negative,exclusive launch consumer sale source,5,1,0
2017-10-31,0.4118390926009962,negative,see broad interest consumer qtrly worldwide total lyrica revenue mln versus ln quarterly profit double report q3 earnings expects broad interest consumer,22,0,0
2017-11-07,0.1827886259054834,positive,park therapeutic amend license agreement investigational spk hemophilia,8,0,0
2017-11-08,0.2266619870611608,negative,novartis take fight ibrance kisqali,5,0,0
2017-11-10,0.0258308480212909,negative,exit china joint venture generic sept qtr profit down pct,10,0,0
2017-11-13,0.2481120819881388,positive,name bourla chief operating officer creates chief operating officer role bourla name albert bourla chief operating officer,17,0,0
2017-11-15,0.4439946914844395,positive,novartis agree uk cut breast cancer,6,0,0
2017-11-16,0.2844905288288624,negative,fda expands approval cancer sutent fda expands approval cancer sutent,10,1,0
2017-11-28,0.0001169396015798,negative,win uk approval sell non prescription viagra uk give world first over counter viagra approval zhejiang hisun pharmaceutical trade resume exited china jv kgaa immunotherapy fails gastric cancer trial provide update phase iii javelin gastric study patient pre treated advanced gastric cancer kgaa avelumab miss goal gastric cancer trial,49,0,0
2017-12-01,0.4557467291629424,positive,basilea extends existing license agreement cresemba entered agreement develop commercialize cresemba china asia pacific,14,0,0
2017-12-04,0.6767978893623239,negative,acentrus specialty sign agreement oncology,5,1,0
2017-12-06,0.2154613365643598,negative,announces updated progression free survival result,6,0,0
2017-12-07,0.484030534583546,negative,announces private offer note due,5,0,0
2017-12-08,0.1307463820595655,positive,breast cancer superior chemotherapy late stage study breast cancer superior chemotherapy phase iii study,14,0,0
2017-12-12,0.8453311278733722,positive,fda extends action date expanded label xeljanz ulcerative colitis month,10,0,0
2017-12-13,0.1752692774638853,positive,second biosimilar jj remicade win fda approval cellectis servier present preliminary ucart19 phase study fda approves biosimilar remicade,18,5,0
2017-12-14,0.0826440704417508,negative,xeljanz get fda nod joint disease treatment initiate phase program pf jak1 inhibitor development moderate severe atopic dermatitis announces fda approval xeljanzxc2xae xeljanzxc2xae xr treatment active psoriatic arthritis announces pricing term private offer pct note due,36,3,0
2017-12-18,0.8222945894947098,negative,announces billion buyback hike dividend announces bln buyback hike dividend authorizes billion repurchase program ups dividend,16,0,0
2017-12-19,0.1276738340400984,negative,exelixis cancer get fda approval wider use array biopharma announces strategic collaboration fda approves bosulif treat type leukemia,18,4,0
2017-12-20,1.24700334684531,negative,fda approves diabetes fda approves diabetes,6,2,0
2017-12-21,0.8093703542414232,negative,compensation committee approved increase coo annual base salary mln announces pricing early result tender offer due announces breakthrough therapy designation avelumab combination inlyta,23,1,0
2018-01-03,0.1084329490347979,positive,angamo partner develop gene therapy al angamo announce collaboration development zinc finger protein gene therapy al,16,1,0
2018-01-04,0.2035642489858435,negative,berkeley light announces research collaboration license agreement arvinas announces research collaboration license agreement,13,0,0
2018-01-08,1.2951857210997677,negative,establishes partnering model early stage academic research corrected end research alzheimer parkinson end research alzheimer parkinson announces expiration result tender offer pct,22,0,0
2018-01-09,0.3360828267533144,negative,gsk ceo looking consumer not priority,6,0,0
2018-01-10,0.3177730643120768,positive,basilea announces completion license agreement extension,6,0,0
2018-01-11,0.4828292968346304,negative,novartis poaches oncology head elizabeth barrett,6,0,0
2018-01-16,0.5060285979573642,positive,foundation announce partnership develop companion diagnostics oncology portfolio,8,1,0
2018-01-18,0.3429361639434636,negative,kite announces clinical collaboration,4,0,0
2018-01-22,0.8401660365149999,negative,law firm go trial over cut million settlement,8,0,0
2018-01-24,0.3375801470592021,positive,india dec qtr profit rise biosimilar roche lymphoma succeeds study biosimilar roche rituxan succeeds study announces positive top line result potential biosimilar rituxanmabthera,23,3,0
2018-01-25,0.7699718108741482,positive,exclusive jj race billion consumer unit deadline loom,8,0,0
2018-01-26,3.623307249594721,positive,ema panel recommends diabetes,4,0,1
2018-01-30,2.100888661420519,negative,report q4 eps report bln gain tax law tax rate higher hoped fall q4 worldwide total lyrica rev mln update tax rate higher hoped fall ceo no pressure immediately deal,30,0,1
2018-02-05,1.1168513751334874,negative,xtandi delay prostate cancer spread early stage disease,8,-1,0
2018-02-06,0.2107731693480108,negative,dl announces research collaboration,4,0,0
2018-02-08,0.1084609122702695,negative,reckitt gsk balance risk reward high stake fight,8,0,0
2018-02-12,0.0047510085372071,negative,investment adviser get prison insider trading king deal eu japan authority accept lorlatinib review,14,0,0
2018-02-14,0.634111753565092,negative,receives breakthrough therapy designation fda atopic dermatitis treatment pf,9,1,0
2018-02-15,0.2016808047264007,positive,kgaa immunotherapy fails lung cancer trial nestle decline comment interest unit canada quebec brunswick provide public funding ibrance,18,-2,0
2018-02-20,0.0633436320649716,negative,park therapeutic enters spk manufacture supply agreement,7,0,0
2018-02-23,0.1389824771700798,negative,receives positive chmp opinion hematology chmp ema recommended expanding use sutent emd serono canada announce canada approval bavencio treating metastatic merkel cell carcinoma previously treated adult albert bourla elected board director,31,3,0
2018-02-26,1.1277991533581444,positive,file potential mixed shelf offering,5,0,0
2018-02-27,0.4667686846348662,positive,escape testosterone replacement claim,4,0,0
2018-03-01,0.4186853874068474,negative,ltd ha not yet made decision strategic alternative global consumer,10,0,0
2018-03-08,1.1025115902802307,positive,fda panel back xeljanz bowel disease treatment ceo partnership solid announces favorable outcome fda advisory committee meeting,17,0,0
2018-03-12,0.3096308316676621,negative,rpt reckitt ceo stand mead johnson deal despite option buy neurology deal nearing mln buy neurology deal nearing million,19,1,0
2018-03-15,0.7417093067489167,positive,ceo ian read total compensation wa mln,7,0,0
2018-03-19,0.1295359595562706,positive,bioduro collaboration lead formation shelf stable fluorosulfation,7,1,0
2018-03-21,0.0267645615986467,positive,continues evaluate potential strategic alternative consumer reckitt benckiser end discussion part consumer,12,0,0
2018-03-22,0.6524659779340358,positive,back drawing board reckitt dropping bid update gsk advance consumer auction reckitt quits gsk advance consumer auction reckitt quits,19,0,0
2018-03-23,0.9865253342212664,negative,quit smoking chantix fails study adolescent smoker gsk pull bln race consumer asset quit smoking chantix fails study adolescent smoker gsk pull bln race asset gsk pull billion race consumer asset glaxosmithkline withdraws process relating consumer continues evaluate option consumer,40,-1,0
2018-03-29,0.7395149080325458,negative,rare disease succeeds late stage study rare heart disease succeeds late stage study announces tafamidis phase attr act study met primary endpoint,22,0,0
2018-04-03,0.5157295171817289,positive,talk pg consumer sale cnbc deal allogene develop cancer cell therapy talk pg consumer unit sale cnbc corrected talk pg consumer unit sale cnbc sign deal allogene develop cancer cell therapy allogene enter agreement car cell therapy talk pg consumer unit sale cnbc,43,1,0
2018-04-06,0.6612696497049209,positive,canada besponsa approved canada treating adult type leukemia,8,0,0
2018-04-10,0.2081996229429394,negative,provides update phase trial axitinib relocate global headquarters east 42nd street spiral,12,0,0
2018-04-12,0.6581429532838801,positive,dos first patient using investigational mini dystrophin gene therapy treatment duchenne muscular dystrophy,13,0,0
2018-04-18,0.3663853925707228,positive,ibt urge shareholder vote proposal corporate political spending disclosure,9,0,0
2018-04-23,0.4791036521445968,positive,granted fda breakthrough therapy designation trumenbaxc2xae provides update proposed trastuzumab biosimilar eu approves mylotarg chemotherapy treat acute myeloid leukemia fda decline approve biosimilar roche cancer,25,3,0
2018-04-26,0.553108432502758,negative,declares q2 dividend,3,0,0
2018-05-01,3.482794938171252,negative,first result miss estimate key sale fall short qtrly worldwide total lyrica revenue mln quarterly profit rise report q1 earnings shareholder proposal regarding independent chair policy not approved shareholder 1st qtr result miss estimate key sale fall short ha not received acceptable offer consumer,44,0,1
2018-05-07,0.0799966614607905,negative,india qtr profit rise,4,2,0
2018-05-08,0.1431434297132217,positive,xtalpi research collaboration develop artificial intelligence powered software platform,9,0,0
2018-05-15,0.2146293308770919,positive,fda approves biosimilar epogen biosimilar retacritxc2xae approved fda,8,2,0
2018-05-17,0.1685649960275759,positive,trial show lyrica reduces seizure child epilepsy,7,0,0
2018-05-22,0.0545477995516185,positive,begin phase study evaluate respiratory syncytial virus vaccine,8,0,0
2018-05-23,0.4247697166608777,positive,fda grant breakthrough therapy designation tafamidis,6,1,0
2018-05-24,0.0175494990925284,negative,pay mln resolve kickback case pay mln settle payment kickback probe pay million settle payment kickback probe maker pay mln settle claim paid kickback,24,-2,0
2018-05-25,0.3468514086011676,negative,australian anti trust watchdog loses appeal over lipitor sale,9,0,0
2018-05-30,0.3540811164383539,negative,fda clear xeljanz inflammatory bowel disease fda approves xeljanz treat ulcerative colitis,12,4,0
2018-06-06,1.0007138408690164,negative,pump mln venture capital arm pump million venture capital arm,10,0,0
2018-06-07,0.3131786441333939,positive,win appeal uk fine epilepsy hike,6,1,0
2018-06-12,0.1292360712990437,negative,win appeal litigation claiming lipitor cause diabetes,7,1,0
2018-06-25,1.0052202043774328,positive,breast cancer combo fall short survival goal australian watchdog appeal high court alleged abuse power,15,-2,0
2018-07-09,0.7657083873120252,negative,trump slam hike,3,0,0
2018-07-10,0.3667460594664051,positive,delaying hike trump conversation delay hike talking trump trump rolling back hike,12,-1,0
2018-07-11,0.1436811360582379,positive,trump told ceo hike hurt plan source separate consumer unit rejig reorganize unit trump told ceo hike hurt plan source,20,0,0
2018-07-19,0.4194574981535304,negative,trump thanks novartis not raising,5,0,0
2018-07-31,2.979457008055353,positive,ceo expects trump eliminate rebate ceo belief eliminate rebate prescription profit rise pct,13,2,1
2018-08-02,1.240062073998438,negative,allergan sue over cost opioid litigation corrected allergan sue over cost opioid litigation,13,0,0
2018-08-16,0.1774606396318656,negative,bet flu vaccine million biontech alliance bet flu vaccine mln biontech alliance,12,0,0
2018-08-21,0.6361427786541474,negative,mylan must face consumer lawsuit over epipen judge,8,0,0
2018-08-22,0.1541025062066991,negative,exact science surge marketing deal cancer test astellas revise cancer trial protocol speed up result loses bid escape lipitor antitrust lawsuit,21,0,0
2018-08-27,2.723500019419567,negative,rare heart disease reduces risk death pct study rare heart disease reduces risk death study,15,0,1
2018-09-11,0.2646423526024177,positive,kgaa immuno shown alleviate kidney cancer,6,0,0
2018-09-27,0.2242370343817024,positive,lung cancer get fda nod lung cancer get fda approval,10,3,0
2018-10-01,0.1064101440378495,positive,update replace longtime ceo read veteran bourla ceo step down replace longtime ceo read veteran bourla,16,0,0
2018-10-09,0.5655358436253644,positive,supreme court decline antitrust case over lipitor,7,-1,0
2018-10-11,1.6167074334812903,negative,hit multi plaintiff suit over anti seizure dilantin settle probe deceptive copay coupon,13,0,1
2018-10-16,0.3081102567535909,negative,fda approves advanced breast cancer fda approves breast cancer,9,2,0
2018-10-17,1.4390315223975714,positive,cut around job through early next cut around pct job through early next,13,0,1
2018-10-18,0.1652205399708006,positive,court dismisses australian watchdog appeal ruling australian watchdog appeal ruling dismissed court combo treatment meet main goal kidney cancer trial,20,0,0
2018-10-23,0.0994468724810349,negative,corrected non opioid help reduce osteoarthritis pain non opioid help reduce osteoarthritis pain,13,0,0
2018-10-29,2.0329003000860824,positive,novartis join force potentially lucrative fatty liver disease,8,0,1
2018-10-30,2.2683372965839665,negative,revenue worse expected generic competition weighs ceo designate doe not see need large acquisition third profit jump pct,18,0,1
2018-11-01,0.3524443893177631,positive,weighing sale woman portfolio bloomberg weighing sale woman portfolio bloomberg,10,0,0
2018-11-02,1.1022270367578302,negative,fda approves treatment certain lung cancer patient,7,2,0
2018-11-14,0.7179816925041882,negative,loses patent fight uk top court face claim,8,0,0
2018-11-16,0.434229522314622,positive,raise previously backing down raise previously backing down plan increase,10,1,0
2018-11-21,1.3285786913593722,negative,fda approves blood cancer treatment fda approves treatment rare blood cancer,11,2,1
2018-12-03,1.8432863484153292,negative,allergan tossing lawsuit could endanger potential opioid accord,8,0,1
2018-12-14,0.1188590264126543,positive,cut version avastin win eu panel greenlight,7,1,0
2018-12-18,1.5373005407626206,negative,win dismissal allergan opioid cost lawsuit,6,1,1
2018-12-19,0.4834184464579505,positive,gsk combine consumer drugmaker gsk split striking consumer deal,9,0,0
2018-12-21,1.989221877309888,positive,kgaa end late stage ovarian cancer treatment study kgaa terminate late stage ovarian cancer treatment study corrected kgaa end late stage ovarian cancer treatment study,25,-1,1
2019-01-09,0.6745743414993455,negative,corrected shut manufacturing plant india shut manufacturing plant india refile india ltd news stopping ops chennai aurangabad unit unrelated,19,0,0
2019-01-29,3.2695544732348147,positive,quarterly profit line tout pipeline future product full revenue forecast miss estimate,12,-1,1
2019-02-06,0.6542610715660313,positive,ceo bourla plan testify senate pricing hearing,7,0,0
2019-02-08,1.1488243330282977,positive,japan recall high blood pressure over cancer causing impurity japan recall high blood pressure amvalo due carcinogen,17,-1,0
2019-02-11,1.35785068029588,negative,refile combo treatment boost kidney cancer survival combo treatment boost kidney cancer survival,13,0,1
2019-02-19,0.2986440697117176,positive,shown help reduce back pain late stage trial receives european approval zirabev biosimilar avastin,14,1,0
2019-02-28,1.164583245688977,positive,unit meridian under civil investigation attorney,6,0,0
2019-03-11,0.0416870515756562,positive,fda approves biosimilar roche herceptin,5,2,0
2019-03-20,0.0063371036908455,negative,buy stake french gene therapy firm vivet,7,1,0
2019-03-26,0.5198055850260008,positive,defeat eliquis bleeding risk lawsuit appeal,6,0,0
2019-04-04,0.4987713030837115,negative,china key gsk consumer venture,5,0,0
2019-04-18,1.4506864868695013,negative,lower dose painkiller miss main goal late stage study,9,-1,1
2019-04-30,2.525365205533548,positive,vaccine blood thinner help drive quarterly earnings beat post pct rise first profit,13,3,1
2019-05-06,1.0396936895947009,positive,get approval heart,3,1,0
2019-05-08,0.4328241979044911,positive,australia anti trust watchdog give go ahead gsk consumer deal gsk deal get approval australia anti trust watchdog,18,1,0
2019-05-15,0.6193710620265414,positive,atopic dermatitis treatment meet goal late stage study,8,1,0
2019-05-21,0.7092132460686518,negative,verily form strategic alliance novartis otsuka sanofi transform clinical research,10,0,0
2019-06-17,0.2426080369311911,positive,buy array bln make billion cancer bet cash deal array biopharma update make bln cancer bet cash deal array biopharma,20,1,0
2019-06-20,0.7255506893173003,negative,gsk offer concession address eu concern over deal,8,-1,0
2019-06-25,0.9807928074731408,positive,asks supreme court send lipitor case california federal court,9,0,0
2019-06-27,0.6688961147142347,positive,name former fda chief scott gottlieb board,7,0,0
2019-06-28,0.7678609019269977,negative,arepta surge gene therapy raise safety concern gene therapy rare muscle disease show promise small early study avastin biosimilar win fda approval,22,4,0
2019-07-02,0.7676671567028226,positive,enator warren asks former fda chief gottlieb resign board wyeth loses bid duck hormone therapy lawsuit gsk jv get conditional approval africa competition regulator sanofi boost south african biovac vaccine output gsk joint venture get conditional approval south africa competition regulator corrected sanofi boost south african biovac vaccine output,49,-1,0
2019-07-29,3.623874293229445,negative,post rise quarterly profit talk transition epipen manufacturing generic spinoff mylan combine off patent unit spinoff merge off patent unit mylan update spinoff merge off patent unit mylan,28,1,1
2019-08-21,0.0623126566289933,negative,invests million expanding gene therapy facility,6,0,0
2019-09-06,0.363058330463839,positive,novartis join fda fast track tag lung cancer hopeful,9,0,0
2019-09-16,0.0921343141641273,positive,brief get second shot interest 500m tax refund,8,0,0
2019-09-27,1.76845782230719,positive,veteran ian read retire executive chairman ian read retire executive chairman,11,0,1
2019-10-07,0.1531401933257958,positive,brief high court rebuff bid move calif lipitor case fed court,11,0,0
2019-10-29,2.524308783602447,positive,raise forecast sale cancer heart surge stock snapshot spur record high alphabet weighs stock hit record high robust earnings raise profit forecast rise stock squeeze higher robust earnings,28,5,1
2019-10-31,0.0195380669242961,negative,european agency highlight blood clot risk arthritis,7,0,0
2019-11-14,0.2821959750874514,negative,judge upholds endo patent adrenalin loss generic unit,8,-1,0
2019-11-25,0.1381035852315415,positive,top court wont consider challenge california lipitor case,8,-1,0
2019-11-27,0.4422139961071325,positive,focus novartis lead bln spending spree gene therapy production focus novartis lead pharma spending spree gene therapy production novartis lead billion spending spree gene therapy production,26,0,0
2019-12-13,0.6048007661622834,negative,rare disease get ema positive recommendation rare disease treatment win ema positive recommendation,13,2,0
2019-12-16,1.426223581355912,positive,fda approves expanded label astellas prostate cancer xtandi fed circuit upholds million patent win fda approves expanded label astellas prostate cancer therapy xtandi,23,3,1
2019-12-23,0.0766397845453292,positive,fda approves first generic blood thinner eliquis,7,2,0
2019-12-31,0.4509789102220329,positive,exclusive drugmakers gsk hike over,5,0,0
2012-01-31,1.2132191295143202,positive,4th profit up forecast fall short profit up forecast fall short,11,-1,0
2012-02-14,0.1244089836025863,negative,acquire developer fibrosis treatment,4,1,0
2012-05-01,2.2487504209272147,negative,profit below street view outlook strong q1 profit fall short street view,12,-1,1
2012-05-09,0.2772335421064809,positive,application accepted eu regulator,4,0,0
2012-07-24,1.0382458044627565,positive,2nd profit up sale,4,0,0
2012-09-10,0.022021483493928,negative,sell royalty right lupus canadian fund,6,0,0
2012-09-26,0.2328913348797257,negative,hemophilia meet late stage trial goal,6,0,0
2012-10-12,0.3958269474107379,positive,look bolster oral,3,0,0
2012-10-18,2.48426207604927,negative,fda extends review multiple sclerosis,5,0,1
2012-10-25,1.3775702626782405,positive,third profit rise doe forecast idec up premarket trading 3rd profit rise third profit rise 3rd profit rise doe forecast,20,2,1
2012-10-31,3.3007766039319986,negative,hemophilia met late stage trial goal,6,0,1
2013-01-03,1.20073211930094,negative,lou gehrig disease fails key trial down premarket trial result,10,-1,0
2013-01-09,0.4689044845985868,negative,teva question safety rival,4,0,0
2013-01-16,0.1192588763389235,negative,elan seek okay first line tysabri use,7,1,0
2013-01-24,1.9655580255186988,positive,injectable effective trial,3,1,1
2013-01-28,2.712139594093055,positive,despite profit dip rise optimism,5,1,1
2013-02-06,2.227633981499255,positive,pay elan billion take over purchase end rocky partnership elan elan seek acquisition bln deal,15,-1,1
2013-03-19,0.2835792344813681,positive,receives patent tecfidera receives patent multiple sclerosis tecfidera,8,0,0
2013-03-20,0.7193829076823643,positive,injectable cut relapse rate pct,5,0,0
2013-03-22,0.0179801618169106,positive,win eu backing big hope eu agency back sanofi,9,1,0
2013-03-27,3.156587046134729,positive,fda approves oral tecfidera fda approves oral tecfidera fda approves multiple sclerosis tecfidera,13,2,1
2013-04-02,2.3182092227823192,positive,elan completes sale tysabri stake,5,0,1
2013-04-25,4.357457428869238,positive,see tecfidera becoming leading oral profit beat estimate raise forecast profit beat estimate helped lower tax,16,2,1
2013-05-30,0.4110474515190643,negative,delay eu launch secure exclusivity,5,0,0
2013-07-22,0.4129118862286729,positive,investigates death patient took tecfidera patient death unlikely linked,9,0,0
2013-07-25,0.1406249450055741,positive,shine debut sale shine first,5,0,0
2013-09-09,0.6757594002619438,positive,bet isi technology neurological,4,0,0
2013-09-25,0.5436830283667149,negative,fda strengthens warning glaxo rochebiogen cancer,6,0,0
2013-10-04,2.004906549187635,positive,maintains efficacy long term study,5,1,1
2013-10-28,0.7010874607201512,positive,top expectation ups forecast top expectation earnings rise,8,1,0
2013-11-12,0.5565301733237993,positive,belgium galapagos sign deal group,5,1,0
2013-11-22,12.6463647778966,positive,idec up premarket win protection europe win protection europe win protection tecfidera europe research alert idec ubs raise target,19,3,1
2013-12-02,1.5897025325426806,positive,fda extending review hemophilia,4,0,1
2014-01-09,0.1550400493354864,negative,angamo bioscience develop blood disorder angamo develop blood disorder,9,0,0
2014-01-29,0.8983556291333405,positive,corrected profit rise multiple sclerosis shine profit rise multiple sclerosis shine idec profit rise multiple sclerosis shine pulse boeing tupperware emc praxair rockwell,23,2,0
2014-02-03,1.6677114575755825,negative,multiple sclerosis tecfidera win european approval,6,2,1
2014-03-18,1.1207033743934949,positive,fda delay decision multiple sclerosis,5,-1,0
2014-03-21,7.828831811783355,negative,idec win canadian approval hemophilia alprolix,6,2,1
2014-03-28,5.542081407867605,negative,fda approves hemophilia alprolix,4,2,1
2014-04-10,2.332691257467745,negative,blood disorder succeeds late stage trial,6,0,1
2014-04-23,0.4138007358735818,positive,raise outlook top forecast post higher profit top forecast,9,1,0
2014-05-12,3.872019153093032,positive,sobi pledge hemophilia donation developing world,6,0,1
2014-05-23,0.3941914617076048,negative,eu agency recommends roche novartis ptc eu agency recommends roche ptc,11,0,0
2014-06-06,1.2841946433482798,negative,fda approves hemophilia eloctate,4,2,0
2014-06-16,0.7308479286676772,negative,slows episode safety issue recur,5,0,0
2014-07-23,10.951315154345064,positive,revenue trounces forecast sale surge idec eu ha approved plegridy multiple sclerosis corrected revenue trounces forecast sale surge tax inversion not adequate rationale merger,24,2,1
2014-08-15,1.6405631503121576,positive,win approval long acting multiple sclerosis fda approves idec multiple sclerosis,11,4,1
2014-10-14,0.2077667258728488,negative,biogened sign mln zloty contract labormed pharma,7,1,0
2014-10-22,4.705570285535143,negative,tecfidera sale miss estimate confirms first pml case confirms case pml patient taking tecfidera profit surge tecfidera sale shy street view stock wall st turn lower boeing weigh,28,0,1
2014-10-28,1.756435927173472,negative,janusz kruk acquire series biogened,5,1,1
2014-11-06,0.8264087823639965,positive,biogened receives loan million zloty,5,0,0
2014-12-02,5.78274308393798,positive,plan late stage trial alzheimer treatment plan late stage alzheimer trial rise rise favorable alzheimer plan larger trial,18,1,1
2014-12-19,1.5474797098174342,positive,biogened issued series,3,0,1
2015-01-08,2.6209544786494288,negative,experimental show evidence optic nerve repair fall optic nerve study result seen mixed,13,-1,1
2015-01-29,0.3349116406546448,negative,forecast earnings well ahead street view,6,0,0
2015-03-06,0.468509636481218,negative,kruk raise stake biogened pct bioniq limited buy pct biogened,10,2,0
2015-03-20,8.88266000278266,positive,alzheimer slows mental decline early study,6,-1,1
2015-03-23,2.3787798892588308,negative,exclusive shortens name expands ambition alzheimer al,7,0,1
2015-04-22,0.1455308087157103,negative,roche confident beating alzheimer,4,1,0
2015-04-24,6.871913940117769,negative,tecfidera sale slow delay readout alzheimer 1st qtr profit jump pct tecfidera shine,13,-2,1
2015-05-15,0.897022739208142,negative,biogened q1 revenue up mln zloty,6,0,0
2015-06-04,0.0342939556652988,positive,obi partner submits marketing authorisation application alprolix europe,8,0,0
2015-07-02,0.1582888776279434,negative,enters eye treatment arena agtc deal,6,0,0
2015-07-22,4.115046960786351,negative,alzheimer disappoints get slight bump mixed result alzheimer 6mg dose fall short alzheimer fall flat get slight bump eisai tank partner alzheimer disappoints,23,-2,1
2015-07-24,21.033328217848624,negative,half sale growth forecast tecfidera demand stall profit rise pct higher tecfidera sale,13,3,1
2015-08-14,0.7303748501739427,negative,biogened q2 net profit up pln,6,0,0
2015-08-28,0.3029031166110529,negative,biogened get million zloty loan bank zachodni wbk,8,0,0
2015-09-02,2.105311695854284,positive,patent survives challenge hedge fund manager bass patent survives challenge hedge fund manager kyle bass,15,-1,1
2015-09-25,2.774265642389251,negative,sobi receive positive opinion ema elocta,6,1,1
2015-10-21,4.581829745513922,positive,cut staff cancel program stock jump cut pct staff cancel program stock jump cut pct global workforce,17,0,1
2015-11-16,1.9805945881782197,negative,biogened q3 net result swing profit zloty,7,0,1
2015-11-20,0.1156647830554247,negative,eu endorses copy enbrel arthritis samsung,6,0,0
2015-11-24,1.8671464871113488,negative,sobi elocta approved europe treatment haemophilia,6,0,1
2016-01-27,6.240900175170383,positive,focus pipeline strong quarterly sale rise,6,2,1
2016-02-24,1.140989569575945,negative,biogened announces change shareholding structure,5,0,0
2016-02-26,1.0458346282638975,positive,life science technology stake biogened down pct x7f,8,0,0
2016-03-02,0.5695812734225703,positive,x7fenrav acquires pct stake biogened med investment sell biogened janusz kruk sell biogened feb,14,0,0
2016-03-31,2.658305863518895,positive,ionis pharmaceutical earns milestone payment mln,6,0,1
2016-04-08,1.079080630057938,negative,explores sale hemophilia asset source explores sale hemophilia asset source,10,0,0
2016-04-15,0.6508141098025777,negative,ceo george scangos fy compensation wa mln mln,8,0,0
2016-04-18,0.9435133223177904,positive,tecfidera confirm strong sustained efficacy newly diagnosed,7,0,0
2016-04-21,5.694109118551005,positive,q1 adj shr cost cutting help top wall street estimate first sale rise,13,2,1
2016-04-27,0.7880038643152565,negative,obi ceo asset not time bet appoints michael ehlers executive vp rd,12,0,0
2016-04-29,1.6267562209226871,negative,receive positive opinion chmp zinbryta multiple sclerosis win eu green light,11,2,1
2016-05-03,0.8776239254955187,positive,announces intent spin off hemophilia spin off hemophilia focus core neuro,11,0,0
2016-05-16,0.6277961885537975,positive,biogened q1 net profit down zloty yoy regenxbio enter agreement development gene therapy treatment,14,0,0
2016-05-27,0.1497850773075626,negative,injection win approval injection win fda approval,7,3,0
2016-06-01,1.2093052407710636,negative,alzheimer aducanumab accepted ema prime program,6,0,0
2016-06-06,0.643224864762515,negative,vascular biogenics vb demonstrated significant increase overall survival,8,0,0
2016-06-07,12.91489640593202,negative,miss main goal mid stage study vascular biogenics announces mln registered direct offering opicinumab missed primary endpoint study,18,-1,1
2016-06-20,0.9882404582387428,negative,biogened issue series,3,0,0
2016-07-05,0.5171130992030926,negative,approved eu multiple sclerosis approved eu,6,0,0
2016-07-18,0.1922755875482407,positive,sobi present long term hemophilia conference sb5 accepted review european agency,11,0,0
2016-07-21,8.014623927987941,positive,ceo leave plan bln buyback profit easily beat street view ceo leave ceo step down see fy rev bln,19,1,1
2016-07-25,0.1221743879974424,positive,enigma biomedical announces research collaboration agreement,6,0,0
2016-08-01,4.187339244108901,positive,ionis nusinersen meet primary endpoint interim analysis phase endear study pay ionis mln develop muscle trial success exercise option develop muscle trial success,23,-1,1
2016-08-02,10.010242328455057,positive,refile draw takeover interest allergan wsj draw takeover interest allergan wsj allergan unlikely pursue deal cnbcciting source draw takeover interest allergan wsj ha drawn takeover interest including allergan wsj draw takeover interest allergan wsj,34,0,1
2016-08-03,2.948961125033378,negative,allergan ha no interest deal cnbc citing source amyris enters partnership not pursuing sale source,15,0,1
2016-08-04,2.2163126446991144,negative,not pursuing sale source,4,0,1
2016-08-08,0.6715259549821107,negative,allergan focused tepping stone deal not big like,8,0,0
2016-08-09,0.1858818063750877,positive,announces bioverativ name hemophilia focused,5,0,0
2016-08-16,0.5253375003441807,positive,biogened q2 net profit down zloty,6,0,0
2016-08-23,0.2279331094096504,positive,biogened update bond issue program,5,0,0
2016-08-25,0.732873931225897,negative,thai lee family trust report pct stake vascular biogenics,9,0,0
2016-08-31,0.439953850346253,negative,nature publishes result phase 1b study aducanumab,7,0,0
2016-09-01,0.1262797258414494,positive,aducanumab granted fda fast track designation,6,1,0
2016-09-06,1.2333932987178442,negative,biomotiv expand strategic partnership,4,1,0
2016-09-14,0.8377612014772051,positive,affirms strong efficacy tecfidera clinical study real world setting,9,0,0
2016-09-26,0.0727512819513331,negative,completes submission application,3,0,0
2016-09-28,1.7617348553216503,negative,anavex sign material transfer agreement,5,1,1
2016-10-26,3.8581144763472186,positive,ceo search find successor progressing profit top expectation focus ceo search q3 non gaap eps drugmaker quarterly profit rise pct,20,2,1
2016-10-28,2.196809940322675,negative,regulatory application nusinersen treatment spinal muscular atrophy accepted fda ema,10,0,1
2016-11-07,4.516319941914504,positive,ionis fatal infant disorder succeeds key study ionis pharmaceutical announce spinraza meet primary endpoint interim analysis phase cherish study ionis muscular disorder treatment meet main goal,26,1,1
2016-11-14,0.6451795144864603,positive,biogened q3 net profit decrease zloty yoy,7,0,0
2016-11-15,0.4412311815082281,negative,announces additional member management team hemophilia spin off bioverativ,9,0,0
2016-11-23,3.8832639930144186,negative,alzheimer setback prompt rethink stock outlook,6,0,1
2016-11-29,0.5275101105272739,negative,vascular biogenics study treat recurrent thyroid cancer met min goal ewa kruk buy biogened via private subscription,17,1,0
2016-11-30,2.633552057704991,negative,sangamo genome editing program transfer spin off bioverativ biogened allots million series,12,0,1
2016-12-08,1.2412804874972982,positive,further promising seen alzheimer study positive trend seen latest study alzheimer further promising seen alzheimer study present phase 1b study investigational alzheimer disease treatment clinical trial alzheimer disease meeting further promising seen alzheimer study,34,2,0
2016-12-09,1.2153567088569297,negative,get canada approval zinbryta proteostasis therapeutic received notice termination collaborative research development commercialization license agreement,15,1,0
2016-12-19,2.8818478868503417,negative,name top executive vounatsos ceo,5,0,1
2016-12-20,2.0607054638599687,positive,see ceo choice friendly potential takeover board approves separation bioverativ,10,1,1
2016-12-21,0.5901136028963805,negative,rpt see ceo choice friendly potential takeover,7,0,0
2016-12-22,0.1586129415883985,positive,separation bioverativ completed feb,4,0,0
2016-12-23,1.4291617468045414,positive,fda approves lead genetic cause infant death,7,2,1
2017-01-05,0.0837918748663901,negative,enters exclusive worldwide license agreement factor ix,7,0,0
2017-01-12,0.4808708790854044,positive,spin off bioverativ commences issued trading common stock,8,0,0
2017-01-17,0.2587157203877033,negative,forward pharma enter settlement license agreement pay forward pharma bln protect bln deal forward pharma protect pay forward pharma billion protect forward pharma agrees enter settlement license agreement,28,-1,0
2017-01-23,1.3930311428115072,negative,ewopharma partner commercialise benepali flixabi,5,0,1
2017-01-25,1.0773720020940123,negative,possible liver injury added label,5,0,0
2017-01-26,2.172324693349559,positive,qtrly adjusted eps phase iii alzheimer trial enrollment ahead expectation profit drop pct due tecfidera related cost see gradual spinraza launch eye mid eu approval,25,1,1
2017-02-01,1.5655540227984988,positive,forward pharma enters license agreement unit party,7,0,1
2017-02-02,6.264206360595925,negative,ionis earns mln milestone payment,5,0,1
2017-02-09,0.0393165533239869,positive,forward pharma receives bln pursuant settlement license agreement,8,0,0
2017-02-14,1.8341624484355057,positive,biogened q4 net profit lower zloty yoy,7,0,1
2017-03-06,0.437479394010476,negative,israel brainstorm name senior executive kern coo,7,0,0
2017-03-21,1.6442118118322857,positive,win ruling tecfidera ip case rise,6,2,1
2017-03-31,1.8532161548801216,positive,forward pharma intends appeal decision patent interference proceeding win tecfidera patent dispute forward pharma patent board rule forward patent case,20,1,1
2017-04-13,1.750190186129308,positive,license phase anti tau antibody license roche enters separate agreement roche license roche,13,0,1
2017-04-19,0.4715128864947848,positive,ewa kruk raise stake biogened pct,6,1,0
2017-04-25,3.040906405762533,positive,drugmaker revenue rise cfo expects spinraza adoption ramp up going forward conf call q1 non gaap earnings profit beat surprisingly strong spinraza sale,23,3,1
2017-04-28,1.7200868968462624,negative,life science technology lower stake biogened pct,7,0,1
2017-05-15,0.8956169370338163,positive,beat security fraud lawsuit over multiple sclerosis sale biogened q1 net profit almost flat zloty vascular biogenics report qtrly loss,20,-2,0
2017-05-18,0.1820167761662494,positive,acquires remedy pharmaceutical late stage cirara,6,0,0
2017-05-22,0.5277373414446784,negative,biogened plan capital increase via issue up mln series,9,0,0
2017-06-01,1.065368313863635,positive,eu approves spinraza lead genetic cause infant death spinraza approved eu first treatment sma,14,1,0
2017-06-05,0.7945422914471534,positive,vascular biogenics present positive mid stage brain cancer patient,9,1,0
2017-06-12,0.8747502550851216,positive,biogened series issue doe not go through equus total return receives mln biogenic reagent investment,15,0,0
2017-06-13,0.7522365827524746,negative,alexion tap veteran paul clancy cfo refile alexion name paul clancy cfo,12,0,0
2017-06-14,2.9525733107428787,negative,biogened sign financing agreement up mln,6,1,1
2017-06-15,0.8436556107465409,positive,vascular biogenics appoints dr corinne epperly chief operating officer,9,0,0
2017-06-20,2.770056465945503,positive,appoints ginger gregory chief human resource officer,7,0,1
2017-06-23,0.2085282256508502,negative,imraldi granted positive opinion committee medicinal product human use,9,2,0
2017-06-29,0.1260661693372133,negative,reaffirm clinically meaningful benefit spinraza individual spinal muscular atrophy across disease,11,1,0
2017-06-30,0.3777108144014662,negative,sue block generic version blockbuster,5,1,0
2017-07-10,0.2351586577889475,negative,appoints amy chevalier efantis vice president affair,7,0,0
2017-07-14,0.4137449171667695,positive,present alzheimer association international conference,5,0,0
2017-07-17,0.6674642936699837,positive,ionis receives mln milestone payment,5,0,0
2017-07-25,0.8542617840108568,negative,revenue rise pct spinraza demand report q2 eps ceo explore deal size strong roll growth strategy learned prosecution office milan investigating interaction provider italy sec filing,26,2,0
2017-07-27,2.498296403961342,negative,abarca sign reimbursement contract select product,6,1,1
2017-07-31,0.8046830094617374,positive,appoints anabella villalobos senior vice president biotherapeutic medicinal science,9,0,0
2017-08-14,0.1558673538136767,negative,vascular biogenics report q2 loss temasek holding take stake jpmorgan celgene biogened q2 net profit rise zloty paulson take stake apple dissolve stake sarepta,24,1,0
2017-08-18,0.7753999905778408,negative,biogened raise up mln zloty through series bond,8,1,0
2017-08-24,1.227269204526238,positive,imraldi adalimumab biosimilar referencing humira approved eu samsung version humira approved europe,12,0,0
2017-08-28,2.535727202793248,positive,report phase 1b study investigational alzheimer disease treatment aducanumab,9,0,1
2017-08-30,2.990372989545764,positive,ionis earns million spinraza regulatory milestone payment,7,0,1
2017-09-06,0.1430576792765814,positive,biogened announces change shareholding structure,5,0,0
2017-09-12,0.6275946402147792,positive,appoints sanjay jariwala svp,4,0,0
2017-10-05,3.160823515152744,positive,update treatment spinraza,3,0,1
2017-10-23,2.435669517528372,negative,eisai expand existing collaboration agreement develop commercialize investigational alzheimer disease treatment including phase aducanumab seek dismissal shareholder lawsuit over sale,20,1,1
2017-10-24,4.077699360020725,negative,dive spinraza sale miss estimate increase profit potential investigational disease treatment post pct jump quarterly profit q3 earnings,18,-1,1
2017-11-02,2.043714045153322,negative,present long term extension phase 1b study,7,0,1
2017-11-14,1.6745521532351648,negative,biogened q3 net profit down mln zloty,7,0,1
2017-11-21,0.7835353875317974,negative,appoints jeff capello executive vice president chief financial officer,9,0,0
2017-11-22,0.3279006492530434,positive,ybroad buy pct stake biogenics korea,6,1,0
2017-11-27,0.9432214759193092,positive,boost multiple sclerosis holding alkermes license,6,0,0
2017-11-30,0.1847787449668958,negative,sarissa capital management buy common stock,6,1,0
2017-12-04,0.4896140270428728,negative,appoints mark hernon svp chief information officer,7,0,0
2017-12-18,1.2409408670813415,negative,vascular biogenics file mixed shelf up mln sec filing,9,0,0
2017-12-19,0.7123129671493866,positive,ionis collaborate identify novel therapy treat spinal muscular atrophy,9,0,0
2017-12-21,3.4896230690139696,negative,alzheimer fails meet main goal mid stage trial result final analysis ban2401 expected second half,15,-1,1
2017-12-22,0.9102156379071192,negative,responds coverage recommendation canadian expert committee spinraza,7,0,0
2017-12-27,0.0420328323095242,positive,vascular biogenics top line globe phase pivotal trial vb expected q1,11,0,0
2018-01-24,0.0332685851857195,negative,biosimilar roche lymphoma succeeds study,5,0,0
2018-01-25,2.047090215526337,positive,forecast robust spinraza sale surge report qtrly loss post fourth loss income tax charge karyopharm announces agreement acquire kpt,19,2,1
2018-02-07,1.2510580764394486,negative,report top line result phase 2b study natalizumab acute ischemic stroke report top line result phase 2b study natalizumab stop developing tysabri treat stroke failed study stop testing tysabri treat stroke study fails,33,-2,0
2018-02-12,1.5158027169044352,negative,norway buy spinraza broadcaster nrk norway buy spinraza broadcaster nrk,10,1,1
2018-02-14,7.946046660440576,negative,biogened q4 net result turn profit zloty,7,0,1
2018-03-02,1.117222912765059,positive,withdraw multiple sclerosis zinbryta withdrawal marketing authorization,7,-1,0
2018-03-07,0.4668855707332331,negative,europe regulator call recall multiple sclerosis,6,-1,0
2018-03-12,2.0415679410790366,negative,buy neurology deal nearing million buy neurology deal nearing mln,10,1,1
2018-03-28,2.807163042113248,positive,defeat security fraud lawsuit over sale,6,-1,1
2018-04-05,3.513129500320089,negative,samsung bioepis settle over humira biosimilar deal delay humira biosimilar launch,11,-1,1
2018-04-20,0.2798043766253588,negative,boost investment neurology bln ionis deal pay billion ionis partnership ionis expand strategic collaboration develop candidate broad range neurological disease boost investment neurology billion ionis deal,26,0,0
2018-04-24,2.44585118908045,positive,revenue miss spinraza sale disappoint report quarterly revenue billion quarterly profit jump higher spinraza sale,15,-3,1
2018-04-27,0.9796656667959924,positive,ceo michel vounatsos total compensation wa million,7,0,0
2018-05-01,0.1914650027450726,positive,neurimmune announce option exercise alzheimer disease investigational treatment aducanumab,9,1,0
2018-05-17,0.2494292591129654,negative,amsung biologics jv partner exercise option late,7,0,0
2018-06-28,0.2869553557463877,negative,corrected exercise call option boost stake samsung bioepis raise stake samsung bioepis pct exercise call option boost stake samsung bioepis raise stake samsung bioepis,24,1,0
2018-07-05,0.989931451581616,positive,alzheimer succeeds mid stage trial,5,0,0
2018-07-24,3.604235025181613,positive,quarterly sale rise pct,4,2,1
2018-07-25,2.095402639267463,positive,biogeneisai alzheimer cut cognitive decline pct study refile easily top street estimate spinraza sale raise forecast,16,0,1
2018-07-26,9.948288941980566,negative,turn wary biogeneisai alzheimer result update turn wary biogeneisai alzheimer result,11,0,1
2018-08-03,1.4976660101314931,negative,corrected focus eisaibiogen advance alzheimer provide fresh hope corrected rpt focus eisaibiogen advance alzheimer provide fresh hope eisaibiogen advance alzheimer provide fresh hope,23,0,1
2018-08-13,0.2699682097607403,negative,pricey muscle spinraza costly britain,5,0,0
2018-10-23,0.7023917862160278,positive,spinraza drive third profit beat third profit rise pct,9,4,0
2018-10-24,1.4300482514779111,negative,forward pharma loses appeal tecfidera patent dispute,7,0,1
2018-10-25,2.9792942358369934,negative,slip alzheimer fails convince biogeneisai alzheimer suggests treatment effect related eisai alzheimer fails convince skeptic,15,-2,1
2019-01-02,1.1487913804707262,positive,fed circuit decline reconsider order upholding patent,7,-1,0
2019-01-29,1.487200799667432,positive,beat estimate multiple sclerosis sale corrected beat estimate spinraza tecfidera strength drugmaker fourth revenue rise pct,16,2,1
2019-03-04,1.6835511260696712,negative,yncona nightstar acquired buy nightstar therapeutic mln cash deal buy nightstar therapeutic mln,13,1,1
2019-03-12,0.0274453391784446,positive,fujifilm buy subsidiary around mln japan fujifilm buy biologics unit boost,11,1,0
2019-03-14,0.363455443625893,positive,fight subpoena kickback case,4,0,0
2019-03-21,30.35994320736055,negative,scrap alzheimer trial wiping billion off value update scrap alzheimer trial wipe bln value scrap alzheimer trial wipe bln value scrap alzheimer trial wipe billion value eisai scrap alzheimer trial,30,0,1
2019-03-25,1.7133353441972976,positive,announces bln buyback day shelving alzheimer trial announces billion buyback day shelving alzheimer trial,14,0,1
2019-04-03,0.9590053243073272,negative,sma novartis estimate treatment far high group sma novartis estimate treatment far high group,14,0,0
2019-04-24,2.301848735571843,negative,dip strategy post alzheimer setback fails impress first profit rise,10,1,1
2019-04-25,2.508119382864271,positive,humira rival aggressive far,4,0,1
2019-05-14,0.6555036650034429,positive,nh england reach deal pricey deadly disorder,7,0,0
2019-07-23,4.188642590268454,positive,multiple sclerosis help beat wall st profit expectation profit rise multiple sclerosis help beat wall st profit expectation,18,3,1
2019-09-13,1.925965403716268,positive,scrap late stage alzheimer trial scrap late stage trial alzheimer treatment,11,0,1
2019-10-22,26.437366115708183,positive,seek approval alzheimer jump third profit rise spinraza strength,9,3,1
2019-10-23,1.373019273583198,negative,eisai revive plan alzheimer surprising update eisai revive plan alzheimer surprising,11,0,1
2019-10-25,0.4166041756023642,positive,secret campaign bring alzheimer back ash,6,0,0
2019-10-30,0.4966432283347144,positive,mall relief approval fda approves multiple sclerosis alkermes,8,3,0
2019-11-11,0.4944709048620654,positive,roche set sight novartis sma trial hit target,8,1,0
2019-11-25,0.4052669161018096,positive,roche eye quick fda approval sma race novartis,8,2,0
2019-12-05,3.2292925400277284,positive,make case skeptic controversial alzheimer present controversial alzheimer build case alzheimer skeptic needed showed no major safety issue alzheimer,19,1,1
2019-12-13,0.9542105131968848,positive,scrap development therapy rare brain disease halt development therapy rare brain disease,12,0,0
2012-01-26,1.1197367791111357,negative,buy micromet billion,3,1,0
2012-02-06,0.1640522788879606,negative,fda staff unsure use xgeva,5,0,0
2012-02-08,1.901499859839784,negative,fda panel vote wider use,5,0,1
2012-04-02,0.5255089157671478,negative,astra collaborate several,3,0,0
2012-04-03,0.1446330765499826,positive,astrazeneca hunting deal like tie up,6,0,0
2012-04-24,0.1177319555041744,positive,sale buyback help first founding ceo george rathmann dy,9,0,0
2012-04-25,0.9038937649258116,positive,buy turkish drugmaker million,4,1,0
2012-04-26,0.1579334798062603,positive,fda reject application xgeva,4,-2,0
2012-06-08,1.1280042913323518,negative,sensipar fails meet trial goal,5,-1,0
2012-06-11,0.2984499045868394,negative,uk watchdog revise bone guidance,5,0,0
2012-07-26,0.0626704315618953,positive,profit beat estimate raise forecast exclusive human genome rejected billion bid source,12,2,0
2012-08-08,0.3663398358599412,negative,pancreatic cancer lack efficacy trial end,6,0,0
2012-08-29,0.4229904934617945,negative,fda approves teva version neupogen,5,2,0
2012-09-12,1.2746902363971913,negative,corrected research alert baird cut neutral,6,0,0
2012-09-20,0.7152492100706231,positive,fda approves prolia use,4,2,0
2012-10-23,0.8409328340253319,positive,profit top street view raise forecast 3rd profit higher raise forecast,11,1,0
2012-11-05,0.3205339295906273,negative,top court review comcast class action experimental lower cholesterol mid stage trial,12,0,0
2012-11-06,0.3060761924709165,positive,cut cholesterol up statin patient cut bad cholesterol up pct statin patient trial,13,0,0
2012-12-10,1.5656579817722172,positive,buy icelandic gene hunter decode million buy icelandic gene hunter decode mln,12,1,1
2012-12-17,0.83890584162849,negative,plead guilty criminal case tuesday prosecutor plead guilty criminal case prosecutor,11,0,0
2012-12-18,1.3475255135961817,negative,pay million pleads guilty marketing case pleads guilty misbranding charge pay mln,12,-1,1
2012-12-19,0.1530251650938785,negative,court approves million payment case,5,1,0
2013-01-08,0.1415026725174462,negative,trim eps estimate citing rd tax credit delay lower eps forecast,11,-1,0
2013-01-16,0.8796779501868079,negative,down extended trading comment build manufacturing plant singapore,8,1,0
2013-01-23,0.4250707646652141,negative,hit revenue eps target early revenue forecast top street estimate,10,1,0
2013-02-07,1.4498587065679414,negative,biosimilar push take aim blockbuster outline pipeline see push biosimilars,10,1,1
2013-02-26,0.7738993250270942,negative,fda halt trial child cite death,6,0,0
2013-02-27,0.483769183969196,positive,loses top court back class action high court rule class action,11,0,0
2013-03-19,2.456000338278641,positive,melanoma show promise key trial,5,1,1
2013-04-16,0.7084580821440589,positive,pay million settle kickback allegation pay mln settle kickback allegation,10,-1,0
2013-04-23,1.6128357881521227,negative,first sale disappoint fall first profit revenue rise,8,-1,1
2013-05-01,1.1934217732114338,positive,others assessed fda radiation treatment,5,0,0
2013-05-29,1.0549027068498915,negative,make move japan take astellas partner,6,0,0
2013-06-12,0.7652615145947173,negative,trebananib reduces risk ovarian cancer trial slowed ovarian cancer trial,10,0,0
2013-06-24,0.9158481838152266,negative,novartis test copy enbrel late stage trial,7,0,0
2013-06-28,0.0763672863037689,positive,offered buy onyx report offered buy onyx report,8,1,0
2013-07-01,1.7718527885939972,negative,novartis join bidding onyx source,5,0,1
2013-07-03,0.3036756316863287,negative,ec alleges insider trading onyx ahead offer ec alleges insider trading onyx ahead news,14,0,0
2013-07-24,0.3478020390783487,positive,exclusive line up bofa jpm barclays finance onyx deal source,10,0,0
2013-07-30,1.6732193471679313,positive,profit top wall street view rebound 1st qtr profit ex item top wall street view rebound 1st qtr,18,1,1
2013-08-06,1.488905105758409,negative,seen raising bid acquire onyx pharmaceutical report,7,1,1
2013-08-07,7.147841827074042,positive,array end agreement cut job array end agreement cut pct job deal onyx possible within week source,17,0,1
2013-08-08,2.163626603804369,negative,array cut job end partnership corrected array cut pct job end partnership,12,0,1
2013-08-15,0.5733950971275936,positive,seek trial finalizing onyx deal source,6,0,0
2013-08-26,8.089907219239779,positive,bradway patient dealmaking brings onyx newsmaker bradway patient dealmaking brings onyx onyx deal expected give big boost,17,0,1
2013-09-03,1.4479439709553787,positive,cytokinetics heart failure miss goal study,6,-1,1
2013-09-05,0.2063287559663673,negative,gain investment banker ceo,4,1,0
2013-10-22,1.6823991905795532,positive,3rd profit rise boost revenue forecast giant raise full revenue outlook,11,3,1
2013-11-18,1.26310510070472,positive,present interim overall survival late stage study talimogene laherparepvec patient metastatic melanoma,12,0,0
2013-11-19,0.2738851907224782,negative,cholesterol appears safe cut ldl pct study,7,1,0
2013-11-20,0.3994068191770283,positive,research alert deutsche bank raise target,6,2,0
2013-11-21,3.671171206176626,negative,slip analyst cite kyprolis risk,5,-1,1
2013-12-19,0.0002553331995724,positive,cholesterol succeeds late stage trial,5,0,0
2014-01-23,0.2001959656422913,positive,cholesterol meet goal 3rd late stage trial cholesterol meet goal third late stage trial,14,1,0
2014-01-28,1.2438798432407472,positive,4th profit top wall street expectation profit top street expectation focus,11,0,0
2014-01-30,0.3832655238177329,positive,cholesterol fighter succeeds fifth late stage study cholesterol fighter succeeds 5th late stage study,14,0,0
2014-02-25,1.0989590730189902,negative,update moody roche exposed biosimilar,5,0,0
2014-03-14,0.8647229541598134,negative,corrected vaccine trigger immune response advanced melanoma study vaccine trigger immune response advanced melanoma study,15,0,0
2014-03-17,0.1728345038501721,positive,meet goal high genetic cholesterol,5,1,0
2014-04-03,1.3361278918589958,negative,end marketing agreement gsk osteoporosis,5,0,1
2014-04-04,2.861938708173738,negative,melanoma fails improve overall survival rate melanoma shrink tumor fails secondary study goal,13,-1,1
2014-04-22,1.4939366448645242,positive,profit fall inventory draw down sale disappoint profit fall cost disappointing sale,12,-2,1
2014-05-09,0.4849496257716357,positive,astra brodalumab meet goal phase psoriasis study,7,1,0
2014-05-19,0.2418566904631935,negative,fitch rate unsecured debt issuance bbb,6,0,0
2014-05-23,0.8622963319841803,negative,qiagen win approval test accompany cancer,6,2,0
2014-06-11,0.3013696715395308,negative,psoriatic arthritis maintains efficacy yr study,6,1,0
2014-07-02,0.4969466091926611,positive,bind therapeutic end cancer partnership,5,0,0
2014-07-17,0.83435229286698,negative,thyroid succeeds late stage kidney patient trial parathyroid found effective kidney patient trial,13,1,0
2014-07-23,0.5211281014920521,positive,growth brazil pick up eye doubling portfolio,7,1,0
2014-07-24,0.1998670044782491,positive,pave way novartis copy,4,0,0
2014-07-29,0.9678435883601066,positive,cut up job prepares introduce 2nd profit rise announces up job cut,12,2,0
2014-08-01,1.138826395483128,negative,express script drop anemia formulary express script excludes formulary,9,-1,0
2014-08-04,1.747057879780134,positive,cancer meet main goal late stage study blood cancer succeeds late stage study,13,0,1
2014-08-13,0.1305754453848839,positive,fails improve survival multiple myeloma trial,6,-1,0
2014-08-18,0.5216666793785851,negative,thyroid succeeds late stage trial,5,0,0
2014-08-19,0.6720165413851453,negative,corrected parathyroid succeeds late stage trial parathyroid succeeds late stage trial,11,0,0
2014-08-21,0.4046284668875577,negative,psoriasis impress battle nears novartis,5,0,0
2014-08-28,0.6788883840648352,positive,submits application sell cholesterol fighting,5,0,0
2014-09-16,0.2318769267631415,positive,ucb announce result several exploratory analysis phase study romosozumab,9,1,0
2014-10-08,1.2209938503477955,positive,psoriasis succeeds late stage trial humira copy succeeds skin disease trial,11,0,0
2014-10-21,2.804024036460051,positive,loeb hedge fund third point bet ebay alibaba exit sony third point loeb urge breakup,15,0,1
2014-10-22,0.3987788205454534,positive,bos make prime breakup target,5,0,0
2014-10-24,0.7627158303400439,negative,despite third point low expectation breakup,6,0,0
2014-10-27,0.7757803145184372,positive,profit top wall street expectation raise forecast profit top wall street expectation raise outlook expects job cut exceed,18,1,0
2014-10-28,4.919104016647102,positive,sanofi ono link academia protein project forecast top street view see cost cut buyback outlook top estimate no plan split jump,21,1,1
2014-11-04,0.3648801817755176,negative,ovarian cancer fails improve overall survival,6,-1,0
2014-11-07,0.1558905295608981,negative,eu plan risk reduction step servier heart,7,0,0
2014-11-11,0.5088649419350277,negative,psoriasis top jj stelara phase iii study,7,0,0
2014-11-20,0.1508273033044238,negative,ingapore press open s200 mln plant singapore strait time,9,0,0
2014-11-24,0.5608445982403065,positive,scrap trial advanced stomach cancer,5,0,0
2014-12-03,1.101097531510975,negative,fda approves leukemia ahead schedule,5,2,0
2014-12-08,2.08637369806699,positive,novartis copy show similar efficacy study,6,0,1
2014-12-17,0.573381449060717,positive,blincyto leukemia cost exclusive leukemia carry tag,7,0,0
2015-01-05,0.6176510006485447,positive,kite pharma ink deal develop cancer immunotherapy fda staff recommends novartis copy neupogen,13,0,0
2015-01-07,2.246357235762764,positive,fda panel unanimously back novartis copy neupogen,7,0,1
2015-01-27,0.7931682967381004,positive,q4 adj shr profit top expectation enbrel sale tax credit,10,0,0
2015-03-19,1.9993164960825367,positive,judge reject injunction bid novartis sandoz unit judge reject bid block biosimilar neupogen plan appeal court ruling could pave way novartis biosimilar judge reject bid block biosimilar neupogen,28,-1,1
2015-03-25,1.7814154818718952,negative,appeal rejection bid block novartis biosimilar,6,0,1
2015-04-15,1.335138189136198,positive,fda approves corlanor heart failure fda approves heart failure,9,2,1
2015-04-21,1.6194038472814642,positive,1st profit boosted rise lower rd earnings boosted higher lower rd,11,1,1
2015-04-27,2.877650234236284,negative,fda staff cite concern over cancer vaccine cancer immunotherapy fails impress fda staff reviewer,14,-2,1
2015-04-29,0.5178237113921069,negative,fda panel recommends approval skin cancer immunotherapy fda panel recommends approval skin cancer immunotherapy,14,1,0
2015-05-19,0.106269866761377,positive,cholesterol could get eu green light week,7,0,0
2015-05-22,0.0801844719489852,positive,end collaboration astrazeneca inflammation first win eu backing kind cholesterol end partnership astrazeneca psoriasis eu agency give nod cholesterol,19,2,0
2015-06-02,0.2764664546819895,negative,roche collaborate cancer study,4,0,0
2015-06-08,0.1475365596847022,positive,rpt repatha effective question patient fda repatha effective question patient fda repatha lower ldl no marked safety event fda staff,20,1,0
2015-06-10,0.7196295650221396,negative,fda panel back cholesterol high risk patient,7,0,0
2015-06-18,1.8651323441796877,positive,cancer meet main goal late stage study corrected cancer meet main goal late stage study,15,0,1
2015-07-16,0.8355935035091244,positive,report positive preliminary result leukemia,5,1,0
2015-07-21,0.0150409372336124,positive,european regulator approves anti cholesterol repatha win first approval class cholesterol,11,3,0
2015-07-30,0.1045797860848019,positive,q2 gaap earnings profit top street view boost full forecast,10,0,0
2015-08-18,0.9199509437296638,negative,pay mln settle enbrel aranesp marketing case pay million settle enbrel aranesp marketing case state mln settlement over marketing,19,-1,0
2015-08-27,1.1711953604747194,negative,fda approves cholesterol lowering repatha fda approves cholesterol repatha,9,2,0
2015-09-01,0.0747026074447099,positive,novartis join force fight alzheimer migraine bone succeeds late stage study valeant pick up astrazeneca psoriasis exit europe get cholesterol europe get cholesterol pct,24,0,0
2015-09-02,1.3773574259055898,positive,cannot stop imminent sale neupogen copycat appeal court cannot stop imminent sale neupogen copycat appeal court,16,-1,1
2015-09-11,0.4087196018797145,negative,seek fda approval dosing option repatha astrazeneca buy manufacturing facility,10,3,0
2015-09-16,1.4825976649714412,negative,buy dezima pharma mln cash xencor announce collaboration cancer immunotherapy inflammation buy dezima pharma million cash,16,2,1
2015-09-23,0.0108143155593265,positive,allergan avastin copycat succeeds lung cancer study,7,0,0
2015-09-25,3.439042091477884,negative,leukemia get conditional european approval eu agency recommends approval leukemia,10,1,1
2015-10-02,0.1035954874166078,positive,novartis biosimilar copycat take aim enbrel,6,0,0
2015-10-23,1.132875502283026,positive,win eu green light first virus based cancer virus based cancer win european green light eu agency back approval melanoma,20,2,0
2015-10-27,2.346936604161576,positive,fda approves injected immunotherapy melanoma cytokinetics heart failure succeeds mid stage study,12,2,1
2015-10-28,0.7213323226893165,negative,profit beat street issue conservative forecast 3rd profit sail past wall street estimate raise quarterly dividend,16,2,0
2015-11-18,0.519992667632474,positive,uk cost watchdog turn down cholesterol fda accepts sandoz submission biosimilar neulasta novartis biosimilar take aim neulasta,17,0,0
2015-11-23,1.715562969022788,positive,cv chooses cholesterol over competitor,5,0,1
2015-11-25,0.7330915879774969,positive,file approval biosimilar humira,4,1,0
2015-12-07,1.3330626750696184,negative,novartis study show copycat work well,6,0,1
2015-12-14,1.402580487190841,positive,reacquires right glaxo reacquires product right prolia xgeva vectibix gsk,10,0,1
2015-12-21,0.5226505059191755,negative,medigene x7famgen acquires medigene spin offx7f,6,0,0
2016-01-14,3.651867984566137,positive,patent office decline humira patent challenge patent office rule humira challenge,11,-2,1
2016-01-21,2.0051730828023806,negative,fda give full approval blood cancer,6,1,1
2016-01-25,0.1861923447116442,negative,top court rule over employee lawsuit,6,0,0
2016-01-28,1.9298329683040016,negative,4th profit top street raise forecast,6,1,1
2016-02-03,0.2131113049408606,negative,biocartis collaborate rapid ra biomarker testing,6,0,0
2016-02-22,2.487084811471507,negative,ucb announce positive top line result phase study romosozumab ucb announce positive top line result phase study romosozumab postmenopausal woman osteoporosis ucb osteoporosis meet main goal late stage trial,29,2,1
2016-03-16,0.0410479444237887,negative,uk cost agency reject virus based cancer jury rule over cholesterol patent beat sanofi cholesterol trial,16,0,0
2016-03-31,0.5437384969997128,positive,janssen pharmaceutical terminates licensing agreement fulranumab,6,0,0
2016-04-01,2.140120636855225,positive,phase result treat osteoporosis showed increase hip bone mineral density,10,0,1
2016-04-04,0.6481340225537702,positive,canada announces study result repatha statin intolerant patient,8,0,0
2016-04-07,0.2314445987296576,negative,ceo fy total compensation wa mln mln fy sec filing,10,0,0
2016-04-19,0.0680503195954029,negative,nplate study lancet show significant increase durable platelet response,9,0,0
2016-04-28,0.6342833999651409,positive,profit sail past street expectation raise outlook profit top street expectation raise outlook q1 adjusted earnings,16,1,0
2016-05-03,0.7901654032021033,negative,xbiotech appoints veteran scott whitehurst cfo fda grant priority review supplemental biologics license application blincytox7f,15,1,0
2016-05-05,0.0649097960053524,positive,anofi cholesterol win uk backing cut,6,1,0
2016-05-11,1.010594994762226,negative,cigna make deal sanofi pricey cholesterol cigna enters contract sanofiregeneron,10,0,0
2016-05-25,1.1878497944912247,positive,announces pricing term senior note offer,6,0,0
2016-05-27,0.3351004012505765,positive,receives positive chmp opinion extend indication kyprolis,7,2,0
2016-06-08,0.8861006184039288,negative,migraine prevention meet main goal study migraine prevention meet main goal mid stage study,14,0,0
2016-06-10,0.3279197208852835,negative,announces expiration final result senior note offer interim phase show blincyto improved overall survival patient,15,0,0
2016-06-13,0.3271568684510173,negative,announces fda advisory committee meeting review abp,7,0,0
2016-06-17,1.3894064726680644,negative,name esteban santos executive vp operation,6,0,1
2016-07-08,1.3910882963272364,positive,fda staff biosimilar highly similar humira,6,0,1
2016-07-11,0.9237660950084492,negative,novartis copy arthritis highly similar fda staff novartis copy arthritis highly similar fda staff novartis copy arthritis highly similar fda staff corrected novartis copy arthritis highly similar fda staff fda approves injection pcsk9 inhibitor,34,2,0
2016-07-12,0.3849128978288929,positive,fda panel back copy arthritis humira fda panel back copy arthritis humira,12,0,0
2016-07-13,0.8751521527202266,negative,fda panel support novartis version arthritis fda panel support novartis version arthritis,12,0,0
2016-07-19,0.1683948146963154,negative,patent trial over white blood cell neulasta wrap up fda knock back novartis copy neulasta fda knock back novartis copy neulasta,21,0,0
2016-07-20,0.0514233933931906,positive,announces settlement security litigation,4,0,0
2016-07-21,0.9535238284322012,positive,allergan biosimilar found effective roche cancer allergan collaborating development commercialization oncology biosimilars,12,1,0
2016-07-22,0.4528808394985262,positive,ucb submit biologics license application romosozumab fda declares quarterly dividend,10,0,0
2016-07-27,1.901304126333403,positive,2nd profit top street view raise forecast raise forecast display confidence refile raise forecast display confidence report second financial result,20,1,1
2016-08-02,0.6349878420760402,positive,report pct passive stake advaxis aug,6,0,0
2016-08-09,0.2104793364171464,negative,change tack uk agency back virus based cancer,8,0,0
2016-08-10,0.2464569788421022,negative,file potential senior note offering size not disclosed,8,0,0
2016-08-24,1.5298010974708842,negative,fda issue complete response letter nda parsabiv,7,0,1
2016-08-29,0.7599216846919221,negative,announces positive top line result phase study,7,1,0
2016-08-30,0.2724264691915556,negative,fda approves novartis biosimilar enbrel fda approves novartis biosimilar enbrel,10,2,0
2016-09-01,0.0365644641895812,positive,fda approves blincyto get commercial right boehringer ingelheim servier extend omecamtiv mecarbil collaboration,13,3,0
2016-09-07,0.1137890363491211,negative,apotex cleared infringement copycat dispute,5,0,0
2016-09-15,0.4700795149418235,positive,present positive ehmtic erenumab reduces migraine,6,1,0
2016-09-19,0.9322570091635174,negative,ucb announce finding frame study,5,1,0
2016-09-20,1.1623143113104195,positive,announces positive top line result phase glagov imaging study repatha cholesterol reduces arterial plaque buildup study,16,1,0
2016-09-23,0.0810098749301158,positive,fda approves cheaper copy arthritis humira fda approves copy arthritis humira fda approves amjevita fda approves copy arthritis humira,19,2,0
2016-09-26,0.0836780543969184,positive,ucb fda accepts biologics license application romosozumab open nomination process labcentral residency,12,0,0
2016-09-27,1.7157115654316324,negative,multiple myeloma fall short patient study phase study carfilzomib not meet primary endpoint multiple myeloma fall short late stage study,20,-1,1
2016-09-28,1.6150403087564214,negative,erenumab significantly reduces migraine day patient episodic migraine first phase study,11,0,1
2016-09-29,1.6054348890292005,negative,arrowhead develop gene therapy heart disease,6,0,1
2016-10-04,0.6352742693492619,positive,nuevolution strategic collaboration oncology neuroscience,5,0,0
2016-10-10,0.0372563758704869,negative,retrospective analysis confirm vectibix treatment provided survival benefit over chemotherapy without bevacizumab,12,1,0
2016-10-14,1.5063854280140454,negative,boeing board elect ceo robert bradway director announces appointment ellen kullman board,12,0,1
2016-10-20,0.4474088505314166,positive,announces positive top line result xgeva phase trial,8,1,0
2016-10-25,0.2097919576254381,negative,invest israel based ehealth venture,5,0,0
2016-10-27,1.2604556044784498,positive,third profit top street view cost cutting unlikely launch humira biosimilar q3 non gaap eps 3rd profit top expectation cost cutting 3rd profit top street view cost cutting,28,1,0
2016-10-28,9.28906372481879,negative,arrowhead pharma file sale aggregate mln common stock selling shareholder,10,0,1
2016-11-02,0.8616214591231186,negative,appoints lori johnston senior vice president human resource,8,0,0
2016-11-03,2.051299861469824,negative,unit sue generic over generic kyprolis plan,7,0,1
2016-11-10,3.2677213440098773,positive,genmab combination jj tested study janssen report clinical trial collaboration supply agreement evaluate daratumumab combination carfilzomib,16,0,1
2016-11-15,0.3431787401591446,negative,cholesterol reduces artery clogging plaque study,6,0,0
2016-11-16,0.3034330510220395,positive,migraine succeeds late stage trial announces erenumab significantly reduces migraine day patient episodic migraine second phase study,17,0,0
2016-11-17,0.4257754023307747,negative,novartis aim big crowded migraine,5,0,0
2016-11-30,1.0820015563065444,negative,cytokinetics lancet published result phase clinical trial evaluating omecamtiv mecarbil,10,0,0
2016-12-02,1.087628805103491,positive,allergan apply european nod avastin biosimilar allergan submit biosimilar marketing authorization,11,1,0
2016-12-16,0.4837676442897343,negative,receives positive response ema single dose delivery injection repatha,9,1,0
2016-12-20,0.7377254534851718,negative,ucb seek marketing approval romosozumab japan astellas astellas announce submission application investigational osteoporosis medication romosozumab japan announces pct increase q1 dividend,21,2,0
2016-12-22,0.3027273584809919,positive,biocartis sign testing collaboration europe,5,1,0
2017-01-03,2.3264431393399176,positive,anofi lose bid overturn win patent case,7,1,1
2017-01-05,0.1514022338561127,positive,court grant permanent injunction infringement repatha patent,7,0,0
2017-01-09,1.644034199803046,positive,corrected ceo not putting patient first patent dispute comment delaware court ruling pcsk9 patent litigation ceo not putting patient first patent dispute immatics enter strategic collaboration develop novel bispecific cancer immunotherapy doe not expect repatha outcome label davita enter sourcing supply agreement davita enters sourcing supply agreement,47,0,1
2017-01-27,2.8893627785428038,positive,ema recommends approval biosimilars receives positive chmp opinion abp opposes doctor weighing cholesterol patent fight,15,2,1
2017-02-02,0.1222695168611842,negative,4th qtr profit top street view outlook light cholesterol succeeds cutting serious heart problem study ceo expects see tax reform cholesterol succeeds cutting serious heart problem study 4th qtr profit top street view cholesterol news lift report q4 eps fourth profit top street view cholesterol news lift,47,1,0
2017-02-03,4.292538991971351,positive,appoints charles holley jr board director,6,0,1
2017-02-07,0.1397028396985966,positive,fda approves secondary hyperparathyroidism fda approves secondary hyperparathyroidism fda approves parsabiv first treatment decade secondary hyperparathyroidism adult patient hemodialysis,19,2,0
2017-02-14,0.1669193861489226,negative,submits supplemental biologics license application blincyto file potential mixed shelf size not disclosed,13,0,0
2017-02-27,0.7431163082419534,positive,perrigo cfo join late,4,0,0
2017-02-28,0.4970218941083182,positive,longer survival seen kyprolis velcade myeloma study announces positive result planned overall survival analysis phase head head endeavor trial,19,1,0
2017-03-01,0.4310799936296128,negative,present kyprolis xgeva,3,0,0
2017-03-03,1.1332075407407327,positive,present phase xgeva study multiple myeloma patient,7,0,0
2017-03-06,0.1128647906163515,negative,coherus bioscience file trade secret action highlight landmark repatha cardiovascular outcome study,12,0,0
2017-03-07,0.8603464486334866,negative,set quarterly dividend,3,0,0
2017-03-13,0.2654313336653113,negative,repatha lower need cholesterol lowering procedure heart benefit key unlocking sale rpt heart benefit key unlocking sale,17,1,0
2017-03-14,0.1310101476590497,negative,report follow up result repatha osler study,7,0,0
2017-03-21,0.1282458957634236,negative,anofi sue protect eczema patent claim,6,0,0
2017-03-29,1.0952444340351808,negative,fda grant priority review blincyto supplemental biologics license application enters agreement inovalon avalere,13,1,0
2017-04-04,0.2230399871881561,positive,submits application europe expand current indication xgeva,7,1,0
2017-04-06,0.2749518057678424,negative,ceo robert bradway total compensation wa mln mln sec filing,10,0,0
2017-04-24,0.6020969133063492,positive,announces expanded commercial collaboration novartis erenumab migraine,7,0,0
2017-04-25,0.374370684111458,positive,coherus bioscience completes formality coherus chs,6,0,0
2017-04-26,0.0082388624944362,positive,first profit exceeds street estimate lower cost report q1 gaap earnings optimistic enbrel sale rebound cost control help offset lower 1st sale cost control help offset lower first sale,29,1,0
2017-05-02,0.5096434723049992,positive,harvard pilgrim agree contract repatha,5,0,0
2017-05-08,0.4594768012556094,negative,file potential part senior note offering,6,0,0
2017-05-09,0.2083405132665916,positive,feldan therapeutic elasmogen announce research agreement,6,1,0
2017-05-18,0.1701810691169702,positive,submits biologics license application fda erenumab,6,0,0
2017-05-22,2.737634002883682,negative,heart safety cloud hope ucb bone approval,7,1,1
2017-06-05,0.7460379731618172,positive,submits regulatory application repatha cardiovascular outcome europe,7,0,0
2017-06-07,1.150148019827224,positive,allergan announce fda advisory committee meeting review abp,8,1,0
2017-06-12,0.5203598458049186,positive,fda reject coherus biosimilar neulasta fda reject coherus biosimilar neulasta multiple myeloma treatment combination dexamethasone receives nice recommendation use first relapse,21,-2,0
2017-06-19,0.8113750898901761,positive,fda accepts sbla expand indication xgeva,6,1,0
2017-06-23,0.8788301845683799,negative,receives positive chmp opinion expand use mimpara,7,2,0
2017-06-27,0.8181499746345855,negative,novartis get european ok biosimilar enbrel,6,0,0
2017-07-11,0.7246731213662039,positive,fda grant full approval blincyto treat relapsed refractory cell precursor acute lymphoblastic leukemia,13,1,0
2017-07-13,0.8535011957320426,positive,allergan discus supporting biologics license application abp,7,0,0
2017-07-14,0.7276025193723612,positive,submits regulatory application europe,4,0,0
2017-07-17,0.1646473917927493,positive,ligand enters commercial license supply agreement,6,0,0
2017-07-18,0.0078508577957325,negative,array biopharma announce preclinical license collaboration agreement,7,1,0
2017-07-20,0.033597504142846,positive,fda accepts biologics license application aimovig,6,0,0
2017-07-25,0.3369836593467346,negative,q2 gaap shr 2nd profit top street view fall second profit top street view fall,15,-1,0
2017-07-27,2.033373372497937,negative,get fast fda review adding heart benefit cholesterol label fda grant priority review supplemental biologics license application repatha get fast fda review adding heart benefit cholesterol label,27,2,1
2017-07-28,1.5056380519577472,positive,set quarterly dividend 15shr,4,0,1
2017-07-31,0.0395127844569187,positive,submits supplemental biologics license application prolia glucocorticoid induced osteoporosis allergan submit biosimilar biologics license application abp fda,17,0,0
2017-08-14,0.3307641686508322,positive,oros fund management llc dissolve stake alphabet american airline,9,0,0
2017-08-17,0.5297201366124327,negative,humana partner improved outcome,4,0,0
2017-08-21,0.4417722702196203,positive,present repatha cardiovascular outcome study,5,0,0
2017-08-24,0.7952018160690355,positive,foundation expands experience,3,0,0
2017-08-28,1.197749128646941,positive,repatha analysis demonstrates cardiovascular outcome efficacy,6,0,0
2017-09-06,0.5865365627660379,positive,astrazeneca offer broad asthma relief,5,0,0
2017-09-07,1.318350914744204,positive,aimovig reduces migraine patient failed preventive astrazeneca look strong rival severe asthma,12,0,1
2017-09-12,2.081295107916792,positive,ucb announce detailed result phase arch study,7,1,1
2017-09-14,0.1050802590384369,negative,fda approved mvasi biosimilar avastin,5,0,0
2017-09-25,0.4897723705426848,positive,provides update hurricane maria hospira must pay million biosimilar patent case jury,12,-1,0
2017-09-26,0.4306481559830599,negative,simcere announce strategic collaboration develop commercialize biosimilars china,8,1,0
2017-09-28,0.1937410004680506,positive,agree settlement allowing commercialization amgevita settlement set humira biosimilar launch,10,1,0
2017-10-03,0.1819575310608057,negative,cytomx therapeutic announce strategic collaboration immuno oncology,7,1,0
2017-10-16,0.7398837158520966,negative,boston child hospital enter neuroscience research collaboration,7,0,0
2017-10-23,0.9392205737350444,negative,phase study kyprolis regimen meet primary endpoint,7,0,0
2017-10-24,0.2643336807686025,negative,declares dividend q4 appoints wanda austin board director,8,0,0
2017-10-25,1.096162785127841,negative,quarterly profit top expectation despite sale decline report q3 non gaap earnings,12,-2,0
2017-10-31,0.2050518359078879,positive,joint venture become wholly owned subsidiary kirin terminating shareholder agreement jv japan kirin cash joint venture,16,0,0
2017-11-02,1.7547183436737337,negative,novartis announce expanded collaboration banner alzheimer institute,7,1,1
2017-11-10,0.9172885281908184,negative,allergan receive positive chmp opinion abp receives positive chmp opinion expand use nplate pediatric patient chronic immune thrombocytopenic purpura,19,2,0
2017-11-14,0.5665727579929891,negative,temasek holding take stake vantiv raise stake,7,1,0
2017-11-17,0.1570314193426902,negative,launch enbrel mini autotouch,4,1,0
2017-11-29,1.217920504973069,positive,aimovig phase published england journal demonstrate significant sustained efficacy migraine prevention,11,0,0
2017-12-01,1.084232950389652,positive,fda approves heart protection claim cholesterol,6,2,0
2017-12-04,0.961859073144966,positive,biocartis sign companion diagnostic agreement idylla ra biomarker test,9,1,0
2017-12-05,0.348465189532221,positive,xencor receives milestone payment,4,0,0
2017-12-06,1.390240756381278,negative,carmot enters multi discovery collaboration,5,0,1
2017-12-11,0.5082250352099527,positive,kyprolis improves overall survival blood cancer patient,7,0,0
2017-12-12,0.4988295438688173,negative,announces increase q1 dividend,4,0,0
2017-12-22,0.120998304286457,negative,expects incur gaap net tax expense bln bln estimate tax bill over billion repatriate cash,15,0,0
2018-01-05,0.0705619461211837,negative,fda expands use blockbuster,4,2,0
2018-01-09,1.312969942011244,positive,expects launch migraine biocartis sign agreement,6,2,1
2018-01-17,0.3780775025482574,positive,analysis kyprolis trial published journal clinical oncology,7,0,0
2018-01-18,0.0553011027478844,negative,european commission approves allergan mvasi,5,1,0
2018-01-22,0.7982742895885186,positive,report aimovig met primary secondary endpoint,6,0,0
2018-01-30,2.3732768177992303,negative,receives chmp positive opinion add updated overall survival kyprolis label,10,1,1
2018-02-01,0.1498546306892723,negative,q4 loss profit miss street view see broad tax reform benefit,11,-1,0
2018-02-08,1.2997687875300643,positive,announces phase xgeva study result,5,0,0
2018-02-14,1.4354162944452575,positive,announces fda advisory committee meeting review potential use blincyto,9,0,1
2018-02-20,0.3155792566081783,positive,loses case over fda denial sensipar pediatric exclusivity,8,0,0
2018-02-22,0.1186425196940454,negative,abarca enter outcome based agreement repatha,6,0,0
2018-02-23,0.7190275445612349,positive,receives positive opinion expanding use xgeva,6,1,0
2018-02-27,0.1890151892405156,negative,receives positive chmp opinion delivery system neulasta,7,1,0
2018-03-07,1.4448353369768907,negative,set quarterly dividend,3,0,1
2018-03-08,0.681208209700912,negative,announces final result tender offer,5,0,0
2018-03-23,1.6452402185573425,negative,chmp recognizes repatha prevents heart attack stroke allergan receive positive chmp opinion abp eu agency recommends approval europe sandoz biosimilar,20,2,1
2018-03-29,1.2660255759465722,negative,fda expands use leukemia blincyto patient relapse risk,8,1,0
2018-04-03,0.0251325683885417,positive,commission approves expanded indication xgeva,5,1,0
2018-04-10,0.4792931321433435,positive,rhode island governor build another plant state rhode island governor build second plant state plan build biomanufacturing plant rhode island,20,1,0
2018-04-11,0.1083591015144214,positive,ceo robert bradway fy total compensation wa mln,8,0,0
2018-04-17,0.9724065266769166,positive,aimovig halved migraine day trial patient aimovig halved migraine day pct trial patient,13,0,0
2018-04-24,0.2105731554812417,negative,express script target migraine pricing shift focus express script target migraine pricing shift expects strong demand migraine prevention post higher 1st profit sale rise,24,2,0
2018-04-25,1.433651805508629,positive,board increased amount authorized under stock repurchase program additional bln sec filing,12,0,1
2018-04-30,0.9101940394063536,negative,receives positive chmp opinion add overall survival result phase aspire study kyprolis label,13,1,0
2018-05-01,3.1579713170526102,negative,express script exclusion impact repatha patient,6,0,1
2018-05-15,1.3685906048119478,negative,biosimilar jj anemia treatment get fda nod fda approves biosimilar epogen,11,3,1
2018-05-16,1.1925813655489614,positive,receives european commission approval repatha,5,1,0
2018-05-17,0.5735521725212633,positive,fda approves prevention migraine corrected fda approves prevention migraine fda approves migraine set 6900yr,14,2,0
2018-05-22,1.3490150564013037,positive,director nominee elected board,4,0,1
2018-06-04,0.5435387719500584,positive,fda approves mylan first biosimilar neulasta,6,2,0
2018-06-28,0.6752721075555468,negative,novartis present demonstrating long term efficacy safety tolerability aimovigxe2x84xa2,9,0,0
2018-07-26,0.7591148122673919,positive,ceo not raise profit beat street view not raise migraine hit insurance hurdle rpt focus migraine hit insurance hurdle focus migraine hit insurance hurdle,24,3,0
2018-09-10,2.984578399761273,positive,win affirmed 8th circuit appeal over alleged enbrel side effect,10,1,1
2018-10-16,1.2645077605820898,positive,novartis kick off fight blockbuster eu,6,1,0
2018-10-17,0.194681922132478,positive,express script cover migraine excludes teva,6,0,0
2018-10-24,1.908411585318792,negative,cut cholesterol repatha,3,0,1
2018-10-30,1.0089201361352718,negative,post higher quarterly eps repatha sale fall short quarterly net profit fall expense increase eps rise,16,0,0
2018-11-08,0.6281464487939648,negative,coherus biosimilar neulasta pct discount coherus biosimilar neulasta discount,9,0,0
2018-12-04,0.6925669268841861,positive,antibody show promise myeloma trial get fda fast track,9,1,0
2018-12-18,1.458111819637531,negative,molecular partner announce strategic collaboration immuno oncology,7,1,1
2018-12-19,0.6370669848348554,positive,molecular partner agrees cancer immunotherapy deal,6,0,0
2019-01-02,1.526954131004965,negative,teva end dispute over generic cinacalcet hcl tablet corrected teva resolve ongoing dispute over teva generic cinacalcet hcl product,19,0,1
2019-01-07,0.5572192390354003,positive,supreme court reject over cholesterol medication patent fight top court reject over cholesterol medication patent fight,16,-1,0
2019-01-16,0.4877438086946184,negative,postmenopausal osteoporosis win fda panel backing,6,1,0
2019-01-25,1.94083000252504,negative,exclusive cv cover migraine teva excludes,6,0,1
2019-01-29,0.2160514312868566,positive,forecast fall short expectation dip,5,-1,0
2019-02-01,0.0695384334416626,negative,exclusive top insurer cover migraine exclude teva,7,0,0
2019-02-11,0.1683622415760477,negative,judge bar willfulness claim retrial cholesterol patent lawsuit,8,0,0
2019-02-15,0.2005073734746787,negative,ptab side sanofi dupixent fight,5,0,0
2019-02-25,1.0958675930948347,positive,anofi lose patent challenge cholesterol corrected sanofi lose patent challenge cholesterol report corrected sanofi lose patent challenge cholesterol,18,-1,0
2019-04-04,0.5711708484853584,negative,novartis dispute over migraine partnership novartis sue over migraine treatment aimovig,11,0,0
2019-04-09,0.4624758296896014,negative,postmenopausal osteoporosis get fda approval postmenopausal osteoporosis get fda greenlight,10,2,0
2019-04-15,0.0494494055085725,negative,set annual evenity bone,4,0,0
2019-04-25,1.2842537592359426,positive,humira rival aggressive far drugmakers astellas pay mln charity kickback probe drugmakers astellas pay million charity kickback probe,18,-2,0
2019-04-30,1.072183343772748,negative,revenue flat first aimovig repatha fall short sale expectation revenue flat migraine cholesterol miss sale expectation,16,-3,0
2019-05-10,1.0923760208193969,negative,migraine pull ahead fierce battle prescription,6,0,0
2019-05-22,1.2559335702891803,positive,offer buy copenhagen based nuevolution mln buy copenhagen based nuevolution mln buy copenhagen based nuevolution million,16,1,0
2019-06-03,3.6496167181622408,positive,show high response rate small lung colon cancer trial,9,0,1
2019-06-04,0.7956378519534235,negative,anofi loses german patent case over cholesterol,7,0,0
2019-07-11,2.577097921005178,negative,novartis banner alzheimer institute discontinue clinical program bace inhibitor cnp520 novartis banner alzheimer institute discontinue clinical research program bace inhibitor cnp520 alzheimer prevention,23,0,1
2019-07-23,0.646780577160766,negative,roche take fight biosimilars avastin herceptin fed circuit,8,0,0
2019-07-30,0.4556037943901914,positive,result beat estimate lung cancer trial planned quarterly revenue dip profit top street expectation,14,1,0
2019-08-07,0.557821914987422,negative,roche loses another bid halt sale biosimilar cancer,8,0,0
2019-08-09,6.63051276495914,positive,win patent battle arthritis enbrel thwarting novartis court upholds patent arthritis enbrel,12,2,1
2019-08-26,2.073781099449712,positive,buy celgene psoriasis otezla billion buy celgene psoriasis otezla bln cash,11,1,1
2019-08-28,0.2053382044880036,negative,judge rule sanofi patent fight judge rule sanofi cholesterol patent fight,11,0,0
2019-08-30,0.83677937890142,positive,patent court review alexion soliris patent challenge patent court review alexion soliris patent challenge filing,15,-1,0
2019-10-24,0.2912759304753542,negative,set lower list cholesterol slash tag cholesterol repatha,8,0,0
2019-10-29,1.971042304283965,positive,post higher biosimilar sale end neuroscience program third revenue fall biosimilar sale rise,13,1,1
2019-10-31,1.3901866309346422,positive,take stake beigene expand china take stake beigene sell cancer china,11,1,1
2019-11-05,0.4231012949455937,positive,novartis get nod long delayed copycat,6,1,0
2019-11-21,1.185235509465532,positive,raise profit sale view buying celgene psoriasis,7,1,0
2019-11-25,0.87185597597641,positive,novartis take sanofi bln takeover heart maker novartis take sanofi billion takeover heart maker,14,0,0
2019-12-03,0.3665510479968437,positive,pharmacy benefit manager abarca ink discount deal enbrel,8,1,0
2019-12-06,0.7591679500728254,negative,fda approves biosimilar jj rheumatoid arthritis,6,2,0
2019-12-16,2.0417282864658937,positive,fed circuit upholds million patent win,6,1,1
2013-01-09,0.309422793861569,positive,see no need major acquisition cfo,6,0,0
2013-01-23,3.628193439945116,positive,abbott result bode well spun off,6,1,1
2013-01-30,0.626883452883209,negative,forecast slower humira growth interested smaller tuck acquisition issue forecast line street estimate,13,1,0
2013-04-23,1.0957689970835238,positive,hepatitis knock virus week hepatitis knock virus eight week,9,0,0
2013-04-26,3.793270391191717,positive,delivers strong growth humira arthritis expects q2 eps excluding item meet expectation fueled humira sale delivers scorching humira sale growth,20,3,1
2013-05-10,1.4151134014259714,positive,chief scientific officer john leonard retire,6,0,1
2013-05-17,1.1097694934316893,positive,galapagos announces 50m extension deal,5,0,0
2013-07-23,1.2552557163302724,negative,fda advisory panel vote use humira,6,0,0
2013-07-26,1.136665796403724,positive,fast growing humira extends domination beat forecast humira sale strong,10,3,0
2013-09-23,1.0840767254493455,negative,ablynx sign deal worth up million ablynx sign licensing deal,10,1,0
2013-09-24,2.1425282776105448,negative,belgium galapagos sign million deal,5,1,1
2013-10-25,2.4015837164719,positive,beat forecast humira sale surge beat forecast surging humira sale,10,5,1
2013-11-18,1.2375989235549167,positive,hepatitis treatment help pct patient trial report phase iii result hepatitis virus program,13,0,0
2013-12-10,2.17437569742005,positive,oral hep cure pct late stage trial oral hep cure late stage trial pct patient oral hepatitis study show improvement,20,0,1
2013-12-13,0.0269474695389293,negative,show promise difficult type breast cancer,6,1,0
2013-12-18,0.4206554855619604,negative,sandoz start late stage trial copy humira,7,1,0
2014-01-31,2.4902070497916373,positive,see approval hepatitis rise expects fda grant priority review hepatitis profit slip give cautious forecast 4th earnings slide hit generic competition,21,2,1
2014-02-05,0.3333765160081547,negative,build manufacturing plant singapore,4,1,0
2014-02-25,0.2177976296240946,negative,update moody roche exposed biosimilar,5,0,0
2014-04-03,0.4323216746590419,positive,drop legal action eu secrecy case drop secrecy case eu agency,11,-2,0
2014-04-23,0.4941275835003145,positive,ablynx initiate phase study anti il 6r nanobody,8,0,0
2014-04-25,0.4549268223351221,positive,beat forecast humira sale soar 1st qtr profit beat estimate humira sale soar see slow flat growth testosterone product like androgel,21,2,0
2014-06-13,0.6269462263876591,positive,hepatitis regimen get nod fda priority review,7,2,0
2014-06-16,0.3778399725849479,negative,slows episode safety issue recur,5,0,0
2014-06-17,0.2776205101658435,positive,oral hepatitis therapy get rapid eu review,7,0,0
2014-06-19,0.8084495065884822,negative,exclusive approach shire possible takeover source,6,0,0
2014-06-20,1.84426785318178,negative,shire reject billion takeover bid hire offer undervalues group shire rejected bid approach hire proposal undervalues,16,-1,1
2014-06-23,0.8748992926263299,positive,raise outlook hire flag existing defence raise adjusted profit forecast raise forecast pursues shire hire flag astrazeneca style defence hire set astrazeneca style defence,24,1,0
2014-06-25,2.179110488033209,positive,patent win help shire plot next bid move hire announcement contains no material information press case shire deal urge talk ceo not ruling hostile move shire press case billion shire takeover buzz shire plc ceo doe not rule hostile move,40,1,1
2014-06-26,2.817036506696857,positive,hire flag astrazeneca style defense,5,0,1
2014-07-03,0.3025154279931108,negative,press case shire deal discreet roadshow,6,0,0
2014-07-08,2.3360886592980745,negative,increase offer shire pct hire get hike bid drugmaker shire billion hostile move shire remains option shire board meet consider proposal raise bid drugmaker shire pound,26,1,1
2014-07-09,1.669475563714251,negative,forced retract claim shire support forced retract comment shire takeover fight,11,0,1
2014-07-11,0.8724152801835916,negative,hire confirms talk takeover bid shire stay silent urge talk corrected shire stay silent urge talk,16,0,0
2014-07-14,0.70368047708389,negative,hire board talk revised proposal hire ready recommend higher offer shire ready bow increased billion offer,16,0,0
2014-07-17,0.8942819743412267,positive,corrected shire announce bln merger friday source corrected shire announce billion merger friday source hire announce billion merger friday source,20,1,0
2014-07-18,1.5752397522447836,positive,drugmaker finally win dublin shire billion deal ceo tax not primary reason buying shire rlpc shire merger backed bln stg bridge loan,22,1,1
2014-07-25,1.1960411025439543,negative,profit beat estimate surging humira sale,6,2,0
2014-09-03,0.8538158722517619,positive,google calico forge deal disease aging,6,1,0
2014-09-08,0.4028579888277428,negative,teva broke law androgel pay delay deal ftc teva broke law reaching androgel agreement,14,-2,0
2014-09-15,0.1617133008163018,positive,eu decide bln shire deal oct eu decide billion shire deal oct,12,0,0
2014-09-23,1.3863476068092906,negative,stock tekmira pharma among premarket active,6,0,1
2014-09-25,0.1646042966949368,negative,abbott win dismissal claim over humira androgel,7,1,0
2014-10-14,0.7963966930540689,positive,reconsider recommendation shire acquisition,4,0,0
2014-10-15,1.6003138127566152,positive,update cool bln shire deal tax change hedge fund bleed reconsiders shire bid hire not renege merger deal turn show shire wa mostly tax cool billion shire deal tax change shire waif notice requirement board meeting,36,0,1
2014-10-16,3.0809350942762825,negative,shire board considering withdrawal recommendation deal uk ftse recovers fed hope shire lag drop bid board ditch planned bln shire acquisition bank could miss mln fee drop shire deal recommends stockholder reject shire deal bank could miss million fee drop shire deal,42,-3,1
2014-10-20,0.9776834823129744,positive,refile shire cfo leave drugmaker drop bid hire cfo leave drugmaker drop bid billion acquisition shire officially dead corrected ceo gonzalez loses shire win praise gusty move,27,0,0
2014-10-21,1.474164695727498,positive,refile ceo gonzalez loses shire win praise gutsy move refile rpt ceo gonzalez loses shire win praise gutsy move ceo gonzalez loses shire win praise gutsy move,27,1,1
2014-10-24,0.5241757932096469,positive,hire ops unaffected failed takeover,5,0,0
2014-10-29,1.407964199910583,negative,law firm investigating over collapsed shire deal express script could displace sovaldi formulary,13,0,1
2014-10-31,2.5831630853305976,positive,ceo remains interested deal failed billion effort buy shire strong result lessen need big deal sale blow past forecast fueled humira,21,1,1
2014-11-05,0.8231305632776298,negative,elliott associate sue over scuttled deal elliott associate mull lawsuit letter,11,-1,0
2014-11-11,0.0039901981648382,negative,enanta show potential hep genotype patient,6,0,0
2014-11-21,2.793659895087597,positive,europe give green light hepatitis others europe give green light hepatitis others,12,0,1
2014-12-10,0.6531531114641997,negative,hire ceo eye deal no urgency spend breakup fee,9,0,0
2014-12-19,0.7323041201071745,negative,fda approves oral hepatitis treatment fda approves hepatitis cost week newly approved hepatitis treatment cost,15,2,0
2014-12-22,1.552900048942485,negative,private equity holding portfolio enanta get fda approval viekira pak refile fda approves hepatitis cost week express script drop hep cheaper rival,22,3,1
2015-01-05,0.0759564504572041,negative,cv cover hepatitis treatment over regimen,6,0,0
2015-01-08,0.7286356547394401,negative,forecast earnings largely above analyst estimate neurocrine successful endometriosis trial,10,1,0
2015-01-12,0.7529493550784028,positive,win approval parkinson treatment hire gamble break fee risky bln deal breakingviews shire gamble break fee risky bln deal corrected win approval parkinson treatment,24,2,0
2015-01-30,3.130978418465547,negative,take meaningful hepatitis drugmaker beat estimate humira sale rise expects billion annual hepatitis sale expects hep sale top billion profit beat estimate higher humira sale,25,3,1
2015-02-03,0.118956860825059,positive,catamaran back hepatitis treatment over competitor,6,0,0
2015-03-04,1.5117993729654944,positive,buy pharmacyclics billion deal,4,1,1
2015-03-12,1.1659076638584676,positive,trlpc nxp boost volume,4,0,0
2015-03-17,1.3290477878230345,positive,ablynx start first phase iib rheumatoid arthritis study,8,1,1
2015-04-23,0.6701009651658096,negative,drugmaker profit beat estimate strong humira sale drugmaker profit rise sale humira corrected drugmaker profit beat estimate strong humira sale,20,3,0
2015-05-13,0.737006730799683,positive,extends multiple myeloma remission study extends multiple myeloma remission study,10,0,0
2015-06-24,0.416286894946305,negative,hepatitis cocktail succeeds late stage study,6,0,0
2015-07-22,0.250302083831766,positive,judge toss shareholder case over spinoff release,7,0,0
2015-07-24,2.4130902437374258,negative,profit jump pct humira sale rise revenue miss raise concern over humira sale corrected get fda approval hep corrected report first revenue miss six corrected get fda nod hep treatment,30,2,1
2015-08-12,0.6079961126855604,positive,seek fda approval leukemia trial success seek approval potential blockbuster leukemia,11,3,0
2015-08-19,0.3938763647331034,positive,buy special review voucher million buy special review voucher mln,10,1,0
2015-09-16,0.3279512508952864,negative,reduces bleeding uterine fibroid patient move jpmorgan north america head gosebruch leaving,12,0,0
2015-09-25,1.4361094057111723,negative,scrap galapagos deal focus arthritis,5,0,1
2015-10-22,11.99341535746242,negative,express script review warning hep fda warns serious liver injury risk hep fda warns serious liver injury risk hep,19,0,1
2015-10-28,0.1459565636857451,positive,express script maintain availability hep,5,0,0
2015-10-30,10.533509177052936,positive,project double digit annual earnings growth through report q3 adjusted earnings,11,1,1
2015-11-11,1.9182242398674052,negative,ceo imbruvica second generation immuno oncology potential exceed long term sale expectation,12,0,1
2015-12-07,0.9856073276724776,negative,sue sandoz over proposed generic androgel,6,0,0
2015-12-17,0.6451905169273298,negative,astrazeneca see acerta superior abbviejj imbruvica,6,0,0
2016-01-12,0.974906215780158,positive,roche get priority review status leukemia roche get priority review status leukaemia,12,1,0
2016-01-13,3.140510565559429,negative,expects humira annual sale bln,5,0,1
2016-01-29,4.138719419714676,negative,expects bln sale viekira pak drugmaker report higher quarterly revenue fall sale outlook humira viekira pak expects mid single digit growth humira outside,23,0,1
2016-02-09,1.1101323181607503,positive,corrected fda staff back biosimilar remicade jj fall fda staff back biosimilar remicade jj fall,15,-1,0
2016-02-26,0.1257414697537373,negative,receives ema orphan designation venetoclax,5,0,0
2016-03-01,0.8172240973882694,positive,uk cost agency reject leukaemia jj,6,-1,0
2016-03-21,1.131813112548774,negative,ceo gonzalez total compensation mln,5,0,0
2016-04-04,3.441176376514554,positive,receives chmp positive opinion humira,5,1,1
2016-04-11,0.2860252337893665,positive,abbvieroche get approval rare type leukemia,6,1,0
2016-04-12,1.4447900878578943,positive,corrected fda granted accelerated approval venclexta tablet,7,2,1
2016-04-20,0.4199177252992569,positive,enters collaboration agreement university chicago,5,0,0
2016-04-21,2.009402335792665,positive,argen collaborate argx novel immuno oncology target get option early argenx cancer mln cytomx announce strategic collaboration argenx collaborate argx novel immuno oncology target,24,1,1
2016-04-25,0.5603868402185963,negative,receives fda approval supplemental application viekira pak without ribavirin,9,2,0
2016-04-28,1.7312985549265414,positive,report q1 adjusted eps deal give strong position solid tumor credit rating lowered moody review baa1 downgrade buy stemcentrx bln deal forge deeper cancer clock tick humira buy stemcentrx bln deal,31,0,1
2016-04-29,0.2130893419777235,positive,galapagos expand cystic fibrosis collaboration galapagos expand cystic fibrosis collaboration receive positive opinion chmp zinbryta,15,2,0
2016-05-16,0.2607163310666127,negative,paulson dissolve take expedia,4,0,0
2016-05-17,2.5894625096779422,negative,coherus patent office review humira humira protected many patent covering aspect manufacture formulation indication,14,0,1
2016-05-24,1.064649662200634,positive,il inhibitor risankizumab induces remission phase ii study,8,0,0
2016-05-27,0.8786352756311455,positive,injection win approval injection win fda approval humira receives chmp positive opinion treat non infectious uveitis,16,4,0
2016-05-31,0.5410842689748674,positive,european commission approves imbruvica,4,1,0
2016-06-01,0.3638285712437406,negative,moody downgrade baa2 stable outlook,5,1,0
2016-06-02,3.292637233798468,positive,entered repurchase agreement jpmorganchase,4,0,1
2016-06-03,0.1604378865036393,positive,late stage pipeline ha potential deliver over indication,8,1,0
2016-06-06,3.862694834099501,negative,report pct passive stake reata sec filing,7,0,1
2016-06-10,1.359275830938933,positive,eu want transparency humira world top,6,0,1
2016-06-28,0.4288445194730927,positive,infinity regains worldwide right duvelisib end collaboration,7,0,0
2016-06-29,1.3310795976862575,positive,announces fourth breakthrough therapy designation granted fda,7,2,1
2016-07-05,0.5404483872349042,negative,approved eu multiple sclerosis approved eu,6,0,0
2016-07-07,0.1566895608935747,positive,interview blockbuster hope grow ablynx backed blockbuster hope grow ablynx backed,11,1,0
2016-07-08,0.338169555042489,negative,fda staff biosimilar highly similar humira,6,0,0
2016-07-11,0.0565575639880355,negative,receives rare pediatric disease designation fda,6,0,0
2016-07-12,1.0607648408892834,positive,fda panel back copy arthritis humira fda panel back copy arthritis humira,12,0,0
2016-07-25,1.0708418504359885,positive,chmp grant positive opinion shorter treatment duration viekirax receives fda approval daily viekira xr,14,3,0
2016-07-26,0.1559542600508168,positive,chem enter discovery partnership,4,0,0
2016-07-28,0.3928125413841465,negative,initiate late stage study venetoclax patient relapsed refractory multiple myeloma,10,0,0
2016-07-29,2.1716700155373747,positive,drugmaker bump up profit forecast strong humira sale ceo no longer looking big acquisition conf call q2 adjusted eps,19,0,1
2016-08-05,0.152228772191254,negative,elliott associate sue over failed bid shire,7,0,0
2016-09-09,1.300755790146868,positive,set quarterly cash dividend 57per,5,0,0
2016-09-20,0.5834587856267559,positive,karolinska development collaboration parkinson disease research bioarctic enters collaboration parkinson disease research,12,0,0
2016-09-23,0.3942700451446179,positive,fda approves copy arthritis humira fda approves copy arthritis humira present eight week treatment viekirax,15,2,0
2016-09-30,0.3566537651887858,negative,enanta pharmaceutical announces investigational hcv regimen receives fda breakthrough therapy designation investigational hcv regimen receives fda breakthrough therapy designation,19,1,0
2016-10-05,0.1765229164782722,positive,oral therapy available canadian,4,0,0
2016-10-14,1.654257285879479,negative,ema committee conditionally approves leukaemia ema committee conditionally approves leukemia ema recommends conditional approval leukemia,15,2,1
2016-10-19,0.4616762705805577,negative,announces positive pivotal phase elagolix,5,1,0
2016-10-28,5.9849665269172565,negative,humira loses momentum plunge nothing alarming slowdown third humira sale quarterly revenue rise report third financial result,17,0,1
2016-11-02,1.204165408024871,positive,announces european fixed income meeting,5,0,0
2016-11-04,0.3785462198625078,positive,receives fda orphan designation investigational veliparib,6,0,0
2016-11-07,2.915640179735912,positive,coherus bioscience receives decision denying institution ipr related humira formulation,10,0,1
2016-11-11,1.1757502745314286,negative,hepatitis treatment show promise,4,1,0
2016-11-14,0.2845722294901653,negative,humirax7f receives chmp positive opinion treat adolescent hidradenitis suppurativa,9,1,0
2016-11-17,0.2540791236186779,negative,entered underwriting agreement pursuant ha agreed issue note underwriter,9,0,0
2016-11-21,0.9203806283321292,negative,halozyme provides update collaboration,4,0,0
2016-11-30,1.04275950741618,negative,investigational il inhibitor risankizumab receives orphan designation fda,8,0,0
2016-12-01,2.329822372791013,negative,asks judge dismiss testosterone bellwether suit,6,0,1
2016-12-05,1.8053149545641525,positive,lurie cancer center collaborate multi cancer research agreement,8,0,1
2016-12-06,0.932026939387698,positive,report positive phase ibrutinib cgvhd patient,6,1,0
2016-12-09,0.4468609099380627,positive,get canada approval zinbryta,4,1,0
2016-12-19,0.2177417415989424,negative,submits application fda chronic hepatitis treatment,6,0,0
2016-12-27,0.0085524019620253,positive,eattle genetics entered tenth amendment development supply agreement,8,0,0
2017-01-09,0.988501504271022,positive,genomics wuxi nextcode announce genomics alliance announces collaboration investment announces high svr rate week treatment investigational zebra biologics collaborate discover antibody therapeutic emergent tech pure mhc embark research license deal,30,1,0
2017-01-11,3.856825866779412,negative,vow keep increase below pct see adjusted eps growth,9,1,1
2017-01-24,1.2645322700880368,negative,enanta pharmaceutical ema grant accelerated assessment investigational hcv regimen glecaprevirpibrentasvir,10,0,0
2017-01-25,0.4550138247027213,positive,initiate phase clinical trial program abbv 8e12,7,0,0
2017-01-27,1.9158130971126064,negative,continues see good humira growth international despite indirect biosimilar competition conf call revenue rise pct report q4 gaap earnings,19,2,1
2017-02-03,1.050595580188507,negative,jury clear abbott depakote birth defect trial,7,1,0
2017-02-16,0.1906161135561412,negative,set quarterly cash dividend,4,0,0
2017-02-17,0.3140656154213328,positive,announces bln increase stock repurchase program,6,0,0
2017-02-27,0.0530855823879905,positive,receives chmp positive opinion eight week treatment option viekirax enanta chmp give positive opinion hep treatment patient genotype 1b,19,1,0
2017-03-08,0.8922021909639088,positive,ceo richard gonzalez total compensation wa mln mln ceo total compensation wa mln sec filing,15,0,0
2017-03-14,0.109311590369554,positive,granted priority review japan investigational regimen glecaprevir,7,2,0
2017-03-20,0.277141836956285,positive,ceo richard gonzalez fy total compensation wa mln,8,0,0
2017-03-28,0.9092256934036924,negative,m2gen announce collaboration,3,1,0
2017-03-30,0.7897567797685356,negative,fda approves addition moderate severe fingernail psoriasis humira,8,2,0
2017-03-31,0.2255353911341573,negative,urge court uphold ban cholesterol sale,6,-1,0
2017-04-04,0.059282415108286,positive,submits supplemental application ibrutinib,4,0,0
2017-04-07,0.8087612941921174,positive,announces positive phase 2b investigational elagolix,6,1,0
2017-04-13,0.276646600606556,positive,argen receives first preclinical milestone payment collaboration,7,0,0
2017-04-19,0.1303585413604313,negative,cancer fails late stage trial phase study evaluating veliparib not meet primary endpoint,13,-1,0
2017-04-20,0.2938164997979831,negative,investigational regimen glecaprevirpibrentasvir achieved pct svr rate chronic hepatitis patient,10,0,0
2017-04-21,0.3814034464522997,positive,enanta announces eight week treatment investigational achieved high svr rate challenging treat genotype chronic hcv patient,16,0,0
2017-04-25,0.098619298861502,positive,aquinnah receives mln investment,4,0,0
2017-04-27,1.4997431832622476,positive,drugmaker profit rise pct profit beat humira demand cheer trump tax plan profit beat humira demand cheer trump tax plan q1 adjusted earnings ceo tax reform announced yesterday encouraging conf call,31,3,1
2017-06-02,0.4766348392915231,positive,face first trial federal androgel injury litigation,7,0,0
2017-06-05,0.4603333641317153,positive,find imbruvica offer targeted approach cll treatment present long term cancer imbruvica asco,13,0,0
2017-06-07,1.111572386196702,positive,rheumatoid arthritis succeeds trial upadacitinib meet primary ranked secondary endpoint phase study corrected rheumatoid arthritis succeeds trial rheumatoid arthritis succeeds late stage trial,23,0,0
2017-06-09,1.475218003785006,positive,must pay mln depakote birth defect trial jury suffers million loss depakote birth defect trial woman awarded mln suing over depakote must pay million depakote birth defect trial jury,29,-2,1
2017-06-12,0.180404617210983,negative,first bellwether over androgel end mistrial,6,0,0
2017-06-13,0.287636393932944,negative,principia collaborate oral immunoproteasome inhibitor,5,0,0
2017-06-22,2.624475423758732,positive,set quarterly cash dividend,4,0,1
2017-06-23,0.8573304341812582,negative,enanta announces receives chmp positive opinion maviret,7,1,0
2017-06-29,0.2754847803709714,positive,cytomx achieves development milestone collaboration,5,0,0
2017-07-20,1.6594626848542626,positive,loses bid overturn million depakote injury verdict,7,-1,1
2017-07-24,0.9404561749196128,negative,jury find liable misrepresentation androgel verdict jury find liable misrepresentation first androgel verdict,13,0,0
2017-07-28,1.681096790960368,negative,remain cautious pricing fall ceo big something not fundamental strategy profit rise pct humira demand ec grant maviret marketing authorization treatment chronic hepatitis type hepatitis win eu approval report second financial result,32,3,1
2017-07-31,0.695712579554042,negative,refile delist euronext paris,4,0,0
2017-08-03,0.5899700159623156,positive,fda approves hepatitis fda approved mavyret hepatitis,7,2,0
2017-08-17,0.7496540383900907,positive,maviret approved canada treatment chronic hepatitis major genotype,8,0,0
2017-08-24,1.0580157102319077,positive,samsung version humira approved europe,5,0,0
2017-08-29,0.6629274253786344,positive,humira reimbursed british columbia ontario brunswick newfoundland labrador saskatchewan yukon,10,0,0
2017-09-06,2.050646426887348,positive,submits nda fda investigational oral treatment elagolix management endometriosis associated pain,11,0,1
2017-09-07,6.151021531376932,positive,coherus bioscience denied petition inter partes review patent positive eczema study drag down upadacitinib meet primary endpoint phase 2b study atopic dermatitis,22,0,1
2017-09-08,4.47061331122196,positive,set quarterly cash dividend 64shr,5,0,1
2017-09-11,0.8785695701134744,positive,death arthritis trial not linked upadacitinib meet primary ranked secondary endpoint report patient death rheumatoid arthritis study,17,0,0
2017-09-15,2.2073075536294784,negative,woodford equity income fund sell holding update,7,0,1
2017-09-18,2.559032251227422,negative,announces positive topline result phase trial evaluating venclextavenclyxto tablet combination rituxan ftc clear hurdle antitrust case over pay delay deal,20,0,1
2017-09-22,0.0600334508424227,positive,announce clinical research collaboration evaluate therapeutic regimen advanced solid tumor,10,1,0
2017-09-27,1.092420811448358,negative,enanta maviret approved japan treatment major genotype chronic hepatitis announces approval maviret chronic hepatitis treatment japan,16,1,0
2017-09-28,4.847575617315347,positive,agree settlement allowing commercialization amgevita settlement set humira biosimilar launch,10,1,1
2017-10-05,0.2810534902413231,negative,econd jury find misrepresented risk androgel hit mln verdict androgel trial lawyer,12,1,0
2017-10-10,0.1657785831247205,positive,turnstone biologics announce global collaboration viral immunotherapy oncology,8,1,0
2017-10-12,0.1973874026994337,negative,abbott duck depakote off label marketing case appeal,8,0,0
2017-10-18,4.1009043067471,positive,harpoon therapeutic announce immuno oncology research collaboration,7,1,1
2017-10-23,1.2655879483366883,negative,cerveau technology sign agreement agent,5,1,0
2017-10-24,3.1595169886217023,negative,alector announce collaboration bet alzheimer immunotherapy big deal,8,1,1
2017-10-25,0.5931677466066265,positive,canada approved inclusion nail psoriasis humira product,7,0,0
2017-10-26,2.5480923892194363,negative,risankizumab meet primary ranked secondary endpoint,6,0,1
2017-10-27,1.8286507523259443,positive,report q3 adjusted earnings humira sale balloon bln rise conf call need see hcv sort receives fda priority review investigational oral treatment elagolix humira sale balloon billion rise increase quarterly dividend humira sale balloon bln,35,2,1
2017-11-03,1.0834070372053306,positive,continues push reversal latest androgel verdict,6,0,0
2017-11-21,0.4995681824014664,positive,roche leukemia superior older study,5,0,0
2017-11-30,0.2724957228102065,positive,enanta pharma maviret commercially available,5,0,0
2017-12-12,0.3527066365717424,negative,phase study venclextavenclyxto combination rituxan meet primary endpoint,8,0,0
2017-12-20,0.4684322404647112,negative,upadacitinib show positive result monotherapy phase rheumatoid arthritis study,9,1,0
2017-12-22,0.3325642409868212,positive,corrected judge toss verdict androgel case,6,0,0
2018-01-08,1.7850842551325186,negative,upadacitinib granted breakthrough therapy designation fda,6,2,1
2018-01-10,0.3956999888369283,negative,looking return additional cash shareholder,5,0,0
2018-01-18,0.3589305775392404,negative,plaintiff granted subpoena ceo upcoming depakote trial,7,1,0
2018-01-26,12.609529750316083,positive,drugmaker boost forecast soar record high win trial lawsuit over androgel risk ceo discus dividend growth buyback board qtrly shr qtrly adj shr stock snapshot wall st climb high strong intel earnings quarterly profit plunge bln tax charge stock hit record upbeat intel earnings,44,5,1
2018-02-06,0.4269813157516955,negative,receives positive recommendation canadian committee maviret,6,1,0
2018-02-15,0.3334682925211885,positive,buy back billion raise dividend increase dividend announces stock repurchase program,11,2,0
2018-02-16,3.1908906614094734,positive,announces phase upadacitinib showing clinical endoscopic outcome crohn disease week,10,0,1
2018-02-20,0.1033557444511501,positive,voyager therapeutic announce global strategic collaboration,6,1,0
2018-02-21,0.4380886912121129,positive,announces positive topline result phase study evaluating investigational elagolix woman uterine fibroid,12,1,0
2018-02-22,0.4264421988750544,negative,canada diagnosed advanced parkinson disease living nova scotia public access,10,0,0
2018-03-02,0.538608604873847,positive,withdraw multiple sclerosis zinbryta withdrawal marketing authorization,7,-1,0
2018-03-06,1.204562855810165,negative,get positive recommendation pan canadian oncology review venclexta,8,1,0
2018-03-07,0.1763109492156633,positive,ceo total compensation wa million europe regulator call recall multiple sclerosis,11,-1,0
2018-03-13,1.8719705379955156,positive,announces positive result second phase study elagolix woman uterine fibroid,10,1,1
2018-03-19,0.1244156295978515,negative,ceo total compensation mln mln,5,0,0
2018-03-21,0.0143762714071904,positive,international myeloma foundation partner study role genetic mutation,8,0,0
2018-03-22,10.26150454814081,negative,lung cancer disappoints slump announces result phase study evaluating rovalpituzumab tesirine third line treatment patient dll3 expressing relapsedrefractory small cell lung cancer not seeking accelerated approval lung cancer,28,1,1
2018-03-26,4.972718998149361,negative,jury order pay mln androgel retrial jury order pay million androgel retrial,12,-1,1
2018-04-05,1.574647091600334,negative,samsung bioepis deal humira biosimilar release deal delay humira biosimilar launch samsung bioepis settle over humira biosimilar,17,-1,1
2018-04-09,0.2868452300988977,positive,upadacitinib met primary ranked secondary endpoint phase study rheumatoid arthritis,10,0,0
2018-04-10,1.8803418799768543,positive,fda need time review neurocrine uterine pain corrected fda need time review neurocrine uterine pain corrected fda extends review neurocrine uterine pain neurocrine bioscience announce pdufa target date q3 elagolix endometriosis associated pain,33,1,1
2018-04-25,0.3110640884312454,positive,upadacitinib meet primary key efficacy endpoint phase 2b3 rheumatoid arthritis study japanese patient,13,0,0
2018-04-26,5.046338726589794,positive,beat fueled demand humira hep report q1 gaap earnings,9,1,1
2018-05-01,5.539557906866244,positive,commences self tender offer up bln common stock estimate complete blackout could begin soon ny time submits marketing authorization application ema investigational treatment risankizumab moderate severe plaque psoriasis,28,0,1
2018-05-18,0.8766524118822727,positive,entered loan credit agreement borrow up bln,7,0,0
2018-06-05,0.068517714398264,positive,rheumatoid arthritis succeeds late stage study,6,0,0
2018-06-29,0.0940480827442469,positive,androgel partner owe million antitrust case judge corrected androgel partner owe million antitrust case judge corrected androgel partner owe million antitrust case judge,23,0,0
2018-07-05,0.1135886980098588,positive,win reversal mln verdict case over androgel risk win reversal million verdict case over androgel risk,16,1,0
2018-07-17,1.2772522242828988,negative,mylan sign license deal humira,5,1,0
2018-07-24,1.890524026665075,positive,citron left reiterates belief fall sharply endometriosis,7,-1,1
2018-07-27,2.920410188607425,negative,cash cow humira barely beat sale estimate stock slide top second estimate set higher earnings target,16,0,1
2018-08-22,0.0429422774003929,negative,double down cancer project group argenx,6,0,0
2018-08-29,0.2090644590481138,negative,europe ready cash cheap copy,5,0,0
2018-09-11,1.0119039380972803,negative,reach tentative settlement androgel litigation,5,0,0
2018-09-18,3.4366060467458937,negative,california insurance commissioner sue over humira california insurance regulator sue alleging humira kickback,13,0,1
2018-09-20,1.0133910922673015,positive,eu approves fifth copy bln humira eu approves fifth copy billion humira,12,1,0
2018-09-21,0.3620897066562767,negative,receives positive chmp opinion fo chemotherapy free combination venclyxto rituximab,10,1,0
2018-10-11,0.3542812653575145,negative,settle humira patent dispute novartis unit,6,0,0
2018-10-16,0.8746355687143881,positive,novartis kick off fight blockbuster eu sandoz launch biosimilar version humira uk,12,2,0
2018-10-17,0.3738558513509238,positive,samsung launch third rival humira eu,6,1,0
2018-10-18,1.1244411400697207,negative,settle humira biosimilar dispute fresenius kabi,6,0,0
2018-10-19,2.0925606357728554,negative,name robert michael chief financial officer cfo chase retire mid,10,0,1
2018-10-23,1.045454718054395,negative,rheumatoid arthritis succeeds late stage trial,6,0,0
2018-10-26,0.6086096798813001,positive,abbott settle case over tricor marketing mln,7,0,0
2018-10-31,5.651975900555306,negative,fda approves novartis copy bestseller humira announces positive result cll14,10,3,1
2018-11-01,1.9672872054362407,positive,roche combo treatment meet main goal leukemia trial,8,0,1
2018-11-02,0.2180726730390603,negative,expects double digit earnings growth corrected see hit humira sale european competition lift profit target cancer power third beat humira biosimilars available up discount europe see hit humira sale european competition humira biosimilars available up pct discount europe,38,4,0
2018-11-21,2.543047311851532,negative,roche cancer get accelerated fda approval corrected roche cancer get accelerated fda approval,13,2,1
2018-12-04,0.0802775676352562,negative,jnj cancer imbruvica succeeds late stage trial,7,0,0
2019-01-04,0.1278818977921814,negative,record bln impairment charge stemcentrx asset record billion impairment charge stemcentrx asset,12,0,0
2019-01-18,1.3066137660406207,positive,cancer fails meet main goal late stage study imbruvica fails meet main goal pancreatic cancer study,16,-1,0
2019-01-25,7.064117827333505,negative,profit miss humira face biosimilar challenge europe not contemplating big deal ceo expects steeper decline humira overseas sale fall,19,-4,1
2019-02-28,0.02783241328006,negative,becomes last defendant settle landmark reverse payment case,8,0,0
2019-03-19,0.1859936713548338,positive,hit antitrust lawsuit over humira patent thicket fda put partial hold clinical trial cancer fda placed partial clinical hold clinical trial evaluating venetoclax investigational treatment multiple myeloma,27,1,0
2019-04-23,0.2465716775152948,negative,skyrizi treat psoriasis win approval,5,2,0
2019-04-25,0.913254146741782,positive,humira rival aggressive far,4,0,0
2019-05-15,0.1522922103316171,negative,announces fda approval venclexta previously untreated chronic lymphocytic leukemia patient,10,2,0
2019-05-17,0.5961923125492152,positive,halt enrollment brain cancer trial miss goal fall halt patient enrollment brain cancer trial miss goal,16,-2,0
2019-06-04,0.7836127000169668,negative,present venetoclax chemotherapy free combination regimen patient previously untreated chronic lymphocytic leukemia,12,0,0
2019-06-06,0.6372916882814161,negative,appeal million ftc win over ham androgel litigation,8,1,0
2019-06-25,15.27159724994387,negative,nears deal buy allergan bln wsj update look beyond humira bln deal botox maker allergan,15,1,1
2019-06-27,2.586578749574797,positive,corrected loan ready feast jumbo us38bn bridge loan,8,0,1
2019-07-22,1.033511740701576,negative,ftc fight appeal million award over ham androgel litigation,9,0,0
2019-07-26,0.9801650165959463,positive,spotlight allergan deal humira sale wane doe not expect divest psoriasis raise profit target quarterly sale beat estimate,18,2,0
2019-08-14,0.6340399466919888,positive,judge certifies niaspan pay delay class action teva,8,-2,0
2019-08-16,0.8268219728704063,positive,rheumatoid arthritis rheumatoid arthritis 59000yr fda approves rheumatoid arthritis,9,2,0
2019-08-28,0.0950455697294572,negative,fda flag risk hepatitis certain patient fda flag serious risk hepatitis,11,0,0
2019-08-29,1.0502708437555075,negative,terminates late stage lung cancer trial abandon late stage lung cancer asset rova,13,0,0
2019-09-12,1.581956993826239,positive,consumer group union urge caution bln deal allergan consumer group union urge caution billion deal allergan,16,0,1
2019-09-27,1.6463795958714167,positive,ftc request allergan information billion deal ftc request allergan information bln deal,12,0,1
2019-11-01,1.8391724474022155,positive,lift profit forecast humira help beat revenue estimate revenue forecast top wall street estimate eye future botox sale multiple party vying asset related allergan deal approval,26,3,1
2019-12-06,0.6135874888184345,negative,belgium ucb psoriasis beat humira trial,6,1,0
2019-12-16,1.1231056338210532,positive,beigene cancer fails study jj imbruvica beigene cancer fails study jj imbruvica beigene fails main goal late stage study jj rival imbruvica,22,-1,0
2019-12-18,0.8388516601592455,negative,reach agreement pcpa combination venclexta rituximab treatment chronic lymphocytic leukemia,10,0,0
2012-03-06,0.7054387081429359,positive,patient relapse hepatitis trial,4,0,0
2012-03-07,1.5694277082171637,negative,quad hiv cause fewer side effect,6,0,1
2012-04-19,12.742496952845794,positive,hepatitis prof key study hepatitis trial impress,7,0,1
2012-04-26,0.4115553042401076,negative,profit narrowly miss street view,5,-1,0
2012-05-08,0.4805964960421516,negative,fda staff truvada help reduce hiv risk,7,0,0
2012-05-09,2.978955584291232,positive,fda report quad focus kidney safety,6,0,1
2012-05-10,0.9983046533360128,positive,fda panel back truvada prevent hiv,6,0,0
2012-05-11,1.4526457722763952,positive,fda panel recommends quad hiv,5,0,1
2012-05-31,0.8690117641406148,negative,urge combo hepatitis study,4,0,0
2012-07-11,1.817235377574422,negative,gsk hiv beat leader study,5,1,1
2012-07-12,0.4647605802143295,positive,gsk warns lung patient,4,0,0
2012-07-16,1.7405154024465963,positive,win first approval prevent hiv,5,2,1
2012-07-24,0.6637645381012858,negative,hiv good isentress study,4,0,0
2012-08-02,7.516987577195444,positive,sign deal indian low cost hiv,6,1,1
2012-08-27,0.1957504477967719,negative,fda approves hiv treatment,4,2,0
2012-09-17,6.434389761999448,positive,hiv pill could leader morgan,5,0,1
2012-10-23,0.8268925736137578,negative,third profit beat wall street estimate science up pct bell 3rd profit beat wall street estimate,16,1,0
2012-11-27,0.5760671624155722,negative,hepatitis show promise late stage trial,6,1,0
2012-12-12,0.1928931118188259,negative,bag blood disorder ym bioscience buy,6,1,0
2013-01-07,1.7992062624249017,positive,track hepatitis treatment,3,0,1
2013-02-04,1.2674774789646737,negative,fourth profit sale beat estimate hepatitis trial meet study goal hepatitis trial meet study goal 4th profit sale beat estimate 4th net profit rise pct hiv sale beat,28,3,0
2013-02-19,0.885157754620769,positive,teva reach settlement viread patent lawsuit hepatitis meet goal 4th late stage study hep meet main goal fourth late stage study hepatitis meet goal fourth late stage study,28,1,0
2013-05-02,3.1398740088388166,positive,combo hepatitis pill shown effective small trial profit rise sale older hiv dip corrected profit rise pct sale older hiv dip combo hepatitis pill effective small trial profit rise sale older hiv dip,33,3,1
2013-05-15,0.3430875478112494,negative,experimental effective early stage leukemia trial,6,1,0
2013-06-07,1.7308754093050993,positive,fda grant priority review status hepatitis,6,1,1
2013-07-25,1.3933119821077256,positive,profit meet wall st forecast sale rise pct profit rise jump vertex hepatitis setback,14,3,1
2013-07-26,2.703174232790939,positive,eu regulator back novartis inhaler hiv,6,0,1
2013-10-09,0.8808692972861576,negative,work leukemia trial stopped early,5,0,0
2013-10-23,1.8300309433892603,positive,hepatitis safe effective fda reviewer hepatitis safe effective fda reviewer hepatitis safe effective fda reviewer,15,2,1
2013-10-25,0.6715587449649063,negative,fda panel back hepatitis sofosbuvir fda panel unanimously back hepatitis sofosbuvir fda panel back hepatitis sofosbuvir ema advises compassionate use sofosbuvir,21,0,0
2013-10-29,0.5854608045794407,positive,third profit rise sale up third profit rise pct sale up pct post pct profit rise ready hcv launch post profit rise ready hcv launch,25,3,0
2013-11-18,0.9664514664016188,negative,european commission give marketing nod hiv treatment leukemia reduced rate disease progression death late stage study,16,1,0
2013-11-20,2.3512693189950973,positive,research alert science credit suisse raise target,7,2,1
2013-11-22,3.185356464161715,positive,gsk hcv hiv win eu green light eu agency back gsk otsuka,12,1,1
2013-12-06,0.0246475835643744,negative,fda approves day hepatitis pill fda approves day hepatitis pill fda approves breakthrough hepatitis pill fda approves oral hepatitis,19,3,0
2013-12-10,2.806990391446995,negative,science hit session low down pct heavy volume,8,1,1
2013-12-18,3.301312833455849,positive,tellar hepatitis put farther ahead pack seek okay combo hepatitis pill q1 submit application sofosbuvir ledipasvir q1,17,1,1
2014-01-06,1.163383779283711,negative,head commercial operation retire,4,0,0
2014-01-17,1.0647961437194486,positive,europe approves hepatitis pill,4,1,0
2014-02-04,3.346217672022367,positive,post higher profit strong hepatitis sale q4 profit beat expectation hiv sale rise,13,3,1
2014-02-05,4.592926629662098,negative,license hepatitis lower cost manufacturer india,6,0,1
2014-02-11,0.0817879426120882,negative,coo analyst sky high hep view not unreasonable,8,0,0
2014-02-12,0.1950427935183185,positive,rpt coo analyst sky high hep view not unreasonable,9,0,0
2014-03-21,4.18828463701687,negative,lawmaker want explain sovaldi hefty offer egypt hepatitis pct discount lawmaker ask sovaldi pricing offer egypt hepatitis discount,18,0,1
2014-04-08,3.485796813327291,negative,aim license hepatitis indian firm,5,0,1
2014-04-10,5.217170326073939,negative,industry group defends hepatitis natco seek block hepatitis patent india source natco seek block hepatitis patent india source natco move oppose hepatitis patent india source,25,0,1
2014-04-11,1.7408028444317436,positive,texas medicaid hold off proposed limit hepatitis doctor welcome hepatitis rival still lead,13,1,1
2014-04-17,0.8995736547045441,positive,england agrees funding hepatitis,4,0,0
2014-04-22,1.3053282897176777,positive,profit triple hepatitis revenue reach bln profit triple hepatitis sale beat bln profit triple hepatitis sale beat billion,18,1,0
2014-05-07,0.0143622673659971,negative,buy back another billion,4,1,0
2014-05-20,0.478582849470377,negative,insurer hepatitis costly,3,0,0
2014-06-16,0.020476480536935,negative,uk cost agency not ready back hepatitis britain cost agency not ready back hepatitis,14,0,0
2014-06-20,1.5779962980795093,positive,week hep cure test sovaldi exclusive week hep cure test sovaldi,11,0,1
2014-07-11,0.3736307870847333,negative,senator ask explain cost sovaldi hepatitis enators ask explain cost sovaldi hepatitis,12,0,0
2014-07-23,0.908641221300588,positive,hepatitis sovaldi rack up bln insurer group asks cut hepatitis ale hepatitis sovaldi soar 2nd fda approves blood cancer zydelig state not yet covering sovaldi fda approves blood cancer zydelig hepatitis sovaldi rack up billion,35,3,0
2014-07-25,0.3049788633590733,negative,europe back leukemia jj eu agency back novo nordisk jj europe back leukaemia jj,14,0,0
2014-08-14,2.0602714102066155,positive,uk cost body back pricey hepatitis pill patient,8,0,1
2014-08-15,3.268668966306909,positive,win favorable ruling hep panel reject roche claim hepatitis panel reject roche claim hep,14,0,1
2014-09-08,1.369043324288599,positive,gsk combo help pulmonary arterial hypertension,6,0,1
2014-09-12,1.9819068277404093,negative,raise hepatitis above,3,1,1
2014-09-15,2.500400667368363,negative,sign hepatitis pact cut cost poor license hepatitis cipla ranbaxy others stock track 3rd straight decline drag science licensed hep sovaldi,21,-2,1
2014-09-17,1.0128745610404333,negative,experimental cancer fails mid stage study experimental fails mid stage study cv sovaldi,13,-1,0
2014-09-24,2.3674152559296724,positive,hiv show potential mid stage study,6,0,1
2014-10-10,0.8614001431358487,negative,fda approves oral hepatitis fda approves hepatitis,7,2,0
2014-10-28,0.383189461111888,negative,third profit triple sale double third sovaldi sale dip net profit triple,12,0,0
2014-10-29,2.2551443517705327,negative,express script change formulary mid due unsustainable cost sovaldi,9,0,1
2014-11-11,0.8270119081404514,positive,hepatitis highly effective cirrhosis patient,5,1,0
2014-11-20,1.8854078189504688,negative,france peg hepatitis lowest europe,5,0,1
2014-12-10,0.597520228145032,positive,sued over exorbitant hepatitis,4,0,0
2014-12-22,14.798408668941343,negative,express script drop hep cheaper rival express script cover hepatitis drop treatment stock snapshot wall st edge higher open weighs refile stock wall st edge up day run slump stock wall st flat day run drag,36,-3,1
2015-01-05,3.781523758862249,positive,cv cover hepatitis treatment over regimen,6,0,1
2015-01-08,1.0602361783584868,positive,anthem selects primary supplier hepatitis,5,0,0
2015-01-09,0.713383343533025,positive,corrected anthem selects primary supplier hepatitis,6,0,0
2015-01-13,3.670905507551747,negative,hit fresh concern hep discounting,5,0,1
2015-01-14,2.712557838008789,positive,india reject hepatitis patent request,5,-1,1
2015-01-15,0.9578056748165032,negative,kite ceo plan learn pricing playbook,6,0,0
2015-01-16,2.086931302023753,positive,aetna back hepatitis treatment get discount appeal india patent ruling hepatitis aetna back hepatitis treatment get discount corrected aetna back hepatitis treatment get discount refile aetna back hepatitis treatment get discount,31,0,1
2015-01-26,1.2534070324436986,positive,pbm envisionrx chooses hepatitis formulary,5,0,0
2015-01-28,1.1740103174695538,negative,unitedhealth back harvoni preferred hepatitis treatment,6,0,0
2015-02-03,0.5138260980127596,negative,4th qtr profit quadruple bln hep sale catamaran back hepatitis treatment over competitor boost hepatitis discount slide science estimate gross net hepatitis adjustment versus end,25,-1,0
2015-02-04,7.783051533957742,negative,drag down worry deep discount fuel worry pricing stock snapshot oil weigh wall st open tumble,16,-1,1
2015-02-10,0.4000908380667578,positive,expects big increase european treated hep face challenge european patent pricey hep,12,-1,0
2015-02-12,0.1415138294089679,negative,agrees eur hep week treatment agrees euro hep week treatment,10,0,0
2015-03-02,0.3415780126224899,negative,uk cost body back pricey combination hepatitis pill india natco pharma tie up hepatitis,14,0,0
2015-03-16,0.3605627803940692,positive,hepatitis largely cost effective hepatitis largely cost effective study hepatitis largely cost effective study,14,1,0
2015-03-18,1.3614533445354904,negative,charity attack over hepatitis restriction,5,0,1
2015-03-23,1.7896960613039803,negative,dip warning hepatitis interaction,4,0,1
2015-04-22,1.4609939630208513,negative,us georgia free testbed hepatitis elimination,6,0,1
2015-04-30,0.7669180490740279,negative,first profit double strong hepatitis sale 1st qtr profit double strong hepatitis sale,13,0,0
2015-05-20,0.2823370200690123,negative,patent costly hepatitis challenged patent costly hepatitis challenged,8,0,0
2015-05-27,1.5013615863439744,positive,globeimmune hep fails mid stage study,6,-1,1
2015-06-01,1.4085285692935656,positive,genmab submits application fda,4,0,1
2015-06-15,0.8203231402503786,positive,get whistleblower case over aid tossed,6,0,0
2015-06-19,0.7542956971759884,negative,china reject hepatitis patent advocacy group china reject patent linked hepatitis,11,-1,0
2015-06-29,1.2744084151591673,negative,group sue fda hepatitis trial,5,0,0
2015-07-28,1.0456569640987956,positive,hepatitis sale beat wall street sale outlook raised 2nd profit increase pct outlook raised,14,1,0
2015-09-02,0.8410790191538675,positive,combo hiv pill match truvada efficacy safer trial,8,0,0
2015-09-21,3.0426816947031865,negative,combo fight form hep infection experimental fight form hep combo fight genotype hep infection,14,0,1
2015-09-28,2.760854045241967,negative,settle insider trading charge tied acquisition,6,0,1
2015-10-22,4.105573528309936,positive,hiv show lower side effect over longer term,8,0,1
2015-10-27,2.347803869964815,positive,3rd profit rise hepatitis sale line hepatitis sale trend flattens dip,11,2,1
2015-10-28,3.6977794758252913,negative,no simple cure apple valuation,5,0,1
2015-11-05,0.9459135118152884,negative,fda approves science hiv cocktail fda approves science hiv cocktail,10,2,0
2015-11-12,1.3654758887294285,negative,fda approves hepatitis expanded use,5,2,1
2015-11-16,0.3117567853063274,negative,leukemia trial unblinded early due success,6,0,0
2015-12-01,1.0573802519191156,negative,put profit ahead hepatitis patient senate report put profit ahead hepatitis patient senate report,14,0,0
2015-12-17,0.5754927652665165,positive,belgium galapagos sign bln deal belgium galapagos sign billion deal group belgium galapagos sign bln deal group galapagos announce global partnership,21,2,0
2016-01-05,1.106244159997627,positive,hep effective viread safer hep succeeds late stage trial,9,1,0
2016-01-13,2.202126756863343,negative,galapagos global partnership cleared federal trade commission,7,0,1
2016-01-25,0.1831130420191895,positive,hold galapagos sharesx7f,3,0,0
2016-01-27,1.709637288564303,negative,massachusetts challenge hepatitis massachusetts official challenge hepatitis,7,-1,1
2016-02-02,0.2019774393089979,positive,hepatitis sale beat estimate growth stall,6,2,0
2016-02-16,0.224067964978758,positive,fda expands use liver rare subset patient,7,1,0
2016-02-26,2.0546965578788545,negative,experimental cocktail hiv get positive ema opinion hiv get closer getting europe approval europe give positive opinion hiv cocktail,19,2,1
2016-03-01,0.4458677381525389,positive,science fda approves odefsey,4,2,0
2016-03-09,1.4301177853436542,negative,florida man pleads guilty insider trading case,7,0,1
2016-03-11,0.4742721621135759,negative,infection worry prompt eu review leukaemia infection worry prompt eu review leukemia infection worry prompt regulatory review leukaemia,18,-1,0
2016-03-18,0.4357826013480226,positive,look cheap fret over growth,5,1,0
2016-03-22,1.1867978211313912,positive,patent hepatitis treatment found valid dispute patent hepatitis treatment found valid dispute,12,0,0
2016-03-23,3.223960840782336,negative,moody hepatitis patent ruling negative,5,0,1
2016-03-24,1.420849236748123,positive,ordered pay mln hepatitis patent dispute ordered pay million hepatitis patent dispute,12,-1,1
2016-03-28,1.1892741227266024,positive,science ceo john martin total compensation mln sec filing,9,0,0
2016-03-29,1.2062125004473343,negative,deceitful hepatitis patent fight,4,0,0
2016-04-25,0.5254570882626486,positive,treatment hiv receives marketing authorization european commission,7,0,0
2016-04-28,2.7858321402803754,negative,pressure hit first hepatitis sale q1 non gaap earnings,9,1,1
2016-04-29,8.521968942341994,negative,science european chmp adopts positive opinion european regulator recommends approval hiv treatment,12,2,1
2016-05-10,0.6480738475826531,negative,india patent office approves hepatitis patent,6,1,0
2016-05-16,0.1138399743612961,positive,temasek holding raise stake pct,5,1,0
2016-05-24,2.171911490560308,positive,science appoints kevin young coo,5,0,1
2016-05-27,0.1914823881131289,positive,eu regulator back approval hep eu regulator recommend approving hepatitis,10,1,0
2016-06-06,1.1742621729267544,positive,gileads escape liability hepatitis patent fight escape liability hepatitis patent fight,11,0,0
2016-06-20,0.2326331183464036,negative,present early stage trial hiv treatment,6,0,0
2016-06-23,0.1864268735050966,negative,european commission grant marketing authorization odefseyx7f,6,0,0
2016-06-28,3.384895751061312,positive,fda approves hep epclusa win nod type hepatitis,8,4,1
2016-06-29,1.7513561437938363,negative,hepatitis patent win over face foe,6,1,1
2016-07-07,0.2412701978183218,negative,appeal order reversing mln verdict,5,0,0
2016-07-08,0.2254432715408816,negative,ligand enters omniab platform license agreement science science european commission grant marketing authorization epclusa,14,0,0
2016-07-14,0.8032438605590553,negative,science get canada approval hepatitis treatment epclusa,7,1,0
2016-07-21,1.0470020989652329,positive,odefsey meet primary objective phase 3b study,7,0,0
2016-07-22,1.239435481910578,negative,ema adopts positive opinion expanded approval hiv truvada,8,2,0
2016-07-25,2.5823970876127977,positive,second net profit fall cut sale forecast cite hepatitis science set qtrly dividend science q2 non gaap earnings,18,-1,1
2016-07-28,0.7879166178079045,negative,lock horn legal fee hepatitis patent fight,7,0,0
2016-07-29,2.340186991942628,negative,anofi celgene interested medivation cnbc citing source,7,0,1
2016-08-05,0.0155802342974187,negative,refile massachusetts attorney general office notifies decision suspend obligation under cid further notice,13,-1,0
2016-08-10,0.2945402615338488,negative,genmab enters commercial license agreement duobodytechnology,6,0,0
2016-08-11,0.3851093627818214,positive,get attorney fee hepatitis patent fight,6,0,0
2016-08-22,0.0941923558922641,negative,science european commission grant marketing authorization truvada,7,0,0
2016-08-23,0.4783373687918146,positive,kelly kramer join science board director,6,0,0
2016-09-15,0.5724612116118521,positive,science bln senior unsecured note,5,0,0
2016-09-21,1.2223708107471642,negative,terminates phase study patient ulcerative colitis,6,0,0
2016-09-27,2.32013021343227,negative,science announce visceral leishmaniasis collaboration,5,1,1
2016-10-20,1.5092758807088935,positive,unveils promising hep fatty liver setback elsewhere science phase study pah not achieve primary endpoint announces svr12 rate phase study combination sofosbuvir velpatasvir voxilaprevir,24,2,1
2016-10-24,0.6137254664103087,negative,present result phase study,4,0,0
2016-11-01,1.322121664408249,positive,third net profit fall 3rd profit fall hiv sale rise q3 earnings,12,1,1
2016-11-09,4.923047733444941,positive,jj vaccine plus immune booster show promise hiv fighter,9,1,1
2016-11-10,1.0524123105921657,negative,hepatitis get approval hepatitis win approval,6,2,0
2016-11-14,0.3532740873576578,positive,combination selonsertib rodent model advanced fibrosis resulted greater anti fibrotic activity either agent alone,14,0,0
2016-11-16,0.2705812175440303,negative,announces top line result phase study,6,0,0
2016-11-17,1.0667042026956677,negative,loses bid invalidate hepatitis patent ahead trial,7,-1,0
2016-11-22,0.8888432826506865,negative,capital lp report stake landauer,5,0,0
2016-11-28,0.7235138895925641,negative,capital dismayed executive chairman remains landauers board face off jury over hepatitis patent,13,0,0
2016-11-30,1.322792443499332,negative,rpt switching course hiv prevention witching course hiv prevention,9,0,1
2016-12-02,0.6266978010811664,negative,pay infringing hep patent,4,-1,0
2016-12-08,1.2891173610067086,negative,science submits application fda hepatitis,5,0,0
2016-12-15,0.6230526478060217,negative,win billion hepatitis trial win bln hepatitis trial science pay bln hepatitis royalty court verdict,15,0,0
2016-12-19,0.1871165580205724,positive,japan ministry labour welfare approves vemlidy patient chronic hepatitis virus infection landauer comment nomination director,15,1,0
2017-01-04,2.398607879957715,positive,poaches novartis cancer specialist riva,5,0,1
2017-01-09,0.7937286629034923,positive,coo slowdown patient starting hep therapy continue science planning phase iii nash trial,13,-1,0
2017-01-11,1.9357230834269656,negative,european commission grant marketing authorization vemlidy treatment chronic hepatitis virus infection,11,0,1
2017-01-20,1.149854131568251,negative,european agency validates marketing authorization application investigational chronic hepatitis therapy,10,0,0
2017-02-06,0.2478932373991882,positive,priced like automaker sputtering lure value bet,7,0,0
2017-02-07,1.017868561911195,positive,hepatitis sale forecast disappoints drop science report q4 earnings science set quarterly dividend quarterly profit fall lower sale expected,19,-2,0
2017-02-08,8.745835578511606,negative,slump bleak sale forecast hep science name kennet brysting general manager science canada slump gloomy sale forecast hep glaxosmithkline face off hiv meeting next week,25,0,1
2017-02-13,1.399685286836272,positive,announces finding preclinical study evaluating novel class hiv capsid inhibitor present phase bictegravir,13,0,1
2017-02-14,0.5473526687885366,negative,challenge gsk strong hiv announces week evaluating safety efficacy genvoya,10,-1,0
2017-02-16,0.8157931148588315,positive,receives approval canada odefsey treatment hiv infection amygdala neuroscience acquires science,11,1,0
2017-02-22,0.5750752448456131,negative,science canada ontario list epclusa public plan treat six genotype chronic hepatitis infection,13,0,0
2017-02-27,0.644398394846224,positive,seek overturn bln verdict hepatitis case,6,0,0
2017-03-20,0.3971170284307157,negative,science epclusa added liste de mxc3xa9dicaments de la ramq,9,0,0
2017-03-21,0.1277806583216967,negative,science list epclusa public plan treat chronic hepatitis infection,9,0,0
2017-03-27,0.0878154471850467,positive,science ceo john milligan total compensation wa mln sec filing hepatitis patent face european challenge,15,-1,0
2017-04-07,0.2523601012616394,positive,fda approves hepatitis pediatric patient,5,2,0
2017-04-20,0.4819858964197454,negative,present supporting efficacy safety vemlidy patient chronic hepatitis week,9,0,0
2017-04-21,0.5384549954914997,negative,announces result phase study evaluating harvoni tablet chronic hepatitis infected patient,11,0,0
2017-05-01,0.8938795965089841,negative,science nova scotia list epclusa public plan treat six genotype chronic hepatitis infection,13,0,0
2017-05-02,0.667030327746998,positive,profit fall hepatitis sale drop down net profit fall lower hepatitis sale,12,-2,0
2017-05-04,1.1770403827810585,positive,science genvoya tablet hiv treatment listed multiple province canada,9,0,0
2017-05-12,0.807264568131083,negative,stockholder not approve proposal requesting board take step adopt policy chairman board independent director,14,1,0
2017-05-30,0.0713799906045475,positive,hiv combination therapy succeeds late stage study,7,0,0
2017-05-31,0.6450950939740463,positive,gsk go head head similar hiv,6,0,0
2017-06-12,1.1488270953242452,positive,submits nda fixed dose combination hiv treatment,7,0,0
2017-06-19,0.2591919257063813,positive,receives approval canada vemlidy treatment chronic hepatitis virus infection,9,1,0
2017-06-21,2.936718792132087,positive,knock patent hepatitis treatment,4,0,1
2017-06-23,0.0626702133726064,negative,european chmp adopts positive opinion vosevi,6,1,0
2017-07-07,0.9795434956090364,negative,whistleblower lawsuit over hiv revived appeal,6,0,0
2017-07-10,0.04962705660978,negative,pring bank pharmaceutical announces clinical trial collaboration science clinical study examining sb,12,0,0
2017-07-18,0.7060132569445265,positive,fda approves chronic hep patient fda approves vosevi treatment adult chronic hepatitis virus,13,2,0
2017-07-26,0.6062105269804663,positive,science profit fall beat wall street estimate science qtrly earnings,10,0,0
2017-07-28,1.4246778432880247,positive,science european commission grant marketing authorization vosevi,7,0,1
2017-08-10,0.2122891727288411,negative,fda grant priority status hiv treatment,6,0,0
2017-08-14,0.4250174038000542,negative,temasek holding cut stake science,5,0,0
2017-08-17,0.1821233959164891,positive,receives approval canada vosevi treatment certain patient chronic hep virus infection,11,1,0
2017-08-28,1.2155884867652178,positive,science acquire kite pharma billion buy kite promising cancer therapy billion deal buy kite promising cancer therapy bln deal buy kite pharma bln deal wsj not going quiet kite deal,30,3,0
2017-08-31,2.451457653688216,positive,science file potential mixed shelf size not disclosed,8,0,1
2017-09-05,0.7026902289766657,negative,science present morgan stanley global conference,6,0,0
2017-09-13,1.0301226938027486,negative,science entered bln term loan facility credit agreement sec,9,0,0
2017-09-21,0.2437343403847713,positive,receives approval canada expanded indication epclusa science entered seventh supplemental indenture,11,1,0
2017-09-25,0.6127683021477592,positive,china food administration approves sovaldi,5,1,0
2017-09-27,0.2700443840682576,negative,kevin young retire science coo,5,0,0
2017-10-04,1.0442347456020018,negative,science present result late stage study,6,0,0
2017-10-18,0.38449892808462,negative,fda approves cancer gene therapy set fda approves car cell therapy fda approves yescarta cancer immunotherapy,16,2,0
2017-10-19,1.9473794657276944,positive,fda approves cancer gene therapy set,6,2,1
2017-10-20,0.9817916714053744,negative,announces multiple scientific presentation,4,0,0
2017-10-24,0.2630202085009192,negative,announces phase result nonalcoholic steatohepatitis,5,0,0
2017-10-25,0.2328386290679773,positive,consumer group challenge patent hepatitis,5,-1,0
2017-10-26,2.645224202075458,negative,weak hepatitis sale outlook sends lower 3rd profit fall beat wall street estimate,13,-1,1
2017-10-27,1.857681537553724,negative,capital report pct passive stake computer program system,8,0,1
2017-11-02,1.4085164225014712,negative,gsk go head head hiv enter phase,7,0,1
2017-11-07,1.2162639575153733,positive,science post trial motion judge denied motion enhanced damage,9,0,0
2017-12-07,1.093033922367348,negative,refile buy cell design lab up million buy cell design lab up million science kite acquire cell design lab,19,2,0
2018-01-17,0.9035259954156328,positive,florida man get prison trading tip deal,7,0,0
2018-02-06,0.5945375459890601,positive,corrected q4 hepatitis sale plummet shrs drop pct hour fourth hepatitis sale plummet see further slowdown science announces pct increase q1 dividend 4th qtr hepatitis sale plummet see further slowdown science announces qtrly loss,34,-3,0
2018-02-07,3.503424316186099,positive,science fda approves biktarvy treatment hiv infection viiv file patent infringement litigation science corrected fda approves hiv regimen fda approves triple hiv rival file lawsuit,25,2,1
2018-02-08,1.7348546176766289,negative,gsk viiv filed patent infringement litigation science hionogi viiv file patent infringement litigation science over bictegravir,16,0,1
2018-02-22,1.7283167451801584,negative,sign bln licensing deal sangamo gene editing platform angamo billion gene editing deal science executive vice president commercial operation retire,20,1,1
2018-02-23,0.3078283127330383,positive,ema pull application extend use zydelig,6,1,0
2018-02-27,0.4997294039398192,negative,natco teva requested fda permission make generic version sovaldi sec filing,11,0,0
2018-03-12,0.5467156263132322,positive,science john mchutchison appointed chief scientific officer,7,0,0
2018-04-16,1.5267759669711056,negative,upreme court seek doj view whistleblower case,7,0,1
2018-04-18,0.2042342763956872,positive,astellas announces sale certain agensys research facility kite,8,0,0
2018-04-20,0.1461588191539742,negative,nonprofit sue over nih licensing cancer tech,7,0,0
2018-04-25,0.4816557973126301,positive,court upholds dismissal million verdict court upholds dismissal mln verdict refile court upholds dismissal million verdict,16,0,0
2018-04-27,0.1480027576373666,negative,hiv regimen win european panel approval european chmp adopts positive opinion biktarvy,12,3,0
2018-04-30,1.437820253965416,negative,verily announce scientific collaboration,4,1,1
2018-05-01,0.2791868310657364,positive,science report q1 eps hepatitis sale slump fall hepatitis sale slump fall pct science board ha declared cash dividend common stock q2 hepatitis sale slump fall,26,-1,0
2018-05-11,0.9033808077362426,positive,defeat nonprofit challenge aid treatment patent,6,-1,0
2018-05-15,0.5992096838214,positive,kite announces facility expands collaboration national cancer institute,8,0,0
2018-06-20,0.5624149032495529,positive,gsk take billion dollar fight top aid meeting,8,0,0
2018-06-29,0.5811829739871044,positive,corrected rival novartis car therapy win european panel recommendation rival novartis car therapy win european panel recommendation,17,1,0
2018-07-25,0.7833016450263353,positive,ceo milligan chairman martin step down,6,0,0
2018-08-28,0.0987070007748558,positive,uk reject car cancer cell therapy expensive,7,-1,0
2018-09-12,2.3847540778993537,positive,galapagos bask bln sale hope,5,0,1
2018-09-24,0.4778792271199039,positive,brazil court strip hepatitis patent launch generic version hepatitis brazil court strip hepatitis patent politician,15,1,0
2018-10-25,0.8971330806152977,negative,corrected hepatitis sale fall profit beat estimate 3rd profit fall hepatitis sale wane corrected 3rd profit fall hepatitis sale wane hepatitis sale fall profit beat estimate,26,0,0
2018-12-03,2.8253939774860792,negative,tell supreme court dismiss whistleblower case high cost cell therapy prof durable lymphoma patient corrected high cost cell therapy prof durable lymphoma patient,23,0,1
2018-12-10,1.1581548694345134,negative,science snare roche veteran oday ceo,6,0,0
2018-12-20,1.7835591482942004,positive,agenus sign deal develop immuno oncology therapy agenus soar cancer therapy deal,12,2,1
2019-01-07,0.3342498459922849,negative,loses bid revive million verdict high court loses bid revive mln verdict high court supreme court wont review whistleblower lawsuit,20,-1,0
2019-02-04,0.7035473598439923,negative,fourth profit miss wall street estimate fall 4th qtr profit miss wall street estimate fall,15,-2,0
2019-02-11,0.1668620160302225,positive,miss key goal nash liver disease trial sink,8,-1,0
2019-03-29,1.4419948822956163,positive,move toss whistleblower lawsuit over hiv,6,0,1
2019-04-01,0.1523309858962429,positive,tart worrying whistleblower bar doj move toss long running case,10,0,0
2019-04-12,2.2299001960094267,negative,novo nordisk team up test fatty liver disease treatment,9,0,1
2019-04-16,1.4257563288360475,negative,team up insitro experimental nash treatment,6,0,1
2019-04-25,2.195353280478274,positive,experimental nash fails another study refile experimental nash fails another study nash fails meet late stage study goal,18,-1,1
2019-05-02,0.8787580939540907,positive,post higher first profit sale line expectation separate kite cell therapy unit post higher profit,15,0,0
2019-07-09,0.2754638807039855,positive,appeal court mull reviving billion patent win,7,0,0
2019-07-15,2.69840187790491,positive,factbox galapagos pipeline ha drawn invests billion deepen tie galapagos,10,0,1
2019-07-19,2.6731864249055937,negative,science license respiratory herpes antiviral research program novartis,8,0,1
2019-07-30,0.9037838943385056,negative,expensive novartis cancer therapy losing patient experimental treatment focus expensive novartis cancer therapy losing patient experimental treatment result beat street estimate demand grows hiv quarterly profit rise,27,3,0
2019-08-07,0.2153676410963534,negative,fda panel back hiv prevention certain focus patient group push back pricey hiv prevention treatment patient group push back pricey hiv prevention treatment fda panel back hiv prevention descovy except woman,31,0,0
2019-08-28,0.1829070372213914,negative,fda flag serious risk hepatitis fda flag risk hepatitis certain patient,11,0,0
2019-10-03,0.1706645693920316,positive,fda approves descovy hiv prevention fda approves hiv prevention treatment,10,2,0
2019-10-07,0.7031982772454537,positive,science appoints merdad parsey chief medical officer,7,0,0
2019-10-24,1.0345311652135811,negative,third result line yescarta sale dip post third net loss sale line street estimate,14,-1,0
2019-10-30,0.7795313548917049,negative,loses bid revive billion patent verdict loses bid revive bln patent verdict,12,-1,0
2019-11-06,0.0077866415175931,positive,win dismissal hiv case over whistleblower objection,7,1,0
2019-11-07,2.5684634021375,negative,sue over patent right hiv,5,0,1
2019-12-06,0.8308712432338883,positive,wi approve insurance cover novartis cell therapy,7,1,0
2019-12-13,2.810171099592296,negative,prevails over yescarta royalty row bloomberg law win million patent case,11,1,1
2019-12-16,0.1548461369808018,negative,nash combination treatment fails mid stage study nash combination treatment fails main goal mid stage study,16,-1,0
2012-01-31,1.2864680835488085,positive,generic take toll profit profit drop sharply zyprexa generic,9,-2,0
2012-02-01,0.7247420455220199,negative,alzheimer unlikely ace hole,4,0,0
2012-04-16,1.1376018654057352,positive,vanda buy experimental,3,1,0
2012-04-25,0.7329374377461839,positive,profit beat forecast focus sale profit beat forecast,8,2,0
2012-05-03,0.256274678444135,positive,pair arrested million heist,4,0,0
2012-05-22,0.7363751157946075,positive,diabetes meet mid stage trial goal,6,0,0
2012-05-29,0.7490289808624206,negative,anofi novo shape up big insulin fight,7,0,0
2012-06-11,1.1734060972652838,positive,insulin show advantage over lantus study,6,0,0
2012-06-19,0.3725901633988115,negative,resume buyback long absence survey show dim faith alzheimer,9,0,0
2012-07-06,0.5069546335629282,positive,gain extension cymbalta exclusivity extends grip right cymbalta,8,1,0
2012-07-11,0.1549004631002937,negative,schizophrenia fails late stage trial,5,-1,0
2012-07-25,2.6931790858668148,positive,drugmakers weather patent cliff corrected beat wall st profit view ups forecast beat wall st profit view ups forecast beat 2nd profit view raise forecast,25,2,1
2012-07-30,0.7212080233388041,negative,solanezumab fail pivotal study jefferies,5,-1,0
2012-08-09,0.3887992290542708,negative,raise net profit forecast raise profit forecast amylin bln payment raise profit forecast amylin billion payment,16,1,0
2012-08-24,2.839102184361031,positive,slows alzheimer fails main goal alzheimer fails late stage trial,10,-1,1
2012-08-29,0.9510591125335256,positive,stop developing schizophrenia,3,-1,0
2012-08-31,0.454630555644897,negative,text summary,2,0,0
2012-09-06,0.1532651672213614,positive,lung cancer fails meet main goal phase study alimta combination cancer therapy fails trial,14,-1,0
2012-10-02,0.6738870375826433,positive,boehringer diabetes show promise,4,1,0
2012-10-08,5.629303340271974,positive,help mild alzheimer study slow memory loss mild alzheimer,9,-2,1
2012-10-10,2.411601549100417,negative,roche chosen alzheimer trial roche set alzheimer prevention trial roche chosen trial prevent early onset alzheimer roche chosen alzheimer prevention trial,21,0,1
2012-10-15,3.290085500903217,positive,gastric cancer meet late stage goal,6,0,1
2012-10-19,0.0990330279319495,negative,eu follows nod brain plaque test eu agency back novo insulin imaging agent,13,1,0
2012-10-22,1.1111859614502118,negative,dulaglutide top diabetes late stage trial,6,0,0
2012-10-24,2.433394220190921,negative,quarterly sale profit fall short estimate result miss estimate research get priority weak result put pressure pipeline down premarket trading text fitch patent cliff cause revenue tumble,27,-3,1
2012-11-13,1.0400166740865524,negative,arthritis show durability study,4,0,0
2012-11-15,0.3933223068464997,negative,corrected jj plan clinical trial site database jj plan clinical trial site database,13,0,0
2012-12-05,0.5544188450478105,positive,india stride arcolab generic cancer tie up corrected test therapy rid brain plaque mouse alzheimer test therapy rid brain plaque mouse alzheimer,22,0,0
2012-12-11,0.2768564269487017,positive,likens alzheimer race 1920s insulin quest,6,0,0
2012-12-12,3.210856228892711,negative,down premarket alzheimer treatment update alzheimer get second chance plan trial alzheimer get 2nd chance plan trial,17,0,1
2012-12-13,0.95823088455933,negative,stop rheumatoid arthritis trial lack efficacy stop rheumatoid arthritis trial due lack efficacy,13,-1,0
2012-12-17,0.0243603289868277,negative,initiate bln stock repurchase program,5,0,0
2012-12-20,0.0993402896281248,positive,pay million settle sec bribery case sec pay mln settle bribery charge pay mln settle sec bribery case,18,-1,0
2013-01-04,3.2615557299389364,positive,bank cost control higher profit expects earnings increase analysis alimta patent seen wild card up premarket,16,0,1
2013-01-07,0.1375158847636171,positive,boehringer diabetes meet goal trial boehringer diabetes meet goal later trial,11,1,0
2013-01-15,0.8599892065481285,positive,brain plaque diagnostic approved europe europe ok diagnostic likely alzheimer cause,11,0,0
2013-01-18,0.6020785929354178,positive,chosen sponsored alzheimer trial chosen sponsored alzheimer trial corrected chosen sponsored alzheimer trial,13,0,0
2013-01-22,1.1530630886280369,negative,stomach cancer extends survival placebo,5,0,0
2013-01-29,2.798339497920144,positive,wrapup profit beat street generic take toll generic competition hurt q4 profit sale wrapup beat street generic take toll profit beat street generic take toll fourth profit fall generic hurt sale generic competition hurt fourth profit sale,37,-1,1
2013-02-07,0.1458281925389659,negative,stop development rheumatoid arthritis,4,-1,0
2013-02-11,0.3548335831824345,positive,ceo keeping animal,3,0,0
2013-03-06,0.9643392355596968,negative,confident keeping dividend through patent cliff,6,1,0
2013-04-12,0.599837323220398,negative,drugmaker cut sale job source drugmaker seek cut pct sale force wsj drugmaker cut sale job source,17,0,0
2013-04-16,0.2548213062567139,negative,report positive result trial diabetes diabetes good insulin study,9,1,0
2013-04-17,1.9683227442830689,positive,acquire alzheimer imaging agent siemens,5,1,1
2013-04-24,3.972174177582,negative,profit beat forecast profit beat forecast helped lower tax weaker yen could crimp japan sale mln mln animal sale disappoint,20,1,1
2013-05-03,0.4839199731231813,negative,broadens diabetes offer eye bigger slice booming,7,0,0
2013-05-06,1.1997009647901955,negative,ceo lechleiter undergo surgery dilated aorta ceo undergo surgery cfo rice become interim ceo,14,0,0
2013-05-10,0.1511466618215218,positive,lymphoma fails late stage trial lymphoma fails late stage trial,10,-1,0
2013-05-14,0.891239916476394,negative,ceo recovering repair aorta,4,0,0
2013-06-13,1.3856782021430591,negative,halt alzheimer trial due liver problem arthritis pill effective mid stage study halt alzheimer trial liver problem,17,1,1
2013-06-18,0.8096604561158016,negative,corrected fda studying death patient long acting zyprexa fda probe death patient schizophrenia,13,-1,0
2013-07-08,0.5169041692493215,positive,ceo return work surgery,4,0,0
2013-07-17,0.9037445926694532,negative,freeze employee base pay ahead generic onslaught,7,-1,0
2013-07-23,0.9234302653179928,positive,transition therapeutic acquires right arthritis,5,0,0
2013-07-24,3.4259836620564976,positive,beat forecast cut cost cymbalta fade beat forecast helped soon face generic,12,2,1
2013-08-13,2.2945287213077314,positive,lung cancer boost survival jump lung cancer increased survival late stage trial,12,0,1
2013-08-19,0.5067835542022281,positive,defends blockbuster alimta unusual ammo corrected defends blockbuster alimta unusual ammo,11,1,0
2013-08-22,0.8352148802035719,negative,deeply concerned bribery allegation china deeply concerned bribery allegation china,10,0,0
2013-09-04,0.8682749800951628,positive,patent ruling alimta lung cancer expected,6,0,0
2013-09-26,3.368747904576763,negative,fails breast cancer succeeds gastric cancer fails breast cancer trial fall,11,-2,1
2013-09-30,0.196194469984845,positive,mull option medicare shuns alzheimer diagnostic,6,-1,0
2013-10-03,2.520722759395233,negative,update must cut cost meet goal fall corrected must cut cost meet goal fall hard reach revenue goal must cut cost meet goal fall,24,0,1
2013-10-23,0.7979209288332734,positive,corrected beat wall st q3 expectation helped cost cut beat wall st q3 expectation helped cost cut profit beat wall st estimate helped cost cut profit beat wall street estimate helped cost cut,33,1,0
2013-11-13,1.1552095894961978,positive,unit raise ractopamine farm animal,5,1,0
2013-11-14,0.4506200378581404,positive,pump mln boost insulin making capacity pump million boost insulin making capacity,12,0,0
2013-12-03,0.4835439422576471,negative,novartis open animal book bayer source,6,0,0
2013-12-05,0.6200174313411022,positive,depression fails late stage trial depression fails late stage trial,10,-1,0
2013-12-11,0.1129971917899652,positive,fda approves generic antidepressant cymbalta fda official zoetis support antibiotic strategy,11,2,0
2014-01-07,1.2739795938244811,negative,corrected see profit decline line estimate see profit decline line estimate issue forecast line wall st estimate,17,-1,0
2014-01-13,1.6001030788697412,positive,buy back right experimental migraine,5,1,1
2014-01-29,0.3704389415112641,positive,ceo time go back offense,5,0,0
2014-01-30,2.247214538621068,negative,anofi sue over patent top selling insulin quarterly sale largely offset cymbalta slide,13,0,1
2014-01-31,1.974989039167263,positive,anofi sue over challenge top diabetes lantus,7,-1,1
2014-02-19,5.802451258697083,positive,lung cancer improves survival late stage trial,7,1,1
2014-02-24,0.4339064808009052,negative,buy german animal lohmann,4,1,0
2014-02-25,0.8133172226357344,positive,diabetes succeeds leader victoza study diabetes effective leader victoza study,10,1,0
2014-03-05,0.7923823843169475,negative,fda spurns boehringer diabetes cite factory problem fda spurns boehringer diabetes cite factory problem,14,0,0
2014-03-21,0.9624538650694792,negative,eu agency back jj takeda eu back jj hepatitis pill plus takeda,12,0,0
2014-03-31,1.3503110102742966,positive,judge upholds validity alimta patent,5,0,1
2014-04-08,0.4805177501576607,negative,jury order takeda pay bln damage actos case lawyer,9,-1,0
2014-04-21,0.3628359471288034,positive,fda approves stomach cancer fda approves stomach cancer,8,2,0
2014-04-22,1.818233984310036,negative,buy novartis animal unit billion buy novartis animal bln eye emerging novartis animal deal refile buy novartis animal unit bln novartis open up deal gsk animal product novartis speed recovery patent cliff,32,1,1
2014-04-24,1.6802224039992208,negative,miss revenue forecast disappointing sale put focus pipeline post sale below estimate,12,-1,1
2014-05-09,0.3844842283463934,negative,italian firm fined mln poisoning brazil italian firm fined million poisoning brazil,12,0,0
2014-05-12,0.8725332397989449,negative,diabetes better sanofi late stage trial diabetes effective sanofi late stage trial,12,2,0
2014-05-15,2.2667305957228545,negative,loses uk alimta patent case actavis,6,0,1
2014-05-28,0.0228733984079632,positive,anofi pursue cialis over counter approval,6,1,0
2014-06-11,0.1209709850250595,negative,cyramza fails liver cancer trial,5,-1,0
2014-06-27,0.099255408732346,negative,copy bln sanofi insulin win eu green light win eu backing copy sanofi top insulin lantus,16,1,0
2014-07-08,0.4034270752531377,positive,anofi sue over insulin rival lantus,6,0,0
2014-07-24,0.1817361950502638,positive,would not pursue tax inversion primary driver potential deal beat forecast vow remain independent beat forecast helped cost control corrected beat forecast vow remain independent,25,2,0
2014-08-18,0.0003325602914827,positive,insulin receives tentative approval insulin receives tentative approval,8,1,0
2014-08-21,0.2593216400809117,negative,corrected psoriasis succeeds late stage study psoriasis impress battle nears novartis,11,0,0
2014-08-28,0.2295345106647528,positive,takeda lose bid overturn bln award hiding cancer risk,9,0,0
2014-08-29,0.4282400830435184,positive,takeda lose bid overturn billion award hiding cancer risk,9,0,0
2014-09-04,0.2537576554766496,positive,diabetes trump sanofi late stage trial,6,0,0
2014-09-10,0.1513432448011498,positive,boehringer copy sanofi insulin get eu approval,7,1,0
2014-09-12,0.7222029794860085,positive,stomach cancer prolongs life colon cancer study colon cancer succeeds late stage study,13,0,0
2014-09-16,0.1818817308069542,positive,astrazeneca get up mln alzheimer astrazeneca get up million alzheimer astrazeneca develop alzheimer astrazeneca partner alzheimer,16,0,0
2014-10-02,0.3995786627539077,negative,drop development lupus stop development lupus xtl soar eu extend zimmer biomet probe clear novartis deal source eu extend zimmer biomet probe clear novartis deal source,26,0,0
2014-10-03,0.194760126472504,positive,eu commission clear novartis deal eu commission clear novartis animal deal,11,1,0
2014-10-08,0.1606489999477212,negative,novartis executive leave gsk deal novartis executive leave gsk deal,10,0,0
2014-10-23,1.6726930537190432,negative,profit plunge cheaper generic take toll,6,-1,1
2014-10-27,0.3645542271142332,positive,judge slash bln award takeda over diabetes judge pares bln award takeda over judge slash billion award takeda over diabetes virbac acquire state veterinary asset,25,1,0
2014-10-29,1.1692492566783286,positive,boehringer revise term diabetes alliance,5,0,0
2014-11-25,0.0471550000415876,negative,diabetes win eu approval,4,2,0
2014-12-01,1.2674997788369111,positive,astrazeneca move alzheimer big trial,5,0,0
2014-12-19,0.4921299533969581,negative,adocia agree develop fast acting insulin adocia agree develop ultra rapid insulin,12,0,0
2014-12-22,1.8135950341835796,negative,must divest sentinel product ftc nod novartis deal,8,1,1
2015-01-05,0.821097857726627,positive,virbac close sentinel brand family acquisition,6,0,0
2015-01-07,1.9489327541855284,negative,forecast earnings revenue shy street estimate revenue forecast fall short wall st estimate,13,-1,1
2015-01-12,0.0540530039035536,positive,insurer squeeze diabetes,3,0,0
2015-01-13,0.223652848649658,positive,test combination cancer,3,0,0
2015-01-30,1.1049432711518703,positive,drugmaker q4 profit fall strong dollar charge drugmaker cut revenue forecast dollar strengthens,13,-1,0
2015-02-02,1.6689611708482266,negative,fda approves boehringer type diabetes patient,6,2,1
2015-02-04,0.5643412492431388,negative,cuban immigrant get six over heist connecticut cuban immigrant get over heist connecticut,13,0,0
2015-02-18,0.7781046255918245,negative,court order benefit ex manager fibromyalgia,6,1,0
2015-02-23,1.084852123009139,negative,long acting insulin delayed liver concern delay submission daily diabetes,10,-2,0
2015-03-06,1.6818098178938867,negative,loses alimta patent case germany actavis,6,0,1
2015-03-23,0.5101493033618953,positive,resume study testing pain fda recommends no change schizophrenia injection use resume late stage study testing pain,17,0,0
2015-04-20,0.996474053020513,negative,psoriatic arthritis succeeds late stage study,6,0,0
2015-04-23,0.1133134874885088,negative,profit beat estimate helped cost cut profit fall hurt strong dollar,11,0,0
2015-05-26,1.0886267985624976,positive,issue triple tranche deal,4,0,0
2015-05-29,3.880029187545808,positive,astrazeneca test cancer combination,4,0,1
2015-06-02,1.2298559947841017,negative,fda panel discus lung cancer approval,6,1,0
2015-06-11,3.772466936669172,positive,sizzle await alzheimer,3,0,1
2015-06-12,1.935922872511453,negative,exclusive alzheimer group scrap early look highly sought exclusive alzheimer group scrap early look coveted exclusive alzheimer group scrap early look coveted rpt sizzle await alzheimer,26,0,1
2015-06-25,3.4107955184509264,positive,win uk alimta patent case appeal win uk alimta patent case appeal jump,13,1,1
2015-07-07,2.1078480282859635,positive,cancer improves survival raise blood clot risk fda fda asks panel weigh benefit risk lung cancer cancer improves survival raise blood clot risk fda,24,3,1
2015-07-09,0.1316003413037725,positive,fda panel cancer ha positive riskbenefit profile,7,1,0
2015-07-22,1.1685428085114191,positive,alzheimer fall flat get slight bump alzheimer disappoints get slight bump slows alzheimer patient mild disease,16,-2,0
2015-07-23,0.9841922877281696,positive,sale rise first time seven sale inch up demand animal ceo best use money internal research,16,2,0
2015-07-27,0.095714987757367,negative,continues test hdl cholesterol panel advice,6,0,0
2015-08-03,0.0956939893863695,negative,face first trial over cymbalta withdrawal,6,0,0
2015-08-06,1.5629089304048938,negative,shift alzheimer study usc,4,0,1
2015-08-07,0.3135681428028225,negative,jury clear first cymbalta withdrawal trial,6,1,0
2015-08-20,6.299856239611479,positive,corrected empa reg outcome met primary endpoint boehringer diabetes cut heart attack stroke risk trial boehringer diabetes reduces cardiovascular risk trial,21,0,1
2015-08-26,0.3501339738526177,negative,patent lawsuit taiwanese generic drugmaker track,6,0,0
2015-08-27,0.9540281981337716,positive,adocia initiate study biochaperone lispro,5,0,0
2015-09-17,6.768099512018644,positive,diabetes slash death patient heart risk diabetes slash death pct heart risk patient,13,0,1
2015-09-28,2.5675058891225784,negative,anofi reach patent deal lantus solostar anofi reach deal insulin product,11,0,1
2015-09-29,0.5867320616541827,positive,incyte rheumatoid arthritis succeeds late stage study incyte arthritis found better common treatment,13,1,0
2015-09-30,2.38140614601281,positive,adocia initiate phase 1b study biochaperone lispro,7,0,1
2015-10-02,1.2533434851704106,positive,exclusive insurer hold back death defying diabetes,7,0,0
2015-10-06,2.4297019250015706,negative,adocia initiate phase 1b study evaluating biochaperone lispro,8,0,1
2015-10-12,7.872408178925971,negative,cholesterol odds dim failure expands cancer tie up fast growing china halt study heart stock tumble discontinues heart development,19,0,1
2015-10-13,0.8567965037119207,positive,jj diabetes survival edge,4,0,0
2015-10-14,0.014693389213416,positive,pill trump humira arthritis study,5,0,0
2015-10-22,1.7035584074960863,negative,astrazeneca deepen collaboration cancer immunotherapy beat forecast cost cut raise view drugmaker revenue rise,14,4,1
2015-11-06,0.1337375671047969,negative,federal agency investigate pricing agency investigate pricing,7,0,0
2015-11-09,0.43398336160545,negative,diabetes cut heart failure death hospitalization study diabetes cut heart failure death hospitalization study,14,0,0
2015-11-24,1.1487954471595452,negative,fda approves lung cancer,4,2,0
2015-12-03,0.3736102261877039,negative,refile swiss lab closure worry animal right group swiss lab closure worry animal right group,15,-1,0
2015-12-04,2.3357640248549583,positive,stop development diabetes treatment,4,-1,1
2015-12-08,0.7066765061159774,positive,plan report result early stage trial n3pg antibody target deposited brain plaque,12,0,0
2015-12-11,0.0302138023508424,positive,adocia report positive result study biochaperone lispro u200,8,1,0
2015-12-16,0.5628263256908239,negative,fda approves basaglar diabetes,4,2,0
2015-12-17,1.4426968812800145,positive,fda approves basaglar diabetes,4,2,1
2015-12-18,0.089440824659448,positive,europe recommends lung cancer astrazeneca,5,0,0
2016-01-05,1.3271836333549558,positive,revenue outlook fall short jardiance boost ceo ha no intention entering tax inversion deal need change tax code revise earnings estimate lower diabetes pill take jj astra,27,-1,1
2016-01-28,6.575219531252586,negative,revenue rise diabetes gain revenue rise pct diabetes gain drugmaker report pct rise quarterly sale,15,2,1
2016-01-29,0.5436479934401328,positive,adocia initiate phase 1b study evaluating lispro u100,8,0,0
2016-02-12,2.2717139156323007,negative,loses latest round uk patent battle,6,0,1
2016-02-26,1.4004496424398938,negative,eu agency recommends approval psoriasis treatment,6,1,1
2016-03-15,3.449537740359765,negative,announces change primary endpoint expedition3 study,6,0,1
2016-03-22,2.4309692524758453,positive,fda approves psoriasis,3,2,1
2016-04-05,0.8074778082088008,positive,antares partner teva first file generic version forteo,8,0,0
2016-04-08,0.5378078721357538,negative,astrazeneca announce continuation clinical trial amaranth,6,1,0
2016-04-19,0.2765719566755198,negative,jardiance studied treatment chronic heart failure,6,0,0
2016-04-26,2.2912750684892624,negative,q1 earnings revenue beat forecast drugmaker raise profit view earnings fall short hurt research spending,15,2,1
2016-04-27,0.1088473209220231,positive,adocia announce positive topline result phase 1b study lispro u100,10,2,0
2016-04-28,0.8422243914243066,positive,pharmacy stuck cialis patent war german firm,7,0,0
2016-05-02,0.8204094975686083,positive,set quarterly dividend 51shr,4,0,0
2016-05-04,1.2520125414135386,negative,fda grant priority review olaratumab,5,1,0
2016-05-24,0.0678255073255584,negative,launch product type pain could lessen need opioids,8,1,0
2016-05-31,0.2436034737401171,positive,adocia announce positive result biochaperone lispro adocia announce positive result biochaperone lispro u100 study,14,2,0
2016-06-03,0.1518618642089797,negative,announces result monarch trial abemaciclib monotherapy,6,0,0
2016-06-14,0.8194916668330277,positive,jardiance slows kidney disease progression diabetic german supreme court grant appeal alimta vitamin regimen patent lawsuit,16,0,0
2016-06-21,1.2527430818608631,negative,canada canada approves taltz treatment moderate severe plaque psoriasis,9,1,0
2016-06-28,1.4564267936052255,negative,panel back claim diabetes cut cardiac death fda panel back claim diabetes,12,0,1
2016-07-13,0.3751487892864946,negative,boehringer ingelheim announce clinical trial collaboration metastatic breast cancer,9,1,0
2016-07-19,0.1266754451750396,positive,fda expand indication type diabetes treatment synjardy,7,1,0
2016-07-26,0.0880189003317433,positive,report quarterly earnings sale beat estimate helped newer quarterly profit sale jump demand ceo john lechleiter view future pricing going challenging across board cnbc,24,1,0
2016-07-27,1.7019206655100927,positive,ceo lechleiter retire rick succeed incoming ceo dealmaking focus john lechleiter retire ceo ceo lechleiter retire david rick succeed ceo john lechleiter retire,23,1,1
2016-07-28,0.6790119332430455,negative,probe contract pbms got civil investigative demand attorney office southern district authority seek document pbm contract,16,-1,0
2016-08-01,0.4327615034237286,positive,express script valeant lack coverage express script add taltz psoriasis excluded list,12,0,0
2016-08-10,0.918144851824776,negative,provides update abemaciclib trial breast cancer stumble trial continues name joshua smiley senior vp finance treasurer effective oct panel recommends continue breast cancer study,24,1,0
2016-08-11,0.1814949533765375,positive,canada approves indication jardiance tablet,5,1,0
2016-08-22,0.2954913661810998,positive,astrazeneca receive fda fast track designation azd3293,7,0,0
2016-08-31,0.258684518696628,positive,jamere jackson elected board director,5,0,0
2016-09-14,0.2045807866687066,negative,levi garraway become senior vice president global oncology,8,0,0
2016-09-20,0.9048672736271746,positive,teva take aim lillypfizer pain,5,0,0
2016-10-05,0.3465272023541299,positive,buy boehringer pet vaccine unit highlight advancement oncology portfolio buy boehringer ingelheim pet vaccine unit,15,1,0
2016-10-17,0.5863008166554273,negative,set quarterly dividend 51share,4,0,0
2016-10-19,0.5333117852820424,negative,fda grant accelerated approval soft tissue sarcoma soft tissue sarcoma treatment get approval,13,1,0
2016-10-25,0.5671040835743102,positive,third revenue rise report third result refile result hurt disappointing humalog animal sale result hurt disappointing humalog animal sale,19,1,0
2016-11-02,0.1496838058190785,positive,pivotal ra beacon study show significant improvement patient reported outcome,10,0,0
2016-11-14,0.915423996382514,negative,incyte baricitinib treatment show improvement rheumatoid arthritis symptom phase,9,0,0
2016-12-01,1.3458031770444023,negative,refile lupin expand partnership india,5,1,1
2016-12-02,2.5874709877215407,positive,diabetes jardiance cut risk cardiovascular death fda fda let cite jardiance heart jump,13,0,1
2016-12-08,0.5268572213603218,negative,neomonarch phase trial met primary endpoint reducing expression ki67,9,0,0
2016-12-09,0.3782468210063783,positive,solanezumab not meet primary endpoint expedition3 clinical trial astrazeneca develop potentially disease modifying alzheimer treatment astra stick alzheimer approach despite setback,21,0,0
2016-12-12,0.2389384298874253,negative,report dividend increase,3,0,0
2016-12-13,0.856042172293825,positive,offer insulin discounted certain patient offer insulin discounted announces program provide insulin discounted,13,0,0
2016-12-15,5.055991019429329,positive,eas jitter strong forecast provides financial forecast update see potential launch through injectable insulin available prescription forecast revenue profit above estimate,21,1,1
2016-12-16,2.91269788796985,positive,adocia announce successful completion insulin pump study biochaperone lispro people type diabetes ema recommends approving rheumatoid arthritis incyte corp amended license development commercialization agreement entered,25,2,1
2017-01-05,1.2437925647830306,positive,adjust organization leadership structure better align growth opportunity,8,2,0
2017-01-11,1.6068529868150103,negative,expand immuno oncology collaboration,4,1,1
2017-01-12,2.7622880087886714,positive,appeal court reject teva appeal patent case over alimta teva loses appeal alimta patent case defeat teva appeal over alimta cancer,21,-1,1
2017-01-18,0.6638461234828252,positive,colucid pharmaceutical termination fee mln payable upon termination build migraine arsenal million colucid buy build migraine arsenal mln colucid buy buy colucid mln beef up migraine portfolio,27,2,0
2017-01-27,1.229653099374317,positive,adocia terminates collaboration biochaperone lispro,5,0,0
2017-01-30,0.2819283419205676,negative,sanofi novo nordisk named patient fixing suit,7,0,0
2017-01-31,3.127934274531785,positive,revenue beat diabetes sale rise revenue rise pct higher demand ceo prepared scenario case aca repeal report q4 eps,19,3,1
2017-02-08,0.3966305187044661,positive,announces label update diabetes trulicity,5,0,0
2017-02-09,1.118165905061108,negative,carolyn bertozzi elected board director,5,0,0
2017-02-15,1.305142058023545,positive,additional result pivotal ra beam study published england journal,9,0,0
2017-02-21,0.6328385235613632,negative,provision included legislation repeal affordable care act could adversely affect result,11,0,0
2017-02-24,0.2607605000376711,positive,aarp support sanofi cholesterol fight,5,0,0
2017-02-28,0.0310703231375719,negative,federal circuit revives cialis patent claim,6,0,0
2017-03-02,0.4913076437427888,negative,senior vp corporate affair communication leave,6,0,0
2017-03-20,0.2287929830527835,positive,breast cancer combination succeeds key study ceo john lechleiter total compensation wa mln breast cancer combination succeeds key study phase breast cancer study meet primary endpoint,26,0,0
2017-03-23,0.1778336753811005,positive,ignyta explore strategic option taladegib through amendment taladegib license agreement,10,0,0
2017-03-24,0.2116534160529259,negative,drugmaker invest mln operation drugmaker invest million operation announces mln investment capital project,13,0,0
2017-03-28,0.1222694714745342,negative,intelgenx technology granted versafilm exclusive license tadalafil film product under erectile dysfunction dosing patent,14,1,0
2017-03-31,0.5341114145040238,negative,endowment report open sale stock,5,0,0
2017-04-17,4.961442700650598,negative,pursue contempt case dr reddy teva court,7,0,1
2017-04-24,0.7685679985951488,positive,buzz get cancer boost ahead q1 report profit profile help rebound alzheimer setback phase monarch breast cancer study abemaciclib demonstrated superior progression free survival interim analysis report positive interim breast cancer combo,32,2,0
2017-04-25,3.243095543543717,negative,drugmaker revenue rise pct q1 non gaap earnings give no time frame arthritis delay fall,15,-1,1
2017-05-01,0.5444812715428959,negative,set q2 dividend got civil investigative demand washington ag office pricing insulin product,13,0,0
2017-05-04,2.085667075238695,positive,file potential part note offering,5,0,1
2017-05-10,0.1422392325193699,positive,leigh ann pusey join senior vp corporate affair communication,9,0,0
2017-05-12,0.1297049357625312,positive,migraine treatment meet main goal late stage study announces positive result phase study galcanezumab,14,1,0
2017-05-16,1.5398296750179008,negative,lupin expand partnership india 3sbio enters distribution promotion agreement subsidiary,10,1,1
2017-05-18,0.1980876608977499,negative,therapeutic entered first amendment license agreement,6,0,0
2017-05-31,1.581959399489985,positive,announces phase range urothelial cancer trial cyramza met primary endpoint,10,0,1
2017-06-01,0.267391082501045,negative,cfo retire end,3,0,0
2017-06-07,0.1942906566670732,positive,peptidream announces completion technology transfer peptide discovery platform system,9,0,0
2017-06-08,0.8450722829869362,positive,announces strategic collaboration keybioscience,4,0,0
2017-06-09,1.3253072248359477,positive,idf announce second phase bridge programme funding,7,1,1
2017-06-12,0.1522114896954973,negative,zymeworks bispecific immuno oncology candidate nominated late stage preclinical development jardiance tablet studied chronic kidney disease,16,0,0
2017-06-13,0.05635544810203,negative,update study jardiance,3,0,0
2017-06-15,0.7439046651821379,positive,file supplemental biologics license application fda taltz,7,0,0
2017-06-19,0.2707133783372839,negative,set quarterly dividend,3,0,0
2017-06-21,0.1082409941821849,negative,unveils expanded center san diego,5,0,0
2017-07-06,0.4156626583380785,negative,purdue university announce strategic research collaboration,6,1,0
2017-07-07,0.1970752521251784,positive,uk supreme court rule favor alimta patent uk supreme court rule favor alimta vitamin regimen patent,16,0,0
2017-07-10,0.1195409344737274,negative,fda grant priority review abemaciclib,5,1,0
2017-07-12,0.6450023321814324,positive,uk supreme court confirms ruling patent case reach settlement agreement cialis patent litigation,13,0,0
2017-07-18,0.0187893247127979,positive,adimab entered agreement transfer adimab platform,6,0,0
2017-07-24,0.1187989347329221,positive,nektar therapeutic develop commercialize nktr,5,0,0
2017-07-25,3.2522967576000816,negative,drugmaker profit jump signal long delay arthritis fall seek external early cancer asset report second result,16,-2,1
2017-07-28,0.2136762381526602,positive,get civil investigative demand minnesota ag insulin product,8,0,0
2017-08-04,0.2815948265856294,positive,acute migraine succeeds late stage study refile acute migraine succeeds late stage study announces positive result second phase study lasmiditan treatment migraine,22,1,0
2017-08-10,0.7817581137328555,positive,elan secure fee patent fight,5,0,0
2017-08-25,0.3223810315378994,negative,nektar therapeutic got notice early termination waiting period related license agreement,11,0,0
2017-08-28,0.0593708537270476,positive,loses bid overturn million patent verdict,6,-1,0
2017-08-30,1.996005036731319,positive,file baricitinib resubmission fda end,5,0,1
2017-09-05,0.3935299686429583,positive,acrux agreed terminate licensing agreement axiron,6,-1,0
2017-09-07,1.2914948491811518,positive,lay off pct employee bid cut cost cut pct job focus developing cut job focus developing,16,0,0
2017-09-08,1.809891631220828,positive,galcanezumab demonstrates positive long term safety result up month patient migraine,11,1,1
2017-09-12,0.8937636614762101,negative,update jardiance tablet,3,0,0
2017-09-14,0.8083946078064397,positive,lillyincyte pill beat placebo mid stage eczema trial corrected lillyincyte pill beat placebo mid stage eczema trial,17,1,0
2017-09-25,1.0744377263298466,positive,boehringer ingelheim collaborate create predictive model help improve outcome people type diabetes,12,0,0
2017-09-28,0.293491212927699,positive,win approval breast cancer set list breast cancer 10948month,9,2,0
2017-09-29,0.2837862287897286,positive,appoints smiley chief financial name cfo replaces head rd management shakeup,11,0,0
2017-10-02,0.5130600326424206,positive,endowment report open sale common stock,6,0,0
2017-10-04,0.4712936520710808,positive,junior kwikpen available prescription,4,0,0
2017-10-05,0.2009575963389354,positive,defeat challenge alimta cancer patent win alimta patent dispute endowment report open sale common stock oct pto rule favor alimta win alimta patent dispute,24,0,0
2017-10-10,1.2862323820576838,negative,breast cancer fails help lung patient lung cancer fails late stage study report topline result phase juniper trial evaluating verzenio,20,-1,0
2017-10-11,0.2731599885253954,negative,selected limited distribution network,4,0,0
2017-10-12,0.5789405262021097,positive,fda grant priority review verzenio,5,1,0
2017-10-16,0.8266003834023761,negative,q4 dividend 52share set quarterly dividend,6,0,0
2017-10-18,0.4813122528750324,negative,collaborate germany curevac cancer vaccine,5,0,0
2017-10-19,0.7074915845796115,positive,novo nordisk vp seek semaglutide novo nordisk take aim backing diabetes,11,0,0
2017-10-23,0.3316188570812395,positive,announces million investment diabetes manufacturing indianapolis,6,0,0
2017-10-24,2.481280424799837,negative,mull sale option animal report q3 eps optimistic prospect arthritis profit fall mull sale animal,15,-2,1
2017-10-25,0.1427742106738905,positive,teva accuses court infringing migraine patent,6,0,0
2017-10-27,1.174083782411195,negative,eagle pharma get tentative fda approval alimta version,8,2,0
2017-11-22,0.2920333758514082,positive,report pct passive stake leap therapeutic nov,7,0,0
2017-12-01,1.0109419846928591,positive,taltz receives fda approval treatment active psoriatic arthritis,8,2,0
2017-12-05,0.9205364673315786,positive,initiate clinical trial evaluate automated insulin delivery system,8,0,0
2017-12-06,0.8788628925541886,negative,juno therapeutic sign licensing agreement oncotracker fred hutchinson cancer research center,11,1,0
2017-12-08,0.130129662116718,positive,refile cyramza meet main goal gastric cancer study stomach cancer meet main goal fails improve survival rate cyramza meet primary endpoint gastric cancer study,24,-1,0
2017-12-11,0.0468245589014593,negative,announces dividend increase fda ok sanofi follow biologic diabetes humalog fda clear sanofi follow diabetes biologic humalog kimberly blackwell become vice president early phase development immuno oncology oncology,28,2,0
2017-12-13,1.3721032533302258,positive,announces financial guidance enhances outlook through forecast beat strength forecast profit largely above estimate,14,1,1
2017-12-14,1.172900052348258,negative,nsav subsidiary sign agreement,4,1,0
2018-01-22,0.8715814833598845,negative,innovative targeting solution announces research agreement,6,0,0
2018-01-31,5.439396122059381,negative,drugmaker post quarterly loss tax charge plan deploy around bln global cash q4 non gaap earnings beat estimate fall diabetes animal concern,22,-2,1
2018-02-06,1.324974828663894,negative,adocia file additional arbitration claim,5,0,1
2018-02-13,0.3011964852657867,negative,announces positive top line phase result taltz,7,1,0
2018-02-23,0.427052263103933,positive,ceo david rick fy total compensation wa mln,8,0,0
2018-02-26,0.6546484516546158,positive,breast cancer win expanded approval show trulicity combo treatment improves blood sugar control type diabetes patient receives additional fda approval verzeniotm initial treatment advanced breast cancer,26,3,0
2018-03-06,0.909870050333128,negative,boehringer ingelheim expand heart failure program jardiance,7,1,0
2018-03-08,1.3885109105441051,positive,efsd jdrf extend collaboration supporting type diabetes research,8,1,1
2018-03-19,0.8335800444032593,negative,ceo david rick total compensation wa mln,7,0,0
2018-03-20,0.6273207262178393,negative,cv appoints former cfo president pbm,6,0,0
2018-04-03,1.148944569618604,positive,tasly pharma unit sign licensing agreement diabetes,7,1,0
2018-04-04,0.2971280197358927,positive,cyramza succeeds late stage liver cancer trial announces cyramza phase reach study met overall survival endpoint sigilon therapeutic announce strategic collaboration develop encapsulated cell therapy tern pharma acquires global exclusive right develop commercialize nash asset,35,1,0
2018-04-16,0.3204199799271778,negative,boehringer ingelheim announce academic collaboration university oxford,7,1,0
2018-04-19,0.5923859549272881,positive,fda staff cite safety issue incyte rheumatoid arthritis fda staff raise safety concern over lillyincyte arthritis,16,-1,0
2018-04-20,0.0172733815930636,negative,report additional top line result cyramza phase range study,9,0,0
2018-04-23,1.4569460166112491,positive,fda panel higher dose incyte arthritis fda panel vote approving higher dose incyte arthritis,14,0,1
2018-04-24,1.2095810852655653,positive,express script target migraine pricing shift profit beat strong sale diabetes cancer drugmaker post quarterly profit interested immuno oncology deal focus express script target migraine pricing shift galcanezumab reduced migraine headache day patient migraine report q1 adj earnings,38,1,0
2018-04-25,1.0638580118747851,positive,china nccd announce collaboration advance scientific understanding care people living diabetes cardiovascular disease,13,1,0
2018-04-26,0.7211609822308063,positive,endowment report open sale common stock,6,0,0
2018-05-03,0.7817917977574917,negative,canada humalog junior kwikpen approved canada available canadian diabetes,9,0,0
2018-05-07,0.0449530801413633,negative,declares q2 dividend,3,0,0
2018-05-08,0.3179448048323152,positive,shareholder elect nominee director yr term ending,7,0,0
2018-05-10,1.0707380167079394,positive,buy armo bioscience billion bolster cancer pipeline armo bioscience upon termination merger under specified circumstance required pay fee mln buy armo bioscience bln bolster cancer pipeline buy armo bioscience bln,30,0,0
2018-05-11,1.6612369897081036,positive,hbm investment announces tender offer hbm portfolio,7,0,1
2018-05-14,0.7043256650741458,positive,acquire aurka pharma buy cancer developer aurka pharma buy cancer developer aurka pharma,13,2,0
2018-05-15,0.3465763153588708,negative,migraine meet main goal cluster headache trial phase study patient chronic cluster headache not meet primary endpoint,17,0,0
2018-05-22,0.7546093112880348,positive,taltz receives fda approval label update include psoriasis involving genital area,11,2,0
2018-05-23,0.284356279306297,positive,unit bluegill acquisition offering buy armo bioscience outstanding 50share ue mahony retire president oncology,14,1,0
2018-06-01,1.205191452149934,negative,fda approves lower dose incyte arthritis get nod arthritis set well below rival,13,3,0
2018-06-12,0.5601701501137368,negative,astrazeneca latest abandon alzheimer trial,5,0,0
2018-06-13,0.5881252248640556,positive,lupus treatment succeeds mid stage trial,6,0,0
2018-06-22,0.3565988050504343,negative,district court rule favor alimta patent,6,0,0
2018-06-25,1.186706029551432,positive,jardiance meet main goal diabetes trial,6,0,0
2018-07-18,0.3032036301416907,positive,pain meet late stage trial goal,6,0,0
2018-07-24,4.526040934044029,positive,post quarterly loss corrected take animal unit public profit beat estimate plan elanco ipo post quarterly profit above estimate take animal unit public corrected take animal unit public,28,0,1
2018-08-02,0.235386449779118,positive,drugmaker elanco animal unit file ipo,6,0,0
2018-09-06,0.0300563697841371,negative,elanco unit expects ipo raise up bln,7,1,0
2018-09-19,1.173178933235286,negative,elanco animal unit ipo priced 24share,6,0,0
2018-09-21,0.3362036449613192,positive,migraine win european panel thumb up,6,1,0
2018-09-27,0.0780192381756528,positive,fda approves migraine rival judge dismisses teva lawsuit migraine defeat teva patent lawsuit over migraine,15,2,0
2018-10-02,0.3928455511327033,positive,diabetes treatment meet main goal late stage study,8,0,0
2018-10-04,4.804771516439499,positive,diabetes impress hurt rival novo diabetes show promise mid stage trial,11,1,1
2018-10-10,1.3386877110924678,positive,cant shake million cialis patent verdict appeal,7,0,1
2018-10-17,2.2878514797727068,positive,express script cover migraine excludes teva,6,0,1
2018-10-23,0.9548212030669024,negative,non opioid help reduce osteoarthritis pain corrected non opioid help reduce osteoarthritis pain,13,0,0
2018-10-29,1.5033644051633988,positive,make bet gene silencing firm dicerna,6,0,1
2018-11-05,2.623950328458924,positive,diabetes trulicity reduces heart risk trial,6,0,1
2018-11-06,4.482441545342697,negative,trulicity lead mixed third sink drugmaker third profit double consider acquisition like billion armo buy consider acquisition like bln armo buy,21,1,1
2018-11-16,1.1927087148824178,positive,considers sale off patent asset china bloomberg considers sale off patent asset china bloomberg,14,0,0
2018-12-12,0.6432779153502155,negative,partner ac immune alzheimer treatment,5,0,0
2018-12-17,1.22765521786663,negative,taltz superior humira late stage psoriatic arthritis trial refile taltz superior humira late stage psoriatic arthritis trial,17,0,0
2018-12-19,3.948273615190301,positive,forecast profit above estimate see profit revenue above estimate rise corrected forecast profit revenue above estimate,16,1,1
2019-01-07,0.2477331876150401,negative,update make bln bet rare cancer loxo oncology buy buy loxo oncology bln make billion bet rare cancer loxo oncology buy,21,1,0
2019-01-08,0.020038925465271,negative,cut job france plant through voluntary redundancy,7,0,0
2019-01-11,0.168375686736133,positive,refile eye cancer deal wary car gene therapy eye cancer deal wary car gene therapy,15,0,0
2019-01-18,3.487764927897952,negative,cancer therapy lartruvo fails meet main goal late stage trial cancer fails key trial no longer prescribed,17,-1,1
2019-01-25,0.8635320700934201,negative,exclusive cv cover migraine teva excludes,6,0,0
2019-02-01,0.8111752576954068,positive,exclusive top insurer cover migraine exclude teva,7,0,0
2019-02-06,0.8313953001485075,negative,back proposal rebate lower cost quarterly sale beat expectation,9,1,0
2019-02-15,0.3429826429377058,positive,bayer gain full vitrakvi right loxo bayer acquires full vitrakvi right loxo,12,1,0
2019-02-19,0.4588149841434186,negative,shown help reduce back pain late stage trial,8,0,0
2019-03-04,0.7073558286704862,negative,seek quell anger cheaper insulin introduce lower priced insulin injection,10,0,0
2019-03-12,0.3771009910084277,negative,combo treatment meet main goal lung cancer late stage study combo therapy succeeds late stage lung cancer study,18,0,0
2019-04-04,1.3987566417695163,negative,astellas must face lawsuit alleging underpaid medicaid rebate,8,0,1
2019-04-18,1.312805032020381,negative,lower dose painkiller miss main goal late stage study,9,-1,1
2019-04-30,2.191511206328345,negative,miss estimate top selling diabetes trulicity slip update miss estimate top selling diabetes trulicity slip quarterly profit triple elanco gain,20,0,1
2019-05-10,0.1396429636417062,negative,migraine pull ahead fierce battle prescription,6,0,0
2019-06-04,1.4941232280040184,negative,fda approves migraine first ever cluster headache treatment,8,2,1
2019-07-11,4.3468790945148,negative,bio head leave next month,5,0,1
2019-07-24,0.1927399202645618,negative,hypoglycemia treatment win fda approval,5,3,0
2019-07-25,0.1673353818951839,negative,qa gc mike harrington urgent need mdl reform,8,0,0
2019-07-30,0.2178782172349458,positive,top revenue estimate diabetes boost newer help top wall street quarterly profit estimate,13,0,0
2019-08-09,0.50566773323234,positive,win fed circuit decision fending off generic alimta,8,1,0
2019-08-19,0.6138977864012629,positive,roche tap executive chief medical officer roche tap executive garraway chief medical officer,13,0,0
2019-08-29,0.1238378798969153,negative,fda approves mylan generic lung cancer alimta,7,2,0
2019-09-09,2.6632162100573287,negative,targeted ret shrink tumor lung cancer trial,7,0,1
2019-10-11,0.3101078533250589,positive,migraine treatment win fda approval,5,3,0
2019-10-16,1.4346602275528308,negative,pancreatic cancer treatment fails late stage study,7,-1,1
2019-10-21,1.3498646306832618,negative,brief scotus reject petition cialis patent infringement case,8,-1,1
2019-10-23,2.512373132762724,negative,ale diabetes trulicity fall short drop report rise third profit target cancer developer deal,14,-1,1
2019-11-13,0.3681404930605536,negative,fda panel vote boehringer ingelheim diabetes,6,0,0
2019-12-05,0.7471418852294409,positive,refile put loxo executive charge cancer research unit,8,0,0
2019-12-17,1.9968127852647344,positive,see higher expected profit rpt see higher expected profit expects higher expected profit,13,0,1
2012-01-19,0.4757005271641024,positive,resolve vioxx litigation canada,4,0,0
2012-01-25,1.0946213072123068,negative,fda label show cholesterol help heart kgaa get eu approval wider use rebif cholesterol vytorin get label,17,1,0
2012-02-06,0.1450806863264375,positive,file application insomnia,3,0,0
2012-02-09,0.8285079253983474,negative,hepatitis pill hamper hiv,4,0,0
2012-02-15,0.0312412288170027,negative,strike brazil joint venture sell,5,0,0
2012-02-24,1.0245568228012814,negative,kgaa cut cost job corrected kgaa cut cost job,9,0,0
2012-02-28,0.3112531422224451,positive,fda fine lack diabetes study,5,0,0
2012-03-05,1.7787827630046935,positive,fda reject cholesterol combo pill fda reject cholesterol combo pill,10,-2,1
2012-03-06,1.1642651837447948,negative,kgaa warns cutback expense hit profit forecast 1st eps below street view vertex hepatitis work hiv patient kgaa q4 profit miss estimate,22,0,0
2012-03-08,0.7670939195921767,negative,hepatitis win uk cost endorsement,5,1,0
2012-03-16,0.2166071635662847,negative,fda ridaforolimus meet study goal fda staff question benefit ariad,10,1,0
2012-03-19,0.7601475302480787,negative,cardiome stop heart development slump,5,-1,0
2012-03-28,0.7670305372320052,negative,key vytorin study cleared continue,5,0,0
2012-04-02,0.4450238059654055,negative,gsk daily hiv match rival,5,0,0
2012-04-09,0.7373107724173433,positive,vaccine group get cut gsk rotavirus shot,7,0,0
2012-04-12,1.865301151875487,negative,exual side effect added label exual side effect warning added,10,0,1
2012-04-16,0.5155998987460886,positive,endocyte soar cancer deal smallmidcaps endocyte double deal boost stock,10,1,0
2012-04-19,0.5379226485209498,positive,ordered pay million criminal vioxx probe,6,-2,0
2012-04-20,0.7975408840591447,positive,kgaa abstain major deal,4,0,0
2012-04-24,0.3801447467616237,negative,kgaa close hq switzerland,4,0,0
2012-04-26,0.5928037945532205,negative,not mix hepatitis pill hiv,5,0,0
2012-04-27,0.1900924548525973,negative,profit beat forecast revenue lag court rule zetia patent valid,10,2,0
2012-05-09,0.8046879892503411,negative,kgaa erbitux fails colon cancer study,6,-1,0
2012-05-15,0.6946475955449061,negative,kgaa target mln eur cost cut kgaa forecast gain adj ebitda kgaa profit down liquid crystal rivalry,17,1,0
2012-05-31,0.701380568969201,positive,text revise outlook positive affirms bbba rtgs,7,1,0
2012-06-04,0.7999095403116052,positive,brief moody rate credit agreement,5,0,0
2012-06-05,0.650440355442905,negative,fda reject merckariad sarcoma,4,-2,0
2012-06-06,1.1801761313225745,negative,kgaa dr reddy biosimilars deal,5,0,0
2012-06-12,0.1612927260873142,negative,sleep hit goal pivotal trial,5,1,0
2012-06-15,0.6309543042991583,negative,loses nasonex patent case refile district court rule nasonex patent lawsuit,11,0,0
2012-06-20,0.1111409369696558,positive,india press talk buy india micro lab financial express,9,1,0
2012-06-21,2.8559623874603868,positive,recall vaccine accidental release fda,5,-1,1
2012-06-27,0.2589622365901656,positive,astra keep alliance,3,0,0
2012-07-05,0.0206854109106369,positive,mdxhealth sign diagnostic deal kgaa,5,1,0
2012-07-11,0.4016634819808184,negative,bone show clear benefit trial halted osteoporosis show clear benefit trial halted blackrock top ranked among corporate board study,19,2,0
2012-07-24,0.4817338134621374,negative,hiv good isentress study,4,0,0
2012-07-27,2.23010613096295,positive,result beat forecast rise stock snapshot climb pct amazon lead trong result boost faith generic loom quarterly earnings beat forecast,20,3,1
2012-08-03,1.4367412822394288,negative,fda approves generic version singulair fda approves first generic version singulair fda approves generic version singulair,16,2,1
2012-08-08,0.0152119823117358,positive,key cholesterol pushed key zetia cholesterol due,7,0,0
2012-08-14,0.0367199544555663,negative,kgaa profit helped rebif sale forex refile kgaa predicts growth adj ebitda kgaa predicts growth adj ebitda,17,1,0
2012-09-04,0.5566701524339579,positive,kgaa cut job germany,4,0,0
2012-09-06,0.1995538269150776,negative,kgaa buy license phase ii cancer symphogen,7,1,0
2012-09-10,1.0448734383695202,positive,brief moody rate senior note a1 text rate senior note aa,11,0,0
2012-09-18,0.2635954753827274,positive,kgaa pull nsclc filing erbitux europe kgaa pull second lung cancer filing drop pct pull nscl filing erbitux europe,19,-1,0
2012-09-25,0.99773508520975,positive,agrees settle coppertone class action suit agrees settle coppertone class action lawsuit,12,0,0
2012-09-26,0.3404293095270128,positive,cardiome pull heart deal,4,0,0
2012-10-02,0.4600580354440442,positive,ablynx enters alliance worth up million euro ablynx hit high deal,11,1,0
2012-10-03,0.2734637005355367,positive,week diabetes effective clinical study,5,1,0
2012-10-05,0.3400778540914473,positive,text fitch revise rating outlook positive,6,1,0
2012-10-08,0.47178331071559,positive,uk sanofi recall typhoid vaccine batch,6,-1,0
2012-10-26,0.2674089975001958,negative,post mixed result third tax gain lift profit sale disappoint psoriasis hdl alzheimer trial moving ahead,16,1,0
2012-11-13,0.4252293055505007,negative,scrap combination diabetes,3,0,0
2012-11-15,0.4115153549586248,negative,kgaa expects publish stimuvax q1 kgaa lift outlook screen chemical kgaa lift outlook screen chemical corrected jj plan clinical trial site database jj plan clinical trial site database,28,1,0
2012-11-27,0.2135246160622439,negative,kgaa resist lure potential proceeds otc sale,7,0,0
2012-11-30,0.93812972315217,negative,text ups affirms rtg outlook stable text rating kgaa,9,1,0
2012-12-03,0.8116249249389584,positive,becomes bigger alzheimer player trial start trial test alzheimer,9,1,0
2012-12-11,0.9153779318979538,positive,india revoke patent asthma cardiome pay million settle debt deal,10,-1,0
2012-12-18,0.2852319170550066,positive,ge collaborate alzheimer development,4,0,0
2012-12-19,0.5680989124848046,negative,kgaa cancer stimuvax miss goal phase iii trial kgaa oncothyreon hit cancer vaccine fails kgaa down cancer vaccine fails trial moody upgrade kgaa baa1 stable outlook,26,2,0
2012-12-20,4.013159892981754,negative,cholesterol fails risk seen under review eu trial failure cholesterol study failed,12,-1,1
2012-12-21,0.6142504126357973,negative,eu start safety review cholesterol ema start safety review tredaptive european watchdog start safety review cholesterol,16,1,0
2013-01-11,1.0586924291295818,positive,begin overseas recall hdl cholesterol rpt steer doctor away hdl cholesterol withdraws cholesterol tredaptive globally,15,-1,0
2013-01-18,0.3150387229455154,positive,eu agency confirms suspension cholesterol,5,-1,0
2013-01-24,0.3935851765108911,positive,ceo jury raising good cholesterol,5,0,0
2013-01-25,0.5075560771550025,positive,fda ok over counter version overactive bladder fda ok otc version overactive bladder,13,0,0
2013-02-01,4.311961108999896,negative,corrected continues believe osteoporosis beat forecast issue cautious view fall worry osteoporosis down premarket trading result,16,0,1
2013-02-05,0.4100653668705378,positive,hit verdict fosamax trial,4,1,0
2013-02-07,0.0867212594274358,negative,appeal court upholds patent vytorin,5,1,0
2013-02-13,0.8092786340744951,negative,lawyer vioxx trial head toyota acceleration case,7,0,0
2013-02-14,0.0051908871036676,positive,pay mln settle enhance lawsuit pay million settle enhance lawsuit pay mln settle enhance lawsuit,15,0,0
2013-02-15,0.6765835061675052,positive,high stake cholesterol study could lift cloud,7,1,0
2013-02-22,0.1286186908740161,positive,eu agency recommends sanofi pediatric vaccine eu agency recommends sanofi paediatric vaccine,12,0,0
2013-02-25,0.8554504766046578,positive,kgaa phase iii trial cilengitide fails kgaa brain tumor fails clinical trial kgaa brain tumour fails clinical trial,18,-1,0
2013-03-07,1.1198744617482603,negative,refile kgaa see profit boost cost cut tv veteran named research chief setback veteran named rd chief setback kgaa profit gain cost cut hike,24,1,0
2013-03-12,3.3851037431792075,positive,vytorin study continue review jump continue large study vytorin panel review up continue study vytorin,15,0,1
2013-03-15,0.2749810098356287,negative,fda take extra mo review sugammadex anesthesia reversal agent anesthesia reversal agent face delay refile anesthesia reversal agent face delay,20,-1,0
2013-03-18,0.4914370181053007,negative,kgaa collaborate nordic bioscience,4,0,0
2013-03-27,0.6533002931385701,negative,kgaa replaces bln eur loan long term funding,8,0,0
2013-04-02,0.7692516090914703,positive,unit sue india glenmark over diabetes,6,0,0
2013-04-03,2.0159052964091817,positive,experimental sleep cause fewer side effect study,7,0,1
2013-04-24,1.4616931874445016,negative,melanoma win breakthrough designation melanoma win breakthrough designation,8,2,1
2013-04-26,1.2748387204651324,positive,kgaa confirms full outlook kgaa restructuring cost totaled million euro,10,0,0
2013-04-29,0.7743181046829695,negative,jointly develop diabetes,3,0,0
2013-05-01,1.9104805352288976,negative,stock future slip ahead open adp fed tap januvia diabetes lag forecast cut first sale disappoint q1 januvia sale hurt million inventory reduction refile stock snapshot wall st dip drag fed tap down pct premarket,35,-3,1
2013-05-09,1.392979238476355,positive,sale rep alleges sexual bias seek over mln gsk cut cervical cancer shot poor sale rep claim sexual bias seek over mln,22,-1,1
2013-05-14,0.0062498001498711,positive,kgaa step up cost saving boosting profit rise q1 result kgaa q1 adj operating profit jump trim cost,18,2,0
2013-05-20,1.690030698243783,negative,uk first eu get schmallenberg vaccine fda staff sleep effective question dose level,13,1,1
2013-05-21,4.545455208189875,positive,sign bln buyback agreement goldman sachs,6,1,1
2013-05-22,0.5681915196505183,negative,insomnia move step closer approval sign billion buyback agreement goldman sachs wi billionaire buy serono hq campus fda panel sleep safe effective lower dose fda panel insomnia effective safe low dos,31,5,0
2013-05-23,1.6166175110773229,positive,halt development experimental parkinson,4,0,1
2013-05-28,0.3765280426235362,positive,judge kentucky ag use contingency fee lawyer case,8,0,0
2013-06-03,3.1966962378508823,positive,stock snapshot hit session high rally stock flat poor factory lift stock dip lift stock wall st end up fed stimulus view gain,23,1,1
2013-06-21,1.1705612307797209,positive,ablynx enters phase trial partner,5,0,0
2013-06-25,1.3492634666406045,negative,win injunction indian firm over diabetes,6,1,1
2013-06-26,0.0049258662574436,positive,kgaa liquid crystal momentum slow second half germany see liquid crystal momentum slowing h2,14,-1,0
2013-06-27,0.6766675003456291,positive,south africa aspen bln deal south africa aspen billion deal,10,0,0
2013-07-01,0.8658326788955839,negative,fda reject insomnia fda reject insomnia seek lower dose,9,-2,0
2013-07-16,0.2230261960534441,negative,reverse anesthesia delayed fda fda cancel advisory committee sugammadex fda need time complete sugammadex review,15,0,0
2013-07-24,0.0327400914019171,positive,fda accepts review long delayed blood clot,7,0,0
2013-07-30,0.5999172526812258,negative,revenue hit weak overseas consumer sale cost control help weather weak,11,0,0
2013-08-06,0.3827960919180917,positive,kgaa q2 adj core profit up liquid crystal,8,0,0
2013-08-12,0.2834499273139168,positive,avanir pharma promote diabetes rise,5,1,0
2013-08-13,0.3781908166707204,negative,study industry use cattle zilmax roll training program zilmax customer,10,0,0
2013-08-16,0.2322832041648181,negative,amid cattle concern halt zilmax sale no safety issue found zilmax cattle product suspends sale zilmax study use cattle product exclusive fda working usda cattle zilmax,26,-1,0
2013-08-30,0.7201418654835257,positive,hundred fosamax lawsuit ordered readied trial hundred fosamax lawsuit versus ordered readied trial,13,0,0
2013-09-11,0.0196213889984475,positive,astrazeneca pay mln right cancer,5,-1,0
2013-09-23,0.2246107835870758,negative,fda concerned aspect study corrected fda concerned aspect study,9,-1,0
2013-09-25,0.5835851997824659,positive,kgaa continue testing cancer vaccine kgaa revives testing cancer vaccine,10,0,0
2013-09-26,0.3635468191278024,negative,ablynx serono sign research alliance kgaa belen garijo head pharmaceutical unit,11,1,0
2013-10-01,1.583981705303339,positive,tock news option volume turn busy call eyed slash annual cost billion cut job plan bln annual cost reduction job cut trigger response pct lung cancer patient,27,0,1
2013-10-03,0.9014208393882228,positive,kgaa prepares fresh investment israel qlight,6,0,0
2013-10-04,1.0264833544809338,negative,germany see long term growth cancer erbitux,7,1,0
2013-10-14,1.5412796326723877,negative,kgaa seek clinical trial cost kgaa talk cost trial ft,10,0,1
2013-10-28,2.716076384437449,negative,stock wall st little changed record level slip stock wall st flat near record level fall,16,-3,1
2013-10-29,0.026227377650656,negative,exclusive work toward bringing zilmax back canada,7,0,0
2013-10-31,0.0479414119320398,negative,analysis bringing cattle feed zilmax back wont easy,8,0,0
2013-11-04,0.7314988548107859,positive,serono kadimastem collaborate cell based screening,6,0,0
2013-11-14,0.5150068401169605,positive,germany kgaa lift profit outlook cost cut germany kgaa lift profit outlook cost cut kgaa eye acquisition unit rpt germany kgaa lift profit outlook cost cut,26,1,0
2013-11-15,0.087695913083019,positive,corrected invests million china plant invests million china plant,9,0,0
2013-11-18,0.225084830732325,positive,nda noxafil receives fda priority review trial show melanoma cancer patient respond,12,1,0
2013-11-19,0.3423410354654765,positive,brings maternity program poor nation death rise,7,0,0
2013-11-22,0.1579152387609195,positive,research alert kgaa commerzbank raise hold,6,1,0
2013-11-26,0.1887763433069733,negative,germany look deal lift sale,5,1,0
2013-12-05,0.5744448933844293,negative,kgaa ceo ha firepower deal kgaa buy az electronic material billion germany buy hi tech material firm az billion germany make bln stg offer az electronic germany buy hi tech material firm az bln,34,1,0
2013-12-09,0.0899713100196208,positive,agrees proposed mln settlement over fosamax lawsuit,7,0,0
2013-12-10,0.0960158318220827,positive,move alzheimer big trial safety review move alzheimer big trial safety review,12,0,0
2013-12-12,0.0580258387203325,negative,fda panel allergy effective,4,1,0
2013-12-19,0.109373751556252,negative,french watchdog fine reckitt subutex generic dispute,7,0,0
2013-12-23,0.4531556464056008,negative,serono ec approves labal change cancer erbitux eu back erbitux broader colon cancer treatment,14,1,0
2013-12-30,0.3175829645836514,positive,pecial report lost hoof dead cattle halted zilmax sale woe show animal no panacea pecial report lost hoof dead cattle halted zilmax sale,23,0,0
2014-01-08,0.6603958319429615,negative,novartis talk unit bloomberg,4,0,0
2014-01-09,0.6076655342135306,negative,novartis discus earnings boosting asset swap,6,0,0
2014-01-13,7.826098809714066,positive,jump early filing skin cancer anti blood clot approved fda review stock wall st down modestly earnings caution gain anti blood clot approved fda staff consumer animal move possible stock wall st flat earnings caution climb,36,0,1
2014-01-14,1.315671900895632,negative,need dose joie de vivre research chief,7,0,1
2014-01-15,1.444670559188488,negative,fda advisory panel back blood clot preventing,7,0,1
2014-01-23,1.3061712487239974,positive,hi tech material firm az offer extended feb,8,0,0
2014-01-27,1.5500216795521935,positive,hare kgaa fall cfo resignation lanxess lure former finance chief back top job,13,-1,1
2014-01-28,0.0517770259242711,positive,fda panel support safety efficacy allergy,6,0,0
2014-01-31,0.4233177427807266,negative,get buyout interest consumer unit source,6,0,0
2014-02-03,0.5703368311026247,positive,ablynx agrees cancer deal worth up bln euro ablynx sign cancer immunotherapy collaboration licensing agreement ablynx sign deal worth up bln euro ablynx agrees cancer deal worth up billion euro,30,1,0
2014-02-05,0.1628109371097252,positive,result flag cancer deal lift 4th sale miss wall st estimate,11,0,0
2014-02-06,0.8703722376772527,negative,extends offer az electronic takeover feb astrazeneca take alzheimer race,10,0,0
2014-02-07,0.6201968174051053,positive,pay million nuvaring contraceptive settlement pay mln nuvaring contraceptive settlement pay mln resolve nuvaring product liability case utrecht university research pig virus vaccine,23,-1,0
2014-02-10,0.0354382066946046,positive,join race copy sanofi diabetes lantus,6,0,0
2014-02-14,0.06517747969772,positive,kgaa extends offer period az third time extends az offer date,11,0,0
2014-02-19,0.5049956700293068,negative,exclusive bayer novartis others eye consumer unit source,8,0,0
2014-02-20,0.8088831152829323,positive,kgaa ready deal ceo,4,0,0
2014-02-28,0.3294885151158278,positive,germany raise dividend eurosshare kgaa extends offer period az fourth time,11,1,0
2014-03-04,0.2712078359183856,negative,dust mite allergy reduces symptom midstage study,7,0,0
2014-03-05,0.4060854117502677,negative,hepatitis work hiv infected patient study,6,0,0
2014-03-06,0.4390451734395117,positive,kgaa profit up cutback cancel forex pain kgaa quarterly adj ebitda edge up cost cut kgaa confident az takeover wrapped up h1,22,1,0
2014-03-14,0.1194886293973129,positive,corrected extends offer period az fifth time extends offer period az electronic material extends offer period az fifth time,19,0,0
2014-03-25,2.14721987256854,positive,kgaa name head lab equipment otc unit,7,0,1
2014-03-26,2.223127022002802,positive,plan propose split glaxo end pay assistance obamacare plan,9,-1,1
2014-03-27,0.3068272583397147,negative,name baxter exec cfo corrected appoints baxter executive cfo appoints baxter executive cfo,13,0,0
2014-03-31,0.591767108563146,positive,korea allow sale zilmax,4,0,0
2014-04-03,0.3104321868359849,negative,kgaa sign license agreement auxogyn,5,1,0
2014-04-04,1.0220946978051535,positive,exclusive want test zilmax cattle beef industry resists,8,0,0
2014-04-10,0.0885485589586676,negative,hepatitis shine easier treat patient study hepatitis shine easier treat patient study,12,0,0
2014-04-14,1.4137295159400431,negative,grass pollen allergy win approval grass pollen allergy vaccine win approval,11,2,1
2014-04-17,0.2335796594467254,positive,corrected ragweed pollen allergy get approval ragweed pollen allergy get approval,11,1,0
2014-04-24,0.150546812115393,negative,kgaa iiib study kuvan reached primary endpoint,7,0,0
2014-04-28,1.295047332280319,negative,reckitt benckiser confirms talk buy unit rpt reckitt benckiser confirms talk buy unit,13,1,0
2014-04-29,3.1336137568056976,positive,bayer offer animal asset cash otc unit source first profit top estimate revenue miss stock wall st climb lifted sprint rosy earnings corrected stock future gain earnings up premarket 1st profit top estimate revenue miss,35,0,1
2014-04-30,0.5707485386815092,negative,reckitt benckiser no longer talk kgaa extends offer period az electronic seventh time exclusive explores billion plus portfolio sale china approves kgaa takeover az electronic explores billion plus portfolio sale source,31,1,0
2014-05-01,1.7994885049531506,positive,refile bayer nears deal buy consumer unit source,8,1,1
2014-05-02,2.204839931087821,negative,endocyte ovarian cancer fails trial kgaa eye asia sale completing az takeover kgaa completes acquisition az electronic,17,-1,1
2014-05-06,1.722133497805467,negative,numerical increase atrial fibrillation stroke seen patient taking osteoporosis odanacatib bayer see closing otc deal second half executive not tempted merger mania bayer win billion consumer unit auction seek approval osteoporosis cite safety risk kgaa clarifies keep consumer bayer win bln consumer unit auction,44,2,1
2014-05-08,1.7022883287452606,negative,kgaa hire henkel executive marcus kuhnert cfo fda approves blood clot preventer kgaa delist az electronic material,17,2,1
2014-05-09,0.5438611384939396,positive,germany kgaa ready deal germany kgaa ready join pharma deal frenzy,11,0,0
2014-05-14,1.5858915773970916,positive,roche immune therapy cancer meeting darling belgium ablynx increase cash position payment roche immune therapy cancer meeting focus,18,0,1
2014-05-15,0.0265113754600698,positive,kgaa consumer asset japan pricy kgaa ekes profit growth cost cut kgaa q1 profit gain cost cut,17,2,0
2014-06-02,0.0068027303045781,positive,immune system booster effective skin lung cancer,7,1,0
2014-06-06,0.9085646483004806,negative,former dealmaker take aim colon germ,6,0,0
2014-06-09,0.0532101394158823,positive,buy idenix boost hepatitis portfolio buy idenix boost hepatitis portfolio triple therapy using idenix hepatitis could speed cure treat genotype buy idenix billion,23,1,0
2014-06-10,0.9390318583708755,positive,kgaa announces fda clearance auxogyn embryo viability assessment system,9,1,0
2014-06-12,0.5889553853772544,positive,research chief aim big hepatitis open deal research chief open deal research chief morphosys enters strategic immuno oncology collaboration serono,20,0,0
2014-06-17,0.2951556412695288,negative,kgaa terminates license agreement ono,5,0,0
2014-06-24,0.3890433526158032,negative,kgaa mersana agree collaboration next generation antibody conjugate,8,0,0
2014-06-30,0.6072988382125999,positive,nausea work child late stage trial kgaa buy peer bet dimmable window,12,1,0
2014-07-01,0.4715580665393126,positive,corrected bayer broadens line keeping consumer brand bayer broadens line keeping consumer brand,13,0,0
2014-07-03,0.2377895752129655,negative,kgaa completes squeeze az electronic,5,0,0
2014-07-29,1.4819954117659906,positive,not interested deal solely primarily tax inversion quarterly profit beat estimate gain beat forecast newer offset generic,17,3,1
2014-08-13,0.760942094542516,positive,kgaa ceo looking interesting takeover target fda approves insomnia kgaa q2 core profit up pct az electronic takeover,18,2,0
2014-08-25,0.439371986478787,positive,advaxis test immune therapy prostate cancer rpt advaxis test immune therapy prostate cancer,13,0,0
2014-08-26,0.7219392023828375,positive,rpt test xalkori lung cancer immunotherapy test xalkori lung cancer immunotherapy,11,0,0
2014-09-04,0.5167372575329399,negative,fda approves immune stimulating melanoma approves immune stimulating melanoma,9,2,0
2014-09-05,1.381364148816977,positive,sue over immunotherapy patent,4,0,1
2014-09-09,0.1694885428633719,negative,ceo tax inversion deal would not fit corporate strategy,9,0,0
2014-09-12,0.3310176167740208,negative,kgaa end lung cancer vaccine trial,6,0,0
2014-09-15,0.0249498416113769,positive,osteoporosis achieves goal large trial osteoporosis pass trial side effect hover,11,0,0
2014-09-16,0.0358059301780899,positive,kgaa agrees lupin emerging,4,0,0
2014-09-18,0.1851016270710381,positive,kgaa seek partner immuno oncology end kgaa seek immuno oncology research partner,12,0,0
2014-09-22,0.921081884078434,positive,still see investment grade rating sigma aldrich deal germany buy sigma aldrich billion boost lab supply operation kgaa buy sigma aldrich bln germany buy sigma aldrich bln boost lab supply operation,31,1,0
2014-09-23,0.0772198978114091,positive,bank line up billion loan sigma aldrich buy rlpc bank line up bn loan sigma aldrich buy,17,1,0
2014-09-29,0.2155857586200293,positive,immunotherapy show promise bladder cancer,5,1,0
2014-10-01,0.3936539051114907,positive,bayer close buy consumer care bayer completes takeover otc unit,10,1,0
2014-10-06,0.4171872723991998,negative,issue multi tranche deal,4,0,0
2014-10-14,0.1836986732857148,positive,ex analyst face insider trading charge merger tip,8,0,0
2014-10-17,0.0768326766364069,negative,roche extend immunotherapy fight breast cancer,6,1,0
2014-10-27,1.8760857702482705,negative,beat q3 forecast cost cut offset gardasil decline weak sale overshadow q3 cost cut,14,-1,1
2014-11-05,0.2947503547060304,negative,take step return zilmax cattle animal food additive zilmax seen safe review,12,1,0
2014-11-10,1.207901851092541,negative,expects no writedowns zetia vytorin cholesterol,6,0,0
2014-11-12,0.0066869229890187,positive,gene study raise hope cholesterol zetia future cholesterol sale could hang long awaited study,14,1,0
2014-11-13,0.275025743320878,positive,kgaa core earnings up az takeover kgaa rule larger acquisition,10,0,0
2014-11-17,0.5965830137791617,positive,dampens astra bid hope german cancer deal zetia cut heart attack stroke risk long awaited study long term cholesterol study met primary endpoint german cancer immunotherapy deal kgaa deal exclusive,30,0,0
2014-11-24,0.9678546791399788,negative,buy right newlink experimental ebola vaccine,6,1,0
2014-11-28,1.2997713297510538,positive,germany aim grow not sell billion consumer arm,8,0,0
2014-12-02,0.2167740907509818,negative,no serious side effect mercknewlink ebola vaccine test,8,0,0
2014-12-05,0.7719241431181523,positive,talk acquire cubist pharmaceutical billion nyt,6,1,0
2014-12-08,1.3025187022327025,positive,take superbug cubist pharma buy issue dual tranche deal cubist option unusually active deal take aim superbug buy cubist bln deal bet bln profitable antibiotic,25,1,0
2014-12-09,2.9542175072450827,negative,still plan buy cubist despite patent setback still plan cubist purchase despite patent setback cubist sale force seen potential boon intestinal breakingviews give frenzy risk assessment give frenzy risk assessment,30,2,1
2014-12-15,0.6470832304132923,negative,trlpc look 8b bridge cubist acquisition,6,0,0
2014-12-18,0.1303374048470695,negative,gsk shingle vaccine challenge strong test,6,-1,0
2015-01-12,0.367752710122271,positive,heat up immunotherapy race lung cancer speed up submission plan hep lung cancer,13,0,0
2015-01-13,0.1047081229275548,positive,test combination cancer,3,0,0
2015-02-02,0.243050605453865,negative,germany take back marketing product diabetes thyroid franchise russia,9,0,0
2015-02-04,2.8476646858377586,negative,issue cautious forecast citing dollar hepatitis treatment lose breakthrough status,10,1,1
2015-02-24,0.1811615066289462,negative,place child hiv shared non profit patent pool,8,0,0
2015-03-03,0.0007005747577393,positive,germany see slight core profit rise kgaa see slight increase adj core earnings,13,2,0
2015-03-05,0.0633639347662917,positive,newlink ebola vaccine phase iii trial start,7,1,0
2015-03-10,0.4346268683794396,positive,serono illumina collaborate cancer diagnostics,5,0,0
2015-03-13,0.6666396164435318,positive,expects denied approval sugammadex injection,5,1,0
2015-03-20,0.2430386404084661,negative,kgaa deputy chief oschmann set become ceo manager magazin,9,0,0
2015-03-24,0.391634031285859,positive,melanoma meet goal study halted increase buyback program bln increase buyback program billion tudy melanoma halted survival prolonged,18,1,0
2015-03-25,0.8343006389677221,positive,guinea start testing vaccine ebola hotspot,6,1,0
2015-03-26,0.8947112049663364,negative,ablynx extends ion channel research collaboration,6,0,0
2015-04-01,0.7250052765983561,negative,newlink ebola vaccine appears safe effective study,7,2,0
2015-04-13,0.4560021422859051,negative,name udit batra leader combined millipore sigma aldrich,8,0,0
2015-04-17,0.5093968992373576,negative,kgaa confirms full outlook,4,0,0
2015-04-24,0.075557002410509,negative,oral hepatitis regimen show pct cure rate,7,0,0
2015-04-27,0.4522747852723441,negative,diabetes januvia succeeds heart safety trial diabetes januvia meet heart safety target,12,0,0
2015-04-28,4.725900785402515,positive,jump strong earnings januvia safety trong cancer sale upstage rival fda decline approve bridion need stock end up ibm slip apple stock wall st edge up ibm slip apple end up ibm slip apple,34,-1,1
2015-04-29,0.0887024768725708,negative,rpt strong cancer sale upstage rival,6,0,0
2015-05-12,0.6342022377393897,negative,kgaa threshold win fast track pancreatic cancer,7,1,0
2015-05-13,0.4564653150106346,negative,loses bid escape lawsuit over vioxx,6,-1,0
2015-05-15,0.6443769147443046,positive,indian court bar glenmark selling copy,6,0,0
2015-05-19,0.8827067846882142,positive,rpt kgaa overcome eu concern sigma aldrich deal see up pct gain adj ebitda weak euro kgaa overcome eu concern sigma aldrich deal kgaa see az deal forex countering weak sale,31,-1,0
2015-05-22,0.9591274495194811,negative,follows eu green light immune cancer,6,0,0
2015-05-27,0.1182859139578162,negative,offer eu concession over bln sigma aldrich buy,8,1,0
2015-05-28,0.5164676731132412,positive,forefront cancer meeting,3,0,0
2015-05-29,2.61459325234229,positive,immunotherapy appears effective head neck cancer study,7,1,1
2015-06-01,0.4335791536754785,negative,kgaa see immunotherapy holding cancer race,6,0,0
2015-06-04,0.678772670014316,negative,accused stonewalling mumps vaccine antitrust lawsuit,6,0,0
2015-06-08,0.4401376873642504,positive,no heart safety issue seen januvia diabetes study no heart safety issue seen januvia diabetes study,16,0,0
2015-06-12,0.9527424403135698,negative,rovi sign deal orvatez spain,5,1,0
2015-06-16,0.4829370770046193,positive,manual guide go digital free global push,7,0,0
2015-06-17,0.1848481407173308,positive,corrected pay mln misleading marketing pink eye pay mln misleading marketing pink eye pay million misleading marketing pink eye,19,-1,0
2015-06-19,0.5297520848587478,negative,aim leader oled material,4,0,0
2015-06-29,0.0588960656501935,positive,german expanding presence israel acquisition german buy remaining stake qlight nanotech,11,1,0
2015-07-22,0.6984528737942752,negative,belgium ablynx triple cooperation deal ablynx expands immuno oncology collaboration,10,0,0
2015-07-28,0.3131195670696529,negative,trong dollar weighs revenue raise forecast strong sale diabetes cancer,10,1,0
2015-07-31,0.9273848693770792,positive,success work go ebola vaccine ebola vaccine prof fully effective guinea trial,12,1,0
2015-08-06,0.3007350459530378,negative,kgaa book billion hedging gain sigma aldrich deal kgaa book bln eur hedging gain sigma aldrich deal,17,1,0
2015-08-11,0.1775337764125528,negative,ha approval sigma aldrich takeover,5,1,0
2015-08-12,0.741046349534269,positive,ltd net income mln rupee,5,0,0
2015-08-27,1.3273055939970746,negative,german place bln eur bond sigma aldrich buy,8,1,1
2015-09-08,0.3964917239797305,negative,judge nix apotex former expert role,6,0,0
2015-09-11,0.7958558139785854,negative,kgaa try get approval pill cladribine kgaa try revive multiple sclerosis pill cladribine,13,1,0
2015-09-16,0.2540275372159506,negative,diabetes found effective study,4,1,0
2015-09-28,0.1926481485745257,positive,diabetes approved japan,3,0,0
2015-10-01,0.3223458985659566,negative,germany sell right kuvan back biomarin pharma kgaa avelumab alliance track corrected kgaa avelumab alliance track,16,0,0
2015-10-02,0.0658713575601765,positive,fda expands approval keytruda lung cancer fda approves keytruda use lung cancer,12,3,0
2015-10-12,0.56542247245428,negative,cholesterol odds dim failure,4,0,0
2015-10-13,1.815066664710052,negative,ex employee get prison insider trading kgaa appoints oschmann ceo replace kley ex employee get prison insider trading,18,0,1
2015-10-14,0.6209006482366441,positive,germany kgaa scrap unit brand,5,0,0
2015-10-15,0.8464627545138992,positive,ablynx get first milestone immuno oncology deal,7,0,0
2015-10-20,1.8371347463708052,negative,clear major hurdle sigma aldrich takeover sigma aldrich sell asset honeywell,11,1,1
2015-10-26,0.312129293748653,positive,keytruda extends survival lung cancer study,6,0,0
2015-10-27,1.2613094114390822,positive,profit top estimate strong diabetes cancer sale revenue down pct hurt strong dollar expects januvia retain strong position add diabetes therapy despite favorable seen rival jardiance,26,1,0
2015-10-30,0.0768492242284812,positive,india sept qtr net profit fall pct,7,-1,0
2015-11-02,0.3598193328000265,negative,elvita sign deal rd financing cooperation,6,1,0
2015-11-04,1.0559510016873608,positive,kgaa widen development cancer immunology,5,0,0
2015-11-06,0.7469298236881028,negative,agency investigate pricing federal agency investigate pricing fda panel back reverse muscle relaxant effect fda panel vote unanimously favor sugammadex under pennsylvania attorney office probe over pricing,27,-1,0
2015-11-10,0.1196144773958129,positive,set complete bln buy sigma aldrich nov,7,1,0
2015-11-12,0.1115379134215666,positive,kgaa ups earnings outlook strong lab demand buy harrisvaccines boost livestock vaccine portfolio,13,1,0
2015-11-13,1.1228275726110848,positive,panel recommends continue cholesterol study panel recommends continue cholesterol study,10,0,0
2015-11-18,0.6184439639046246,negative,kgaa receive fda breakthrough status avelumab kgaa close takeover sigma aldrich,11,1,0
2015-11-20,0.6960348560708374,negative,plan double africa sale,4,0,0
2015-12-07,0.6804294351944962,positive,kgaa threshold fails late stage cancer trial immunotherapy keytruda show promise multiple myeloma trial,14,0,0
2015-12-14,0.4093733674283006,negative,fda panel reject claim zetiavytorin cut heart risk fails win fda panel backing vytorin heart claim acquires ormet circuit no purchase disclosed,22,-1,0
2015-12-15,0.2912179526598724,positive,fda approves reverse effect muscle relaxant,6,2,0
2015-12-16,0.6540017613115401,positive,bayer consumer still looking bulk up deal,7,0,0
2015-12-22,0.4640067846851003,negative,elvita sign deal commercialization oncological terapeutical molecule x7f,8,1,0
2016-01-07,1.5216292807564755,positive,kgaa biocartis collaborate liquid biopsy technology ra biomarker testing biocartis group announces collaboration,13,0,1
2016-01-12,0.1882909732522586,positive,biolinerx study combo fight pancreatic cancer,6,0,0
2016-01-15,0.8724821522454129,positive,agrees pay mln settle vioxx security lawsuit fight over name see german firm win british court agrees pay million settle vioxx security lawsuit germany win uk court ruling dispute over name,31,0,0
2016-01-19,0.2579700470955792,positive,germany appoints executive board membersx7fx7f,5,0,0
2016-01-20,0.2572531567685554,negative,vaccine alliance sign mln advance deal ebola shot vaccine alliance sign million advance deal ebola shot,16,1,0
2016-01-22,1.207068421636226,negative,see deal opportunity funding get tighter,6,0,0
2016-01-28,2.8437254445745186,negative,fda approves hepatitis pill fda approves hepatitis pill,8,2,1
2016-01-29,0.5500702388558487,positive,payer see leverage entry hepatitis,5,0,0
2016-02-03,1.313638642708459,negative,give cautious outlook sale top lag jj evaluating technology zika vaccine see accelerating decline remicade due biosimilars,17,-1,1
2016-02-23,0.809935803480144,positive,kgaa consumer saw nice growth,5,1,0
2016-02-26,0.4757519367611595,negative,judge trim antitrust case over potassium,6,0,0
2016-03-07,0.995438948788463,positive,neuron bio designated reference laboratory millipore,6,0,0
2016-03-08,0.7308380205455656,positive,china major growth driver cnbc anofi pasteur end european vaccine venture anofi pull plug european vaccine venture,17,1,0
2016-03-09,0.6655491643635991,negative,name kgaa ceo kley supervisory board chairman,7,0,0
2016-03-22,0.4893511138404416,positive,patent hepatitis treatment found valid dispute patent hepatitis treatment found valid dispute,12,0,0
2016-03-24,0.025455575135147,positive,ordered pay million hepatitis patent dispute ordered pay mln hepatitis patent dispute,12,-1,0
2016-03-29,0.002493494449185,positive,deceitful hepatitis patent fight,4,0,0
2016-03-31,0.3397929072172068,negative,elvita sign another deal kgaa,5,1,0
2016-04-11,0.3252542280174353,negative,ceo kenneth frazier total compensation wa mln,7,0,0
2016-04-13,0.1102449551432016,positive,fda ha accepted review supplemental biologics license application keytruda,9,0,0
2016-04-14,0.8708201586375086,positive,kgaa file answer trademark right violation claim made msd launch project partnership farm kgaa appoints maya martinez davis global head oncology,21,0,0
2016-04-18,0.0436025538709028,negative,receives breakthrough therapy designation fda use keytruda classical hodgkin lymphoma,10,1,0
2016-04-19,0.3039374099286229,positive,animal buy worldwide right whisper veterinary stethoscope system,8,1,0
2016-04-25,0.7441875195298708,negative,kgaa publishes chinese phase iii study erbitux,7,0,0
2016-04-26,0.4687719745152252,negative,kgaa selects unisys deliver global end user service,8,1,0
2016-04-27,0.2759744744392334,positive,sex discrimination case could collective action judge sex discrimination case could collective action judge,14,0,0
2016-04-29,1.0747526695421228,negative,see negative fx effect,4,0,0
2016-05-05,1.2941205828798874,negative,sale disappoint januvia remicade fall short eu zepatier launch delayed q1 earnings eu manufacturer zepatier cited recordkeeping lapse,18,-1,0
2016-05-12,0.3788982125287221,negative,present phase ertugliflozin mk,4,0,0
2016-05-13,0.4279599865302907,positive,germany gene editing help outperform,5,1,0
2016-05-16,0.44257892487507,positive,vitamin formula patent invalid due sale bar federal circuit,9,0,0
2016-05-18,0.6150411498850428,positive,cancer show promise combo keytruda show longer survival deadly cancer german immunotherapy show promise rare skin cancer,17,1,0
2016-05-19,0.1818728836041949,positive,kgaa expects file first approval avelumab h2 kgaa see gain adj ebitda up pct,14,2,0
2016-05-24,0.0580626321560195,negative,set quarterly dividend,3,0,0
2016-05-27,0.2703241547394652,negative,receives positive chmp opinion zepatier eu shareholder proposal report disposal unused expired defeated global innovation fund hike stake opgen pct pct,21,1,0
2016-06-06,0.4268857829763384,positive,gileads escape liability hepatitis patent fight updated keytruda finding show response rate benefit head neck cancer patient corrected kgaa present positive mid stage merkel cell carcinoma asco escape liability hepatitis patent fight,32,2,0
2016-06-07,0.4534917047322007,negative,fda staff question efficacy infectious diarrhea fda staff review question efficacy difficile,12,0,0
2016-06-09,0.6270729069371095,negative,agenus announces lead product candidate selection collaboration acquire afferent pharmaceutical panel back approval infectious diarrhea regulatory panel back approval difficile,20,2,0
2016-06-13,0.3487154144977689,positive,investigational insulin glargine met primary endpoint phase study,8,0,0
2016-06-16,2.215383866963716,positive,keytruda show superior progression free overall survival lung cancer patient keytruda prolongs life big lung cancer study,17,0,1
2016-06-20,0.1966991685678376,negative,announces result study relebactam combination imipenemcilastatin kgaa plan apply authorization avelumab h2,12,0,0
2016-06-27,0.7709425410994064,positive,receives chmp positive opinion keytruda advanced non small cell lung cancer,11,1,0
2016-06-29,0.9420768964663262,positive,moderna announce strategic collaboration hepatitis patent win over face foe,10,2,0
2016-06-30,0.3829611576537939,negative,3rd circuit weigh fosamax warning lawsuit kgaa zeiss hamilton thorne join global fertility alliance,14,0,0
2016-07-01,0.3627723424341145,positive,animal buy controlling interest vallxc3xa9e,5,1,0
2016-07-06,1.4002207302073133,positive,germany begin large ovarian cancer trial,6,0,1
2016-07-07,0.5803183612392293,negative,refile germany kgaa initiate phase iii trial appeal order reversing mln verdict,12,0,0
2016-07-11,0.3695414270833752,negative,invests majority stake staywell,4,0,0
2016-07-14,0.3904197891163807,negative,uk charity pocket mln cancer immunotherapy uk charity pocket million cancer immunotherapy,12,0,0
2016-07-18,1.291705955828648,negative,ema accepts cladribine review marketing authorisation application corrected kgaa get ema acceptance review marketing application,15,0,0
2016-07-21,0.37771984658862,positive,provides regulatory update biologics application ruling invalidating patent over sale bar stayed,12,0,0
2016-07-22,0.3974847998436503,negative,ema ha accepted file formulation isentress review,7,0,0
2016-07-25,0.1704324379076638,negative,designated breakthrough therapy fda get prime status ema ebola vaccine,10,1,0
2016-07-26,0.3876902224413614,negative,set quarterly dividend,3,0,0
2016-07-27,0.5173517639136982,positive,plan end partnership agreement alk abello,6,0,0
2016-07-28,0.4055651617248079,negative,seek curb plaintiff firm misleading communication robert lift stay ruling invalidating patent germany kgaa amoydx collaborate bring liquid biopsy ra biomarker testing china lock horn legal fee hepatitis patent fight,30,1,0
2016-07-29,0.2321761054357773,positive,quarterly result beat forecast rise q2 adjusted earnings,8,3,0
2016-08-01,0.0829002415910551,positive,motion bar plaintiff firm communication denied moot,7,0,0
2016-08-02,0.0781657610163799,positive,draw takeover interest allergan wsj ha drawn takeover interest including allergan wsj refile draw takeover interest allergan wsj european commission approves anti pd therapy keytrudax7f draw takeover interest allergan wsj draw takeover interest allergan wsj,35,1,0
2016-08-04,0.2231771089221235,positive,kgaa lift fy profit forecast strong lab supply kgaa lift profit forecast fertility treatment kgaa fertility unit benefiting production problem rival,21,1,0
2016-08-05,9.590135264234268,positive,announces fda filing acceptance application mk,6,0,1
2016-08-08,1.5063462137885009,negative,corrected fda approves keytruda type head neck cancer,8,2,1
2016-08-11,1.1163929604702585,positive,get attorney fee hepatitis patent fight,6,0,0
2016-08-17,0.208471205698002,positive,exclusive enters race cancer drugmaker medivation source,7,0,0
2016-08-24,0.8254150896189194,negative,biothera pharmaceutical expands relationship,4,0,0
2016-08-25,0.5847359251609063,negative,lung cancer doctor eye keytruda over opdivo,7,0,0
2016-08-29,0.2378587860387249,negative,judge invalidates nuvaring patent claim,5,0,0
2016-08-30,0.3112490855195604,negative,moody change outlook kgaa rating stable negative affirms rating,9,1,0
2016-09-02,0.3236148575657349,negative,refile abort development osteoporosis due stroke risk provides update odanacatib development program scrap development osteoporosis due stroke risk,18,0,0
2016-09-07,0.5759397428773738,negative,aralez acquires canadian right zontivity fda grant breakthrough therapy designation keytruda,11,1,0
2016-09-12,0.3145530547822295,negative,canada brenzys approved canada,4,0,0
2016-09-14,0.706697034682302,negative,roche work better rebif,4,1,0
2016-09-15,0.6795929614259677,positive,investigational ertugliflozin met primary endpoint,5,0,0
2016-09-16,0.2242778669038991,positive,present examining durable efficacy investigational cladribine tablet multiple sclerosis,9,0,0
2016-09-20,0.9899362685334534,positive,bayer integration disrupts expected,4,0,0
2016-09-23,0.4527192120497791,positive,kgaa announces isabel de paoli chief strategy officer,8,0,0
2016-10-06,0.2924907565866608,negative,vaccinex announces clinical collaboration kgaa,5,0,0
2016-10-07,0.5184952581511748,positive,asks justice change federal circuit review pto trial,8,0,0
2016-10-10,1.2793845708701124,positive,lung cancer setback put rival driver seat,7,0,0
2016-10-11,1.819983663495106,negative,aetna sign contract januvia janumet transgene announces collaboration kgaa darmstadt germany evaluate combination tg4001 avelumab,15,1,1
2016-10-12,0.5671732203720747,negative,ablynx extends research collaboration,4,0,0
2016-10-13,1.70607968816604,positive,germany expects extra benefit sigma aldrich deal kgaa still plan apply avelumab approval,13,2,1
2016-10-17,0.6505294846556042,negative,kgaa announces cooperation agreement durxtreme gmbh,6,0,0
2016-10-19,0.621037194109908,negative,phase study letermovir meet primary endpoint antiviral meet main goal late stage trial,13,0,0
2016-10-20,0.2674834562501726,positive,debiopharm report clinical collaboration kgaa advaxis initiate combination portion phase study,11,0,0
2016-10-21,1.2095416782583523,negative,bladder cancer meet primary endpoint stop early keytruda succeeds key bladder cancer trial,13,-1,0
2016-10-24,1.1605689177276002,negative,fda approves lung cancer first line treatment fda also approves labeling update keytruda treatment patient metastatic nsclc,17,2,0
2016-10-25,2.3103642531968727,positive,aim leader second line lung cancer report pct jump quarterly profit win early approval keytruda untreated lung cancer q3 non gaap eps predicts lung cancer dominance keytruda immunotherapy,28,2,1
2016-10-26,1.5425695852643306,negative,eur bln debt offering,4,0,1
2016-11-02,0.1738542096779927,negative,kgaa present mid stage atacicept acrarhp annual meeting,8,0,0
2016-11-04,0.7776272365970227,positive,kgaa invests mln eur production value chain china,8,0,0
2016-11-07,0.1145762511651327,negative,idemitsu sign collaboration agreement oled material,6,1,0
2016-11-11,1.3243032304283142,negative,sept net profit million rupee,5,0,1
2016-11-14,0.7353131386803935,negative,opgen collaborates develop rapid diagnostics informatics tool help combat antimicrobial resistance,11,0,0
2016-11-15,0.591390357219379,negative,kgaa expects profit gain lower development cost see continued pressure erbitux eu,12,1,0
2016-11-16,1.414679771382632,negative,genexine entered clinical research collaboration,5,0,1
2016-11-17,0.4023051001117883,negative,loses bid invalidate hepatitis patent ahead trial,7,-1,0
2016-11-22,1.1584068730682962,negative,raise quarterly dividend 47share 46share quintilesims form collaboration kgaa darmstadt germany generate real world insight usage anti cancer therapy across europe,21,1,0
2016-11-25,0.5531759445442042,positive,opexa therapeutic receives notice trading unit serono,7,0,0
2016-11-28,0.1895708583499633,negative,fda grant priority review supplemental biologics license application keytruda face off jury over hepatitis patent,15,1,0
2016-11-29,0.4360353014460916,positive,german get fda priority review cancer,6,1,0
2016-11-30,1.3680593072085467,negative,natrix separation announces collaboration agreement sanofi evotec collaborate target discovery technology,11,0,1
2016-12-01,0.3351831559852969,negative,fda grant priority review application expand use keytruda hodgkin lymphoma win uk okay keytruda lung cancer cut ceo kenneth frazier cnbc continue great hope alzheimer ceo importing outside not possible,30,4,0
2016-12-02,0.5588617180903421,positive,pay infringing hep patent,4,-1,0
2016-12-05,2.0404322509644857,negative,biothera pharmaceutical further expand research collaboration present updated finding keytruda,10,1,1
2016-12-06,0.2669481929973738,negative,present updated keytruda small cell lung cancer mesothelioma,8,0,0
2016-12-07,1.6730415546181931,negative,biocartis launch second liquid biopsy assay developed canada zostavax ii showed vaccine effectiveness shingle observational effectiveness study,17,1,1
2016-12-12,0.915044324327352,positive,update triple negative breast cancer study interim result phase 1b2 study evaluating combination keytruda eisai halaven injection presented sabcs,19,0,0
2016-12-15,0.5106101662586626,positive,science pay bln hepatitis royalty court verdict win billion hepatitis trial win bln hepatitis trial,15,0,0
2016-12-16,0.3067023858391082,positive,europea chmp recommends keytrudax7f lung cancer treatment,7,0,0
2016-12-22,0.4251395044608919,positive,advanced nano technology sign revised supply agreement kgaa,8,1,0
2016-12-30,0.0775630653384706,positive,ltd received demand notice nppa,5,0,0
2017-01-05,0.0461844025403501,positive,cerveau technology sign license agreement novel investigational tau imaging agent,10,1,0
2017-01-09,1.7072273154092987,positive,incyte advance clinical development program investigating combination epacadostat keytruda,9,0,1
2017-01-10,1.931260229209386,negative,get fda acceptance supplemental biologics license application keytruda combination chemotherapy fda accepts application lung cancer combo therapy clearink display sign development agreement,22,1,1
2017-01-11,2.5711949081742347,positive,leapfrog rival lung cancer combination race expand immuno oncology collaboration stock lift flat ahead trump speech kgaa darmstadt germany license oncology research development program vertex,25,1,1
2017-01-12,1.1920939421109833,positive,kgaa darmstadt germany palantir launch partnership,6,1,0
2017-01-20,3.2792069258722467,positive,ono pharmaceutical enters license agreement agree settle keytruda patent suit lung cancer delay slam keep lead announces license agreement resolving keytruda patent litigation,23,-1,1
2017-01-23,0.8912325276524524,negative,kgaa darmstadt germany announces research collaboration domain therapeutic immuno oncology ono pharmaceutical reach settlement sign license agreement,17,1,0
2017-01-27,1.0556722708496724,positive,reveals increase history,3,0,0
2017-02-02,3.283533131393379,positive,ceo development priority forecast reassuring full speed ahead keytruda quarterly sale slip pct q4 adjusted earnings,16,1,1
2017-02-03,0.5178953473612191,negative,fda accepts sblas keytruda,4,0,0
2017-02-06,1.1898188918817554,positive,immunovaccine princess margaret cancer centre conduct phase clinical trial evaluate use combination immunotherapy,13,0,0
2017-02-07,1.1438854760942083,negative,announces stoppage work section worker goa,6,0,0
2017-02-13,0.4222279543284468,positive,capital world report pct passive stake dec sec filing,9,0,0
2017-02-14,0.974559935339947,positive,stopping late stage study another alzheimer fails announces epoch study verubecestat halt study mild moderate alzheimer doravirine meet primary efficacy endpoint pivotal phase trial,24,-1,0
2017-02-22,0.2013637195777851,negative,canada effective feb ontario reimburse zepatier followed british columbia,9,1,0
2017-02-23,0.7899942088245293,positive,biothera pharmaceutical initiate patient dosing phase trial investigating imprime pgg keytruda record bln impairment charge related uprifosbuvir program sec filing,20,0,0
2017-02-24,0.3438835422919339,positive,first phase trial virus vaccine v2120 reduced incidence confirmed herpes zoster case,12,0,0
2017-02-27,0.6248489716878303,negative,dec qtr profit rise pct,5,2,0
2017-02-28,0.3002889726724689,positive,set quarterly dividend 47share kgaa get priority review bladder cancer uk reject keytruda initial treatment lung cancer,17,0,0
2017-03-02,0.4333968863850068,positive,beigene expects decision q1 partner kgaa bgb nice expands positive recommendation erbitux,12,1,0
2017-03-09,0.0099591254977271,positive,germany well advanced talk sell biosimilars unit development cost keep kgaa profit flat kgaa predicts stable adj ebitda,18,0,0
2017-03-10,0.7905458741056082,negative,kgaa announces release fertility technology product,6,0,0
2017-03-14,0.4606024324399937,positive,provides update supplemental biologics license application keytruda win fda nod treating blood cancer,13,2,0
2017-03-22,0.8768426864419032,negative,appeal court revives fosamax warning claim appeal court revives claim over fosamax must face renewed fosamax warning claim appeal court,20,0,0
2017-03-23,0.2397467729679636,negative,fda approves german immunotherapy skin cancer,6,2,0
2017-03-24,0.0853884073489075,negative,european agency chmp recommends approval keytruda,6,1,0
2017-03-31,0.3746037227248422,positive,incyte provide additional detail previously announced collaboration,7,0,0
2017-04-06,0.8002283026515511,negative,seek reverse ruling reviving fosamax injury lawsuit,7,0,0
2017-04-07,0.0720016221945174,negative,fda reject bid add heart diabetes label fda reject application add heart safety diabetes label fda reject application add heart diabetes label receives complete response letter fda tecos study sitagliptin,30,-2,0
2017-04-10,0.9782624950117724,negative,ceo total compensation wa mln,5,0,0
2017-04-11,0.1669375827054287,positive,kyorin holding unit get license krp 114v,7,0,0
2017-04-18,0.5455255549670301,negative,german aim role child formula schistosomiasis,6,0,0
2017-04-21,0.7364680135119706,negative,report result real world observational study veteran affair system evaluating use zepatier atara bio announces collaboration,16,0,0
2017-04-24,0.6958495179069324,negative,fresenius snap up akorn kgaa biosimilars separate deal pay pdl biopharma million settle patent lawsuit pdl biopharma announces settlement keytruda lawsuit,21,-1,0
2017-04-25,0.3243801224028342,negative,fresenius pick up pace akorn kgaa deal fresenius see no change relationship kgaa unit partner dr reddy,17,0,0
2017-04-26,0.7049382456196573,positive,fda approves impax generic cholesterol vytorin,6,2,0
2017-04-27,0.275285212926768,negative,yndax pharmaceutical announces expansion ongoing phase collaboration unit,8,0,0
2017-04-28,0.1815490119880913,negative,kgaa dominance liquid crystal could risk,6,0,0
2017-05-02,0.4752729303339142,positive,eye key cancer growth others lose patent protection revenue rise pct,11,2,0
2017-05-04,0.510306280355477,negative,cerveau technology finalization clinical supply agreement,6,0,0
2017-05-09,1.0330267009550975,negative,kgaa acquires grzybowski scientific invention,5,0,0
2017-05-10,0.8474357112373765,positive,european commission grant approval pergoveris pen fertility treatment fda approves immunotherapychemo combo lung cancer oncosec announces clinical collaboration fda approves keytruda chemo combo lung cancer kgaa pergoveris fertility pen get eu approval,32,3,0
2017-05-12,1.167679840284741,negative,vaccine alliance dos ebola shot available emergency,7,0,0
2017-05-16,0.5324280939240311,positive,kgaa considers making division legally separate subsidiary upsher smith pay mln pay delay case kgaa considers transferring unit subsidiary upsher smith pay million pay delay case,26,-2,0
2017-05-17,0.5359678063633022,positive,incyte immunotherapy combination effective lung cancer study test show keytruda improves survival bladder cancer patient german glucophage receives label extension uk aduro announces clinical collaboration glucophage sr receives label extension patient high risk type diabetes uk,36,2,0
2017-05-18,1.0098500658404008,positive,kgaa tv crystal sale decline raise stake cancer kgaa q1 earnings up lab supply licence prepayment kgaa losing liquid crystal chinese rival,22,-1,0
2017-05-19,0.8225886127685156,negative,receives chmp positive opinion recommending approval isentress,7,2,0
2017-05-23,0.5751018003062436,positive,fda clear keytruda cancer patient certain biomarkers set quarterly dividend fda clear keytruda based cancer genetics not location uk cma issue statement objection unit uk competition watchdog accuses obstructing biosimilars unit confident complied uk competition law fda grant priority review supplemental marketing application keytruda,44,4,0
2017-05-25,0.308536162495221,negative,optum collaborate advance value based contracting pharmaceutical enters exclusive worldwide license agreement teijin pharma,14,0,0
2017-05-30,0.0252695721495554,positive,britain back first line use keytruda under cancer fund receives fda approval isentress hd treatment hiv infection appropriate patient,19,2,0
2017-06-02,0.0110492386282912,negative,announces updated longer term overall survival evaluating keytruda,8,0,0
2017-06-05,0.5372505913211367,negative,incyte corp update echo trial epacadostat combination keytruda present positive mid stage breast cancer combo therapy,16,1,0
2017-06-12,0.0205427057373031,positive,pause late stage study testing keytruda myeloma corrected pause late stage study testing keytruda myeloma provides update multiple myeloma study keynote keytruda combination therapy,24,0,0
2017-06-13,1.4984618490059498,negative,corrected kgaa bln eur pipeline potential driven cancer,8,0,1
2017-06-14,0.2848154133920366,positive,awarded first crispr patent australian patent office,7,0,0
2017-06-15,0.0916120015126309,negative,human longevity agreement kgaa darmstadt germany engage cancer biomarker discovery advanced melanoma,12,0,0
2017-06-20,2.009207959505588,positive,effector therapeutic collaborate evaluate immuno oncology combination microsatellite stable colorectal cancer pv nano cell cooperating single crystalline metal particle technology application,21,1,1
2017-06-21,1.4658796635729887,positive,knock patent hepatitis treatment leap therapeutic sponsor fund initial trial combo study leap therapeutic announces collaboration,16,0,1
2017-06-23,0.0926330500105709,positive,ema recommends approval multiple sclerosis,5,1,0
2017-06-27,0.2291629323126875,positive,heart surprise positive result question linger tweet computer network wa compromised part global hack,14,2,0
2017-06-29,0.3795549934278219,negative,ale hope novartis heart under microscope,6,0,0
2017-07-05,0.4023560305120965,negative,provides further update multiple myeloma study evaluating keytruda combination pomalidomide lenalidomide fda place clinical hold combo therapy multiple myeloma fda put hold multiple myeloma trial death,26,0,0
2017-07-06,0.7376735318710193,negative,eu charge kgaa ge canon over merger rule eu charge kgaa ge canon misleading merger info,16,0,0
2017-07-10,0.6298713734228412,negative,netscientific update clinical trial collaboration deal pd unit pd biotechnology enters clinical trial collaboration agreement subsidiary,16,0,0
2017-07-12,0.0456692479272602,negative,kgaa refines western european life science production site network,9,0,0
2017-07-13,0.0071891360997389,positive,aduro report mln milestone payment under licensing deal,8,0,0
2017-07-17,0.7013891159824759,negative,announces presentation clinical real world association international conference,8,0,0
2017-07-20,0.4664826280460277,positive,announces fda grant tentative approval lusdunaxe2x84xa2 nexvuexe2x84xa2 fda tentatively approves copycat sanofi lantus,13,2,0
2017-07-21,0.4034997904274973,negative,kgaa chmp recommends approval avelumab european agency chmp recommends approval keytruda,11,1,0
2017-07-24,0.0714974293917536,negative,announces launch renflexis provides update phase study keytruda announces week result oncemrk immunotherapy fails improve survival head neck cancer corrected fda tentatively approves copycat sanofi lantus samsung bioepis launch discounted remicade alternative,32,1,0
2017-07-25,0.5787162326586492,negative,investigational nnrti doravirine meet primary efficacy endpoint,7,0,0
2017-07-27,3.1512080105516205,positive,astrazeneca establish strategic oncology collaboration,5,0,1
2017-07-28,0.776758098616781,positive,report q2 non gaap earnings 01shr cyber attack halted production hurt profit,12,-1,0
2017-07-31,0.3020575620968357,negative,generex announces collaboration evaluate keytruda combination ae37 patient triple negative breast cancer,12,0,0
2017-08-03,0.320089825833969,positive,kgaa patent office grant patent application crispr kgaa decide over next mths over filing cladribine germany reshuffle board tackle chemical competition,21,0,0
2017-08-07,0.5979705695978943,negative,india qtr profit down pct,5,0,0
2017-08-08,0.5814016639931308,negative,received investigative subpoena california insurance fraud liaison bureau sec filing,10,-1,0
2017-08-14,0.5264231525372365,negative,ceo frazier resigning president american manufacturing council tweet refile ceo resigns trump council charlottesville refile trump chides ceo resignation presidential council,21,0,0
2017-08-17,0.1874723326822813,positive,fda expands use astrazenecamerck ovarian cancer,6,1,0
2017-08-25,0.1331515289381357,positive,european commission approves cladribine tablet,5,1,0
2017-08-28,0.5996606264697002,positive,acquire natrix separation,3,1,0
2017-08-29,0.4303426195599313,negative,cholesterol cut heart risk future unclear announces result reveal outcome study anacetrapib cholesterol cut heart risk pct study,18,0,0
2017-09-05,0.3892063901427711,positive,germany considers sale consumer german eye sale consumer european commission approves keytruda,12,1,0
2017-09-06,0.2559162963865047,positive,snap up old german firm up million snap up yr old german firm up mln,15,0,0
2017-09-07,0.5121506682664978,positive,immunotherapy chemo mix show extended lung cancer gain,8,1,0
2017-09-08,0.0397344151768508,positive,germany hire jp morgan advise consumer review germany hire jp morgan sell consumer,13,0,0
2017-09-11,0.2715139059253024,positive,rpt germany hire jp morgan sell consumer announces finding phase study keytruda kgaa enter strategic collaboration project sphere llc,19,0,0
2017-09-12,0.169613823912007,positive,isentress hd available canada,4,0,0
2017-09-21,0.0208619940158194,negative,kgaa cancer bavencio get eu nod,6,1,0
2017-09-22,0.7365123341803947,negative,fda approves keytruda previously treated patient,6,2,0
2017-09-28,0.553613917380058,negative,kgaa cfo profit guidance damn challenging,6,0,0
2017-09-29,0.755925372200561,negative,discontinues mk 3682b mk 3682c development program stop development hepatitis treatment,11,-1,0
2017-10-02,0.3782539368353488,positive,judge upholds patent antifungal noxafil,5,1,0
2017-10-03,0.4928675523783066,negative,refile police search kgaa french plant thyroid pill inquiry police search kgaa french plant thyroid pill inquiry,17,0,0
2017-10-10,0.0617484536421963,negative,kalvista pharmaceutical announces collaboration,4,0,0
2017-10-11,1.212014628685465,negative,provides update anacetrapib development program not seek approval cholesterol treatment,10,1,0
2017-10-16,0.2122362767425167,negative,aeglea biotherapeutics announces clinical collaboration,5,0,0
2017-10-18,0.3608567480520852,positive,astra win speedy review lynparza breast cancer announces updated overall survival finding phase trial keytruda,15,1,0
2017-10-19,0.3505195551015694,positive,corrected cyber attack cost insurer mln verisk pc cyber attack cost insurer million verisk pc,15,-1,0
2017-10-20,0.3121267519643478,negative,cut sale job add job chronic care cut sale job add chronic care,13,0,0
2017-10-23,0.3624703051117284,negative,astrazeneca submit application breast cancer japan,6,0,0
2017-10-24,0.6331190009633447,negative,kgaa canadian patent office grant patent application crispr technology,9,0,0
2017-10-25,0.5507821459977635,negative,committee recommends gsk shingle vaccine over rival gsk look consumer asset offered sale,13,0,0
2017-10-27,6.866982704587265,negative,withdraws european application keytruda keytruda sale soar european application pulled withdraws marketing application keytruda europe cyber attack impact fourth result,20,0,1
2017-10-30,5.6886146358299925,negative,cancer setback sends down stock wall st slip amid loss tax talk stock snapshot wall st end lower trump tax talk weigh,22,-2,1
2017-11-02,0.0153738761646593,positive,corrected kgaa samsung biologics sign mou strategic alliance,8,1,0
2017-11-06,0.4758533661698538,negative,announces tender offer top massachusetts court weighs case over generic injury,11,0,0
2017-11-07,0.4494308769768307,negative,update investigation italian unit,4,0,0
2017-11-09,0.2911610353497629,negative,kgaa tone down outlook consumer shine receives fda approval prevymis prevention cmv infection allogeneic stem cell transplant patient germany tone down outlook strong euro fda ok stop infection post stem cell transplant,32,1,0
2017-11-13,0.7779223241975219,negative,announces pricing tender offer orexigen therapeutic announces commercialization distributorship agreement kgaa darmstadt,12,0,0
2017-11-14,0.0326240378555442,positive,india sept qtr profit up pct,6,0,0
2017-11-15,0.1550064372147552,positive,report pct passive stake spero therapeutic nov,7,0,0
2017-11-16,0.1749189067421053,negative,cue biopharma announces collaboration,4,0,0
2017-11-27,0.4179161457623981,positive,brexit loom uk pitch industry plan win support qiagen,9,1,0
2017-11-28,0.3178785685615803,negative,provide update phase iii javelin gastric study patient pre treated advanced gastric cancer announces billion repurchase authorization kgaa immunotherapy fails gastric cancer trial kgaa avelumab miss goal gastric cancer trial,30,-2,0
2017-12-01,1.293119219010952,positive,nestle stada prepare rival bid germany consumer source nestle stada prepare rival bid germany consumer source,16,0,0
2017-12-04,0.747455554031351,positive,scotus asks weigh fosamax appeal,5,0,0
2017-12-05,0.4407691368876199,negative,kgaa fda clearance genea fertility benchtop incubator geri,8,1,0
2017-12-06,2.5651694592399688,negative,anand nambiar md assigned head integrated circuit material unit kgaa,10,0,1
2017-12-07,0.457467463277994,positive,kgaa approval cladribine tablet,4,1,0
2017-12-11,1.0843328147458475,positive,sign distribution agreement avanti polar lipid newlink genetics bps sharp dohme amended license collaboration agreement raise stake lung cancer rival close,21,2,0
2017-12-14,0.3293850748457338,negative,keytruda fails pivotal gastric cancer trial provides update keynote phase study keytruda germany make bid enter pill perrigo preparing non binding bid kgaa consumer unit source perrigo line up bid consumer unit source perrigo line up bid consumer unit source,40,-1,0
2017-12-15,0.4179869885102549,negative,germany fresh bid enter pill,5,0,0
2017-12-20,0.1610081192055301,negative,fda approves diabetes fda approves diabetes bluebird bio sign supply agreement commercial production viral vector,15,3,0
2017-12-26,0.0841355359650131,positive,htg molecular diagnostics expands collaboration,5,0,0
2018-01-02,0.8045883902092155,negative,keytruda approved japan use treatment patient urothelial carcinoma,8,0,0
2018-01-08,0.7619178019835249,negative,fda accepts application doravirine keytruda significantly improved recurrence free survival compared placebo adjuvant therapy,14,0,0
2018-01-09,0.0207444346485008,positive,eisai receive breakthrough therapy designation fda lenvima keytruda,8,1,0
2018-01-10,1.033264861835137,positive,nestle frontrunner kgaa consumer bloomberg nestle frontrunner kgaa consumer bloomberg,10,0,0
2018-01-11,0.2060472614938691,negative,forty seven agreement kgaa conduct clinical trial patient ovarian cancer,10,0,0
2018-01-16,6.154985572156457,positive,keytruda succeeds key lung cancer trial positive keytruda lung cancer sends up pct keytruda phase keynote trial met dual primary endpoint,21,1,1
2018-01-19,0.2095901316325088,negative,first time keytruda patient previously treated advanced hepatocellular carcinoma presented asco gi symposium,13,0,0
2018-01-23,0.5224472470381158,positive,announces second dividend,3,0,0
2018-01-24,0.8039582142785218,negative,inge thulin join board director effective,6,1,0
2018-01-25,0.1537666563982798,positive,prokaryotics announces licensing agreement novel investigational antibiotic candidate,8,0,0
2018-01-26,0.0493945451225164,positive,ema panel recommends diabetes,4,0,0
2018-02-02,0.0052671614604871,positive,exclusive consumer sale risk nestle bow source q4 non gaap earnings profit beat lower tax overcoming sale miss post bigger quarterly loss,22,-1,0
2018-02-09,1.2463530464037031,negative,appeal court end patent challenge amneal generic nasonex,8,-1,0
2018-02-13,1.2048983925708634,negative,scrap another late stage alzheimer study announces discontinuation apecs study evaluating verubecestat treatment people prodromal disease,16,0,0
2018-02-15,0.7094163293728473,positive,pangaea oncology sign contract genetic analysis german kgaa immunotherapy fails lung cancer trial nestle decline comment interest unit,18,-1,0
2018-02-21,0.2846818014729191,negative,buy virus based cancer firm viralytics mln kgaa invests additional mln enhance manufacturing distribution asia buy virus based cancer firm viralytics million buy viralytics mln boost immuno oncology viralytics announce acquisition agreement,32,3,0
2018-02-22,0.0929420171731809,negative,india dec qtr profit rise,5,2,0
2018-02-26,1.0075379655226646,positive,feb executive vp michael holston notified resign kgaa cladribine tablet win first approval latin,14,1,0
2018-03-07,0.3497216510355283,positive,kgaa announces positive phase iib result evobrutinib relapsing multiple sclerosis kgaa announces positive phase iib result evobrutinib eisai sign deal further develop sell eisai cancer,25,2,0
2018-03-08,0.0484967130278457,positive,germany seek development partner kgaa q4 core profit dragged lower chinese competition chinese competition cost weigh kgaa outlook ceo partnership solid,21,0,0
2018-03-09,1.046303607598431,negative,eisai clinch deal develop sell cancer soar corrected eisai clinch deal develop sell cancer soar,15,1,0
2018-03-13,0.6643367421540147,positive,fda grant priority review supplemental biologics license application keytruda,9,1,0
2018-03-15,0.9301399135375976,positive,9th circuit revives whistleblower case millennium,6,0,0
2018-03-16,0.6522609956282954,positive,massachusetts court sued over generic injury,6,0,0
2018-03-27,1.1645411159566963,positive,kgaa get fast track designation tepotinib lung cancer japan receives fast track designation tepotinib non small cell lung cancer japan india appoints milind thatte md,25,0,0
2018-04-03,0.2576252295413139,positive,seek arbitrate zetia pay delay case,6,-2,0
2018-04-06,0.0829721106618608,positive,incyte melanoma combo therapy fails study slide incyte tumble combo therapy fails study incyte provide update phase study,18,-2,0
2018-04-09,4.754537870636222,positive,keytruda help lung cancer patient live longer trial kgaa get first approval cladribine tablet middle east africa keytruda meet main goal lung cancer trial ceo kenneth frazier total compensation wa mln versus mln last judge rule antitrust claim over mumps vaccine untimely,42,1,1
2018-04-13,1.0511530613533715,positive,mylan seek deal german consumer product unit source mylan seek deal german consumer product unit source,16,0,0
2018-04-16,1.7665942075806962,positive,immunotherapy impress key lung cancer trial survival boost keytruda lead lung cancer,12,0,1
2018-04-17,0.012720276634992,negative,labcyte reach agreement supply acoustic mass spectrometry equipment announces first phase study pcv investigational pneumococcal disease vaccine,17,0,0
2018-04-18,0.6645399529550566,negative,pg nears deal acquire kgaa consumer unit wsj open offer buying procter gamble overseas india,15,1,0
2018-04-19,0.0795336056937823,positive,pg buy german consumer unit bln signed agreement sell global consumer pg bln euro cash pg acquires consumer kgaa darmstadt germany corrected pg acquire german consumer bln,27,2,0
2018-04-20,1.17194129432876,positive,germany seek partner cancer immune system,6,0,0
2018-04-23,2.428737677392212,positive,kgaa receives patent crispr technology china ema validates type ii variation keytruda combination pemetrexed platinum chemotherapy pg buy german consumer unit billion,22,1,1
2018-04-25,1.0126854739648803,negative,court upholds dismissal million verdict,5,0,0
2018-04-30,0.239854433270259,negative,fda ha set pdufa date sept,6,0,0
2018-05-01,1.6894927176570929,negative,keytruda sale power quarterly beat post fall quarterly profit announces q1 gaap eps,13,0,1
2018-05-03,0.6217609021723081,positive,provides update keynote trial kgaa family unreservedly behind pharma unit,10,0,0
2018-05-08,1.0805158591817077,negative,oncosec expands relationship combination immunopulse il keytruda,7,0,0
2018-05-15,0.1155944017746435,negative,kgaa first earnings down liquid crystal currency kgaa q1 earnings down liquid crystal currency,14,0,0
2018-05-16,0.508545016611639,positive,eiger announces expanded license agreement lonafarnib keytruda boost response hard treat lung cancer,13,0,0
2018-05-17,1.0535910351059163,negative,kgaa lung cancer show promise early stage trial oncolytics biotechxc2xae announces collaboration northwestern university,14,1,0
2018-05-22,0.0731284406466858,positive,set quarterly dividend 48share,4,0,0
2018-05-23,0.9567037689004464,positive,keytruda succeeds late stage lung cancer study cancer keytruda notch another trial success keytruda succeeds squamous non small cell lung cancer study,22,0,0
2018-05-29,0.0176092252621495,negative,roche chasing notch another lung cancer win,7,1,0
2018-06-01,0.7484528759214459,positive,ema recommends restriction roche immunotherapy refile ema recommends restriction roche immunotherapy,11,0,0
2018-06-04,1.935686033898465,positive,keytruda show promise treating advanced melanoma,6,1,1
2018-06-27,0.5549750560557953,negative,astrazeneca eye billion boost cancer success astrazeneca eye wider cancer use study success astrazeneca eye bln boost cancer success,19,0,0
2018-06-28,0.1296560073972053,positive,corrected supreme court hear appeal over fosamax suit,8,0,0
2018-07-03,0.7666194578971885,positive,germany see performance material unit turning corner,7,0,0
2018-07-19,0.3060466697182851,negative,lower trump call industry,4,0,0
2018-07-27,0.1347419523721194,negative,quarterly profit fall pct profit beat keytruda sale fail impress,10,-1,0
2018-08-09,0.8980162833611915,negative,kgaa profit dragged lower liquid crystal decline forex,8,-1,0
2018-08-28,0.5701272686625014,negative,eu clear billion pg deal german consumer unit eu clear bln pg deal german consumer unit,16,1,0
2018-08-30,0.0124456924330051,positive,fda approves hiv,3,2,0
2018-09-10,0.3317397556519164,negative,keytruda clock up win eu approves chemo cocktail,8,2,0
2018-09-26,0.153710874178492,negative,update frazier remain ceo drugmaker beyond ceo stay post amends retirement policy,12,0,0
2018-10-02,0.3658363208058013,positive,cancer center ceo leaf board disclosure scandal,7,0,0
2018-10-18,1.987131911234885,positive,combo treatment meet main goal kidney cancer trial,8,0,1
2018-10-22,0.7529461797263215,positive,roche land tecentriq trial win still trail lung cancer,9,1,0
2018-10-25,2.61628852583361,negative,report third profit ago loss cancer keytruda power profit beat forecast raise,12,2,1
2018-11-14,0.0132847933205781,negative,keytruda succeeds late stage esophageal cancer trial kgaa third earnings down weak latam currency,14,-1,0
2018-11-19,2.0727257151128557,positive,palantir offer cancer analytics under jv deal germany lack argument overturn fosamax ruling plaintiff tell scotus,16,0,1
2018-11-20,0.2057064258111252,negative,corrected palantir offer cancer analytics under jv deal germany,9,0,0
2018-11-29,1.0990024084474026,positive,corrected india krishnan resigns cfo,5,0,0
2018-12-11,0.423134577660067,negative,roche collaborates develop companion diagnostic test identify patient eligible anti pd therapy,12,0,0
2018-12-14,0.6595333957525873,negative,bolster animal unit billion purchase antelliq bolster animal unit billion antelliq purchase bolster animal unit bln antelliq purchase,18,0,0
2018-12-21,1.2340673647685207,positive,kgaa end late stage ovarian cancer treatment study corrected kgaa end late stage ovarian cancer treatment study kgaa terminate late stage ovarian cancer treatment study,25,-1,0
2019-01-07,1.8898127656646333,negative,supreme court could side over fosamax lawsuit loses bid revive mln verdict high court loses bid revive million verdict high court,21,-1,1
2019-01-24,3.06216286890878,negative,cannot arbitrate rotavirus vaccine antitrust claim judge,7,0,1
2019-02-01,2.665798790564033,positive,keytruda top billion quarterly sale rise quarterly sale rise pct keytruda strength,12,2,1
2019-02-05,0.0549279577034322,negative,ceo frazier plan testify senate pricing hearing kgaa win gsk immunotherapy deal worth up bln gsk pay up billion kgaa cancer immunotherapy gsk pay up bln kgaa cancer immunotherapy,29,0,0
2019-02-14,0.1205860561911298,positive,further study keytruda prostate cancer early success,7,0,0
2019-02-19,0.8872502594285625,negative,keytruda fails late stage study liver cancer patient,8,-1,0
2019-02-21,0.8591787404061191,positive,buy immunotherapy developer immune design million buy cancer developer immune design mln buy immunotherapy developer immune design mln,18,1,0
2019-02-27,0.1056637385507763,negative,germany make billion counterbid versum update germany make bln counterbid versum germany make bln cash counterbid versum,17,0,0
2019-03-01,0.1815131394217184,negative,versum material reject kgaa unsolicited offer,6,-1,0
2019-03-05,0.5415605994649964,positive,kgaa urge versum shareholder support takeover bid french court dismisses damage claim over thyroid kgaa urge versum shareholder pipe up rival bid,22,0,0
2019-03-07,0.4526951232522003,positive,kgaa encouraged reaction versum swoop kgaa currency headwind quell gain q4,11,1,0
2019-03-08,0.6079625238624042,negative,versum entegris see extra merger benefit hire goldman kgaa mandate goldman additional advisor versum deal,15,1,0
2019-03-12,0.0680579060085229,positive,kgaa call versum vote down entegris merger,7,0,0
2019-03-26,0.0532452668044802,negative,kgaa go hostile bln versum takeover battle kgaa make takeover offer versum shareholder kgaa go hostile billion versum takeover battle,20,0,0
2019-03-28,0.0341276897136699,positive,kgaa mln eur investement aubonne site,6,0,0
2019-03-29,0.022971694596463,positive,corrected versum urge shareholder reject kgaa hostile bid versum open book begin warm rival suitor kgaa kgaa welcome versum decision talk keep tender going versum urge shareholder reject kgaa hostile bid,31,0,0
2019-04-08,0.3226951793760646,negative,kgaa win versum support sweetened bln offer kgaa raise offer versum material kgaa win versum support sweetened billion offer,19,2,0
2019-04-12,1.1901170403995298,negative,kgaa agrees bln takeover versum kgaa clinch bln versum takeover bet electrochemicals kgaa clinch billion versum takeover bet electrochemicals,19,0,0
2019-04-22,0.2827019040742451,positive,keytruda win fda approval combination therapy kidney cancer,8,3,0
2019-04-30,2.4626324578681524,positive,raise full forecast vaccine power profit beat revenue up pct higher keytruda sale,13,2,1
2019-05-01,0.7643544136838321,positive,step up measles vaccine production increased demand,7,0,0
2019-05-14,0.5804050760826351,negative,kgaa see currency supporting outlook,5,0,0
2019-05-20,0.8644611003648994,positive,supreme court give another shot avoid fosamax lawsuit keytruda fails monotherapy breast cancer study supreme court toss ruling fosamax osteoporosis,20,-1,0
2019-05-21,0.115563120475115,negative,buy cancer developer peloton bln cash buy peloton expand kidney cancer treatment portfolio,13,2,0
2019-05-22,2.168779822275535,positive,congo want use vaccine rather jj newcomer minister congo want use vaccine rather jj newcomer minister,16,0,1
2019-06-03,1.5798859859193382,positive,win fda approval expanded use antibiotic,6,3,1
2019-06-10,0.4346368294379621,negative,buy tilos therapeutic up million buy tilos therapeutic up mln,10,1,0
2019-06-11,0.6304315331521537,positive,keytruda win fda approval treat head neck cancer,8,3,0
2019-06-13,1.3802619959845774,negative,ibm walmart blockchain collaboration fda walmart blockchain collaboration fda,9,0,1
2019-06-20,1.8457825133989303,negative,ceo see legal challenge adopts pricing based ceo see legal challenge adopts pricing based,14,-1,1
2019-07-09,0.8510711719418751,positive,appeal court mull reviving billion patent win,7,0,0
2019-07-22,0.4668080279647491,negative,unit asks patent office open front crispr battle,8,0,0
2019-07-30,1.1910411961726042,positive,cancer keytruda vaccine propel quarterly profit beat profit surge strong sale keytruda vaccine,13,2,0
2019-08-07,0.1776224433694517,negative,brief probing tie electronic record vendor,6,0,0
2019-08-08,1.3922769936930646,negative,kgaa profit bolstered lab supply milestone payment kgaa q2 profit bolstered milestone payment,13,0,1
2019-08-13,1.1469190750985625,negative,breakingviews nile rodgers mercuriadis,4,0,0
2019-08-21,0.6575627021806474,positive,hhs provide mln ebola vaccine production hhs provide million ebola vaccine production,12,0,0
2019-08-28,0.4183927277347177,positive,fda flag risk hepatitis certain patient fda flag serious risk hepatitis,11,0,0
2019-09-11,0.7945930662654588,positive,special report court let hide secret baldness risk special report court let hide secret baldness risk kgaa lung cancer 3rd watchdog priority lane,23,0,0
2019-09-13,0.1136691866833849,negative,3rd circuit revives claim over vytorinzetia nondisclosures,7,0,0
2019-09-30,1.0680035216223072,positive,astrazeneca cancer treatment attains meaningful improvement progression free survival stock apple drive wall street higher trade worry abate astrazeneca ovarian cancer treatment improves progression free survival,26,0,0
2019-10-07,0.2861879118204791,negative,kgaa completes acquisition versum material,5,0,0
2019-10-18,1.4878365196429488,positive,get eu panel nod first ever ebola vaccine hail triumph ebola vaccine get european green light corrected welcome ema recommendation conditional marketing authorization v920 ebola zaire vaccine,27,2,1
2019-10-29,3.557654125643006,positive,ramp up gardasil vaccine production flag tempered sale growth stock squeeze higher robust earnings ramp up gardasil vaccine production flag tempered sale growth stock hit record high robust earnings stock snapshot spur record high alphabet weighs quarterly profit fall deal related charge,42,3,1
2019-10-30,1.0093805912772646,positive,loses bid revive billion patent verdict,6,-1,0
2019-11-11,0.1798821643580139,negative,win european approval first ever ebola vaccine,7,2,0
2019-11-14,0.4639051038689779,negative,kgaa raise guidance versum takeover,5,2,0
2019-11-18,0.9807169523559311,negative,bayer heart meet main goal late stage study,8,0,0
2019-12-05,0.0895761970216346,negative,refile astrazeneca lynparza win approval china ovarian cancer treatment astrazeneca lynparza win approval china ovarian cancer treatment,17,2,0
2019-12-09,0.168101460732728,positive,push deeper targeted cancer therapy bln arqule deal buy cancer developer arqule bln cash,14,1,0
2019-12-19,0.0029540890751578,positive,receives fda approval ebola vaccine,5,2,0
2019-12-20,1.3305900022458017,positive,ebola vaccine available lowest access poor nation,7,-1,1
2019-12-30,0.0376613524695423,positive,astrazeneca score win lynparza approval pancreatic cancer astrazeneca lynparza get fda okay treat pancreatic cancer,15,3,0
2012-01-12,0.9234538528416714,positive,corrected post eylea sale mln,5,0,0
2012-02-13,11.569602345743004,positive,raise eylea sale forecast jump,5,1,1
2012-03-13,0.059509963187998,negative,eye capturing roche patient,4,0,0
2012-03-26,0.7490365449166481,negative,cholesterol face sudden challenge,4,-1,0
2012-04-26,8.342525535649624,positive,nearly double eylea sale forecast,5,0,1
2012-04-27,0.8532178437236304,positive,corrected research alert jefferies raise target,6,2,0
2012-05-04,0.2659215073006149,negative,fda staff question side effect gout,6,0,0
2012-05-08,0.8923789430609119,positive,fda adviser rebuff gout,4,0,0
2012-07-25,6.071144375838533,positive,boost eylea sale forecast boost eylea sale forecast,8,0,1
2012-07-30,1.0445580715851,negative,fda reject expanded use gout,5,-2,0
2012-08-03,1.6242605452365,negative,fda approves sanofiregeneron colon cancer pulse knight capital viacom,9,2,1
2012-09-21,0.7315361999237102,negative,eye eylea win approval use bayer eye get eu agency backing,11,2,0
2012-10-24,6.623129104005166,positive,profit boosted eylea raise forecast report strong eylea sale third,10,1,1
2013-01-08,2.944615011995844,negative,see sale eylea up bln,5,0,1
2013-02-11,2.714481920013234,positive,anofi boosting stake corrected sanofi plan buy anofi boosting stake,10,1,1
2013-02-14,0.7319487045535089,negative,4th profit beat rising eylea sale profit beat street eylea sale strength profit beat estimate rising eylea sale,18,1,0
2013-04-24,1.1110655532625135,negative,pharma up pct bell add drop metropcs,7,-1,0
2013-05-01,11.172374962937182,positive,pharma resume trading up allergan delay would rival eylea pharma halted last up pct,14,-1,1
2013-05-03,6.036552986430643,positive,raise eylea sale view profit beat street raise eylea sale view hit time high,14,3,1
2013-05-20,1.241340985018613,negative,settle pending litigation roche genentech,5,0,0
2013-05-21,1.5396156547958673,negative,sanofi asthma seen potential game changer,6,0,1
2013-05-30,1.435324793537518,positive,uk cost agency recommends bayer eye,6,0,1
2013-08-06,5.5168470014947175,negative,eylea improves vision diabetic eye condition sale eylea eye slow drop,11,-2,1
2013-09-13,5.757537525422274,positive,sanofi could acquire loreal stake buy,6,2,1
2013-09-16,0.9358983417132594,positive,pulse tesco gsk cooper tire pulse tesco gsk boeing boise pulse tesco gsk boeing,14,0,0
2013-10-16,4.532557348100585,positive,sanofi slash cholesterol late stage trial slash cholesterol late stage trial,11,0,1
2013-10-21,2.861841797989162,negative,eylea beat laser eye edema study refile eylea improves vision another eye disorder,13,1,1
2013-11-05,7.636532150683772,positive,earnings beat forecast eylea outlook higher,6,2,1
2013-11-22,5.7484836306522125,positive,anofi arthritis meet goal phase trial,6,1,1
2014-01-13,0.7469014948703334,negative,up extended trading bayer develop eylea combination treatment,8,0,0
2014-01-14,10.686322230161306,positive,q4 eylea sale mln report mln 4th eylea sale ceo,10,0,1
2014-02-11,6.313511091676749,positive,forecast strong eylea sale rise,5,2,1
2014-03-07,3.097616639164502,negative,fda asks sanofi ass cholesterol cognitive risk fda probe cognitive impact cholesterol sanofi fall,14,-2,1
2014-05-08,1.7982445318187934,negative,eye sale grow fall short expectation adjusted quarterly profit beat estimate,11,0,1
2014-06-19,2.604726398762081,negative,judge reject merus bid dismiss patent lawsuit,7,-1,1
2014-07-01,6.736772698913707,positive,anofi raise stake jump anofi raise stake,7,1,1
2014-07-09,0.3163939090499612,negative,tames eczema study anofi tames eczema study,7,0,0
2014-07-29,1.2074606480496852,positive,fda ok expanded use eye,5,0,0
2014-07-30,5.787532805448858,positive,anofi cut cholesterol nine late stage trial anofi cholesterol cut heart risk trial hint,14,0,1
2014-08-01,2.863902450224698,positive,unusual option volume seen priceline others,6,0,1
2014-08-05,3.354086060918715,positive,sale top forecast eylea pick up steam sale top forecast eylea delivers,12,0,1
2014-09-19,0.9635061479953632,negative,allergy darling pipeline,3,0,0
2014-09-30,1.829611501297257,positive,anofi ha positive trial result chronic sinusitis,7,1,1
2014-10-17,7.310010904988128,positive,eylea work better avastin lucentis study buzz pharmaceutical study show eylea better rival,13,1,1
2014-10-20,1.9219020382431504,negative,anofi start phase trial dupilumab eczema,6,1,1
2014-11-04,5.439135196738787,negative,cut top end eye sale forecast refile third revenue rise strong eylea sale,13,1,1
2014-11-17,1.062361538446721,positive,highly effective cant take statin study highly effective cant take statin study,12,1,0
2014-11-20,2.402995249597084,negative,anofi eczema get fda fast track designation,7,0,1
2015-01-09,2.733163974860564,positive,anofi cholesterol also effective dos anofi announce positive trial cholesterol,10,3,1
2015-01-12,1.3404771275120742,positive,anofi submit cholesterol ema review,5,0,1
2015-01-26,0.6130148378132638,positive,regeneronsanofi cholesterol get fda priority review,6,1,0
2015-02-10,0.8176640670822799,negative,revenue beat street strong eylea sale profit rise pct strong eylea sale,12,3,0
2015-03-16,3.878441293674939,positive,anofi announce month result odyssey long term trial praluent,9,1,1
2015-03-25,2.703576554550835,negative,fda expands usage eye eylea corrected fda expands usage eye eylea,11,0,1
2015-05-07,0.6947001266126462,negative,refile profit rise eylea sale jump expects eylea sale grow faster expected,12,2,0
2015-06-05,4.178109757695414,positive,fda staff sanofiregeneron lower ldl well tolerated fda staff sanofiregeneron lower ldl well tolerated,14,0,1
2015-06-09,0.0143940122256491,negative,fda panel back sanofiregeneron cholesterol limit fda panel back sanofiregeneron cholesterol,11,0,0
2015-06-10,3.8215485639357394,negative,corrected fda panel back sanofiregeneron cholesterol limit,7,0,1
2015-07-09,0.1850239145609111,negative,anofi japan study show praluent lower cholesterol,7,0,0
2015-07-24,1.6048458459141155,negative,sanofi high cholesterol praluent get ema nod fda approves sanofiregeneron cholesterol limit,12,3,1
2015-07-28,1.0567649452149608,positive,anofi invest bln cancer therapy collaboration anofi link billion cancer push anofi link bln cancer push,16,0,0
2015-08-04,5.00722379187658,positive,raise eylea sale forecast record drugmaker revenue jump eylea sale,10,1,1
2015-09-01,0.4052653876961409,negative,anofi cholesterol positive,3,1,0
2015-09-02,2.6061433255364808,positive,scientist discover key excess bone growth rare disease,8,1,1
2015-11-04,2.1283064663604967,negative,raise eylea sale growth estimate revenue jump pct eylea sale surge,11,4,1
2016-02-09,6.294279922867374,negative,see gradual adoption cholesterol praluent pharma revenue rise pct,9,1,1
2016-03-16,0.241047655101978,negative,sanofi comment verdict ongoing patent litigation regarding praluent beat sanofi cholesterol trial,12,1,0
2016-03-23,2.7578832598364245,negative,anofi unveil positive praluent cholesterol study,6,1,1
2016-03-24,1.5276822213379893,positive,bayer jointly develop combination therapy eye disease bayer jointly develop combination therapy eye diseasesx7f,14,0,1
2016-04-01,11.750831544689476,positive,sanofi announce positive dupilumab topline result phase trial inadequately controlled moderate severe atopic dermatitis patient sanofi eczema clear hurdle big trial,21,3,1
2016-04-11,1.9384445856947097,negative,pharmaceutical intellia therapeutic announce collaboration discover develop crisprcas therapeutic,9,1,1
2016-05-02,1.2783700961654487,positive,pain clear late stage trial suuceeds study patient osteoarthritis pain,10,1,0
2016-05-05,4.758306010027491,positive,report q1 adj earnings secures coverage cholesterol praluent,8,0,1
2016-05-11,2.6952817648242755,negative,deal payer ass praluent value cigna enters contract sanofiregeneron pharmaceutical report pct passive stake intellia therapeutic,16,0,1
2016-05-12,1.701727232593897,negative,ceo critique independent group unscientific,5,0,1
2016-05-26,0.2694855491392367,negative,rpt replaces intel sponsor science talent search replaces intel sponsor science talent search,13,0,0
2016-05-31,0.8742264828560553,positive,present positive phase study evinacumab,5,1,0
2016-06-06,0.2746821992437143,positive,anofi report positive skin disease trial,6,1,0
2016-07-05,1.0289422259892378,positive,sanofi announce approval praluent japan,5,2,0
2016-08-02,0.848102960779118,positive,adicet bio initiate strategic collaboration develop immune cell therapeutic,9,0,0
2016-08-04,1.912139127493384,negative,stick growth forecast eylea fall refile stick growth forecast eylea fall eylea sale lift quarterly revenue reimbursement situation improving praluent conf call,22,1,1
2016-08-22,3.5539176223051028,positive,announces agreement barda,3,0,1
2016-08-29,1.3833183471181454,negative,anofi praluent show positive phase trial,6,1,1
2016-09-12,2.487958453558403,positive,bonnie bassler huda zoghbi elected board,6,0,1
2016-09-20,0.8418279308911814,positive,teva take aim lillypfizer pain teva collaborate develop commercialize fasinumab teva announce global collaboration develop fasinumab,16,1,0
2016-09-26,0.7175923285236752,negative,anofi accepted priority review fda,5,1,0
2016-09-30,1.822634703344106,negative,eylea combination therapy fails mid stage study announces phase study aflibercept,11,-1,1
2016-10-13,0.9487534471490976,positive,ocular enter strategic collaboration develop sustained release formulation aflibercept,9,0,0
2016-10-17,0.9845732495284644,negative,teva provide update fasinumab clinical development program fda place teva pain study hold,13,0,0
2016-10-28,2.3101794217304183,negative,fda spurns sanofi arthritis over manufacturing lapse sanofi receive complete response letter fda sarilumab fda spurns sanofi arthritis due manufacturing lapse advised sanofi manufacturing deficiency raised fda,27,0,1
2016-11-04,1.7113047165579376,positive,profit top street lower cost ceo eylea rival offering discount rebate conf call eylea sale lift revenue pharmaceutical q3 gaap eps,21,1,1
2016-11-11,0.5283655229231243,negative,sanofi present clinical trial,4,0,0
2016-11-16,1.8114661526987372,negative,sanofi present result late stage monarch study american college rheumatology annual meeting,12,0,1
2016-11-17,4.208606998101249,negative,no early win sanofi cholesterol study,6,1,1
2016-12-08,1.727446769453067,positive,eu regulator accepts sanofiregeneron dupixent product review,7,0,1
2016-12-30,1.4085519979559202,negative,pharmaceutical purchase existing corporate headquarters bmr landmark eastview llc bmr landmark eastview iv llc,14,0,1
2017-01-03,2.6701242272029413,positive,anofi lose bid overturn win patent case,7,1,1
2017-01-05,0.4921917189706359,negative,sanofi appeal judge ban cholesterol sale judge block sanofi selling cholesterol,11,-1,0
2017-01-09,0.6791650664433213,negative,corrected ceo not putting patient first patent dispute ceo not putting patient first patent dispute sanofi plant used fill deemed acceptable pharmaceutical report preliminary q4 net sale eylea injection mln,30,0,0
2017-01-13,0.7911922187839426,positive,sanofi buy common stock jan,5,1,0
2017-01-31,4.301969554426554,positive,tony cole elected board,4,0,1
2017-02-08,1.3723383399001698,negative,sanofi win stay order blocking cholesterol sale pharmaceutical appeal court grant stay permanent injunction praluent sanofi win stay order blocking cholesterol sale,22,1,1
2017-02-09,1.3175629013439272,positive,pin hope eczema eylea sale slow revenue rise pct eylea eye increase unrelated innovation pushed back post q4 adj profit 04shr,21,0,1
2017-02-24,0.1130314017196765,negative,aarp support sanofi cholesterol fight,5,0,0
2017-03-01,0.0861899013002931,positive,adverum pharma elect extend research term deal,7,1,0
2017-03-07,2.1651160620874133,negative,sanofi present phase praluent injection clinical trial analysis acc scientific session,11,0,1
2017-03-14,0.9535303010005602,positive,uk regulator give positive opinion sanofiregeneron dupilumab product,8,1,0
2017-03-21,1.6059512492022532,negative,anofi sue protect eczema patent claim,6,0,1
2017-03-22,0.7312991500171506,negative,gsk mine gene briton,4,0,0
2017-03-28,1.0221988404376048,negative,fda approves sanofi eczema fda approves sanofi eczema list sanofi dupixent sanofi announce fda approval dupixent,16,5,0
2017-04-06,0.280682239046226,positive,announces evinacumab ha received fda breakthrough therapy designation,8,1,0
2017-04-21,1.3497499704456462,negative,ema panel recommends nod sanofi arthritis,6,1,1
2017-04-25,0.4770047839933067,negative,anofi announce fda approval dosing option praluent pharmaceutical ceo leonard schleifer total compensation wa mln sec filing fda approved praluent injection,21,3,0
2017-04-28,6.183244317687498,positive,sanofi announce kevzara license application resubmission review fda,8,1,1
2017-05-04,6.584798834564554,positive,over prescription written dupixent eylea fear fade focus turn eczema profit jump pct higher eylea sale corrected eylea fear fade focus turn eczema pharmaceutical received subpoena q1 non gaap earnings,30,0,1
2017-05-08,1.293338704235536,negative,anofi hope led case shine light praluent injunction appeal inovio enter immuno oncology clinical study agreement sillajen report immuno oncology clinical study agreement,23,0,0
2017-05-22,1.9322012401290944,positive,sanofi rheumatoid arthritis win approval sanofi ra win fda nod 39000patientyr,11,3,1
2017-06-06,0.2071135774261656,negative,sanofi urge court reverse ban cholesterol,6,-1,0
2017-06-22,0.909228790796901,positive,detail royalty agreement novartis canakinumab,5,0,0
2017-06-27,1.8673275887071128,negative,anofi announce eu approval kevzara,5,2,1
2017-07-21,0.9107177619179564,negative,eu follows backing sanofi eczema,5,0,0
2017-07-27,1.3072732628112038,negative,win merus court rule obtained patent through deception,8,1,0
2017-07-28,0.1763214098058907,positive,court appeal federal circuit affirms merus inequitable conduct claim,9,0,0
2017-08-03,1.842421447897935,negative,q2 non gaap earnings beat profit view end antibody deal sanofi expects dupixent broad access state end quarterly profit nearly double,21,1,1
2017-08-14,0.7125356006383532,positive,abandon common respiratory virus respiratory virus fails late stage study,10,-1,0
2017-09-07,5.645360027037761,negative,positive eczema study drag down,5,0,1
2017-09-08,0.0263535950825843,positive,anofi cemiplimab receives fda breakthrough designation advanced cutaneous squamous cell carcinoma,11,1,0
2017-09-11,6.661619490778503,negative,sanofi asthma fails excite sanofi announce positive dupilumab topline result phase trial uncontrolled persistent asthma anofi announce positive dupilumab topline result,21,1,1
2017-09-28,0.1934665775461086,negative,eu approves sanofi dupilumab eczema,5,1,0
2017-10-02,2.9477771297111044,positive,pharmaceutical collaboration hhs develop antibody ebola influenza multiple emerging,9,0,1
2017-10-05,1.019154722610649,positive,court revers ban sale sanofi praluent appellate court rule sanofi continue manufacturing praluent court revers ban sale sanofi cholesterol,19,-2,0
2017-10-16,0.4806914479023039,positive,aimmune therapeutic collaborates study ar101 dupilumab peanut allergy sanofi throat infection succeeds key study corrected sanofi succeeds mid stage study sanofi announce positive phase study result dupilumab aimmune team sanofi peanut allergy sanofi succeeds mid stage study,37,2,0
2017-11-07,0.4813309978874858,negative,sanofi present analysis praluent injection odyssey clinical trial,8,0,0
2017-11-08,2.495642564546019,positive,q3 non gaap earnings third profit easily top street view eylea dupixent sale q3 profit easily top street view eylea dupixent sale drugmaker quarterly profit surge pct,27,1,1
2017-11-27,2.631633380629661,negative,drop eye combination novartis chase eylea provides update eylea combination program,11,-1,1
2017-11-29,1.9527946143037207,negative,decibel therapeutic announce strategic collaboration,5,1,1
2017-12-11,0.1594927478357988,negative,announces fda acceptance sbla filing week dosing eylea injection patient wet amd,12,0,0
2017-12-18,2.063612198283038,negative,isa pharmaceutical announce strategic immuno oncology collaboration,7,1,1
2017-12-26,1.8072857382029903,positive,appeal court denies bid revive patent case merus,8,0,1
2018-01-03,2.289600797378699,positive,momentum mylan plan trial biosimilar eye,6,0,1
2018-01-08,3.4495528243800977,negative,pharma enter letter agreement relating immuno oncology licensecollaboration agreement sanofi form consortium accelerate gene sequencing project anofi boost investment cancer cemiplimab,21,0,1
2018-01-22,0.3523558623362621,positive,announces approval dupixent japan treatment atopic dermatitis,7,1,0
2018-02-08,0.1676112338921842,positive,ceo fear over eylea greatly exaggerated report q4 adj earnings ceo fear over eylea greatly exaggerated post drop quarterly profit,20,-1,0
2018-03-19,0.1237814297635475,positive,novartis file patent infringement over latter manufacture eylea zaltrap,9,0,0
2018-03-21,0.4944393429872296,positive,alnylam pharmaceutical announce collaboration discover treatment nonalcoholic steatohepatitis,8,1,0
2018-04-03,0.785574939208189,negative,european agency review sanofi dupixent cemiplimab,6,0,0
2018-04-23,0.5750668319147167,positive,pharma ceo compensation wa million,5,0,0
2018-04-30,2.2240744643926336,negative,fda conduct priority review cemiplimab potential treatment advanced cutaneous squamous cell carcinoma,12,1,1
2018-05-01,0.9877502684853324,negative,regeneronsanofi cut heart express script anofiregeneron cut praluent express script deal regeneronsanofi cut heart express script deal sanofi lower net praluent express script patient,24,0,0
2018-05-03,1.0391746653345524,negative,report q1 gaap earnings newer disappoint slip first profit soar,10,-1,0
2018-05-16,0.4981130295947933,positive,phase trial dupixent met primary endpoint,6,0,0
2018-08-02,6.454678613780929,positive,post quarterly profit beat strongly back eylea future profit beat expectation sale eczema,13,1,1
2018-08-06,1.5898700831760038,negative,invest million bluebird jointly develop cancer therapy,7,0,1
2018-08-17,0.3150228632905261,positive,anti blindness approved le frequent treatment,6,0,0
2018-09-28,0.4930788930206597,negative,anofi skin cancer get fda nod,6,1,0
2018-10-01,2.7753907466741223,negative,cotus denies request review inequitable conduct finding,7,0,1
2018-10-25,5.906299964390637,negative,win dismissal willfulness claim eylea patent dispute fda decline approve pre filled syringe version eylea fda decline approve pre filled syringe version eylea,23,1,1
2018-11-06,0.1222828262994912,positive,sanofi dupixent get positive feedback fda sanofi dupixent get positive feedback fda,12,1,0
2019-01-07,1.0198797319287078,negative,corrected sanofi pay mln revised immuno oncology deal drugmakers sanofi restructure immuno oncology deal anofi pay million revised immuno oncology deal,21,-1,0
2019-02-11,0.3500858893483283,positive,anofi cut list cholesterol pct anofi cut list cholesterol,9,0,0
2019-02-25,0.642617307025295,negative,corrected sanofi lose patent challenge cholesterol anofi lose patent challenge cholesterol corrected sanofi lose patent challenge cholesterol report,18,-1,0
2019-03-11,0.8869550665920878,positive,regeneronsanofi skin disease cleared use teen regeneronsanofi win approval expanded use skin,12,2,0
2019-04-08,1.954264117521709,negative,alnylam partner rnai treatment foray gene silencing therapy alnylam tie up,11,0,1
2019-04-26,2.2742967895312827,negative,fda approves expanded label cholesterol fda approves expanded label regeneronsanofi cholesterol fda approves expanded label regeneronsanofi cholesterol,17,2,1
2019-06-26,2.3994624063841563,negative,refile fda approves expanded label regeneronsanofi dupixent fda approves expanded label regeneronsanofi dupixent,13,2,1
2019-08-06,1.17196709079046,negative,eu regulator approve sanofi dupixent adolescent case second revenue beat eylea sale eu approves sanofi dupixent adolescent eczema case beat second profit estimate eylea boost,25,3,0
2019-08-12,1.7411063978028607,negative,ebola treatment prof superior rival trial,6,0,1
2019-08-28,1.509699969168632,positive,judge rule sanofi cholesterol patent fight,6,0,1
2019-11-05,7.04220023224792,positive,eylea power third profit beat rise profit rise nearly higher demand eczema dupixent,13,3,1
